PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES

Abstract

<strong>The present invention relates to compounds of formula (i), or pharmaceutically acceptable salts, enantiomers or diastereomers thereof, r1 to r4 being as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis b virus infection.< / strong>

Description

[0001] The present invention relates to organic compounds useful for therapy and / or prophylaxis in a mammal, and in particular for treating hepatitis B virus infection, and their pharmaceutical activity, manufacture, pharmaceutical compositions containing them and their potential use as medicaments.FIELD OF THE INVENTION

[0002] The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R 1< to R 4< , Y and Q are as described below.The compounds of this invention are useful for the treatment or prophylaxis of hepatitis B virus infection.

[0003] Hepatitis B virus (HBV) infection is a major public health problem worldwide, roughly 30% of the world's population show serological evidence of current or past infection. Despite the introduction of a safe and effective prophylactic vaccine against the virus in the early 1980s, it is estimated that there are still more than 240 million chronic HBV carriers worldwide, a high percentage of whom will eventually develop liver cirrhosis or hepatocellular carcinoma (HCC) (WHO Hepatitis B. Fact Sheet N°204). In the 2010 Global Burden of Disease study (R Lozano, et al. Lancet, 380 (2012), 2095-2128), HBV infection ranked in the top health priorities in the world, and was the tenth leading cause of death (780,000 deaths per year). Recent studies have shown that progression to liver cirrhosis and HCC in patients with chronic HBV infection is significantly associated with circulating HBV DNA levels. Thus, antiviral therapy against HBV is critical to prevent the progression to cirrhosis or development of HCC.

[0004] HBV is a small, enveloped virus that belongs to the Hepadnaviridae family. It contains a partly double-stranded DNA genome with approximately 3200 base pairs. HBV have a strong preference for infecting human hepatocytes. The life cycle begins when HBV attaches to the host cell membrane via its envelope proteins. The precise mechanism of viral entry has not been fully elucidated. The viral relaxed circular DNA (rcDNA) containing nucleocapsids are released into the cytoplasm and transported to the nucleus. In the nucleus, the rcDNA is repaired by both viral and cellular enzymes to form covalently closed circular DNA (cccDNA). There is evidence that each infected cell contains 1-50 cccDNA molecules as unique episomal minichromosomes. Both subgenomic RNA (sgRNA) and pregenomic RNA (pgRNA) are transcribed from the cccDNA using the cellular transcriptional machinery. After nuclear export, the pgRNA is translated into the core protein and the viral polymerase. The sgRNA is translated into the regulatory X protein and the three envelope proteins. Self-assembly of the RNA-containing viral nucleocapsid takes place via complex formation of the pgRNA with the core protein and the polymerase. Inside the nucleocapsid, the pgRNA is reverse transcribed into negative-strand DNA. rcDNA is then generated by plus-strand synthesis from the negative-strand DNA. The nucleocapsids are either re-imported to the nucleus for cccDNA amplification or enveloped and released via the endoplasmic reticulum (ER). The reverse transcriptase lacks proofreading activity; thus, mutations of the viral genome are frequent and result in the coexistence of genetically distinct viral species in infected individuals (quasispecies).

[0005] Currently, seven treatments are approved for chronic hepatitis B (CHB), including two formulations of interferon (IFN) (conventional IFN and PEG-IFN) and five nucleos(t)ide analogues (NUCs: lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil). The main difference between immunomodulatory agents and NUCs is that PEG-IFN has the advantage of a finite duration of use, whereas the use of NUCs is indefinite. The major drawback of PEG-IFN is its high frequency of adverse events. Some viral genotypes do not show good responses to interferon therapy. Long-term use of NUCs, on the other hand, poses the risk of drug resistance. The ultimate goal of antiviral therapy for CHB is to prevent progression to cirrhosis or HCC via eradication of HBV or persistent viral suppression. The majority of currently treated patients fail to achieve this goal. As indicated above, nucleocapsid assembly is a critical step for HBV genome replication. As the synthesis of viral DNA takes place exclusively within the nucleocapsid, the assembly and disassembly of nucleocapsid must be precisely regulated to ensure correct packaging and release of the viral genome. Nucleocapsid assembly is an evolutionary constraint process that limits the diversity of HBV, and it is highly sensitive to even subtle molecular disturbances. Both assembly and disassembly of nucleocapsid make the process an attractive therapeutic target for the development of new antiviral therapies against various HBV genotypes and drug resistance isolates. A few capsid related anti-HBV compounds have been reported. For example, heteroaryldihydropyrimidines (HAP), including compounds named Bay 41-4109, Bay 38-7690 and Bay 39-5493 (Deres K. et al. Science 2003, 893), and phenylpropenamide derivatives such as AT-61 and AT-130 (Feld J. et al. Antiviral Research 2007, 168-177). Capsid has become a promising drug target with several molecules under clinical stage.

[0006] WO 2009 / 085983 A1 (Genentech Inc., US) disclose imidazopyridines with anti-cancer and / or anti-inflammatory, in particular anti-MEK kinase activity. WO 2009 / 085983 A1 does not disclose fused compounds with a hydrogenated pyrazine ring.

[0007] WO 2014 / 111871 A1 (Aurigene Discovery Tech. Ltd., India) discloses substituted 4,5-dihydroisoxazole derivatives which are therapeutically useful as NAMPT inhibitors. WO 2014 / 152725 A1 (Biogen Idec Inc., US) discloses S1p and / or atx modulating compounds. While both WO 2014 / 111871 A1 and WO 2014 / 152725 A1 disclose hydrogenated fused pyrazine compounds, these compounds do not match the definition of R1 and / or R4 of the compounds of the present invention.

[0008] There is still a need to develop new treatments for the prophylaxis and treatment of hepatitis B virus infection.SUMMARY OF THE INVENTION

[0009] The present invention relates to novel compounds of formula (I), wherein R 1< is heterocyclyl, said heterocyclyl being unsubstituted or substituted with one, two or three substituents independently selected from (C 1-6 alkyl) 2 aminocarbonyl, (C 1-6 alkyl) 2 morpholinylcarbonyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkoxycarbonyl, C 1-6 alkyl, C 1-6 alkyl(C 1-6 alkylsulfonyl)amino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylimidazolyl, C 1-6 alkylmorpholinylcarbonyl, C 1-6 alkyloxadiazolyl, C 1-6 alkyloxazolyl, C 1-6 alkylpyrazolyl, C 1-6 alkylsulfonyl, C 1-6 alkylsulfonylamino, C 1-6 alkylsulfonylC 1-6 alkyl, carbamoyl, cyano, dioxopyrrolidinyl, haloC 1-6 alkyl, haloC 1-6 alkyloxadiazolyl, halogen, halopiperidinylcarbonyl, halopyridinyl, halopyrimidinylamino, halopyrimidinyloxy, halopyrrolidinylcarbonyl, hydroxy, hydroxyazetidinylcarbonyl, hydroxyC 1-6 alkyl, hydroxyC 1-6 alkyl(C 1-6 alkyl)aminocarbonyl, hydroxyC 1-6 alkylaminocarbonyl, hydroxypyrrolidinylcarbonyl, morpholinylcarbonyl, oxadiazolyl, oxazolyl, oxazolylaminocarbonyl, oxazolyl(C 1-6 alkyl)aminocarbonyl, oxazolylcarbonyl, oxazolylcarbonyl(C 1-6 alkyl)amino, oxomorpholinyl, oxooxazolidinyl, oxopyrrolidinyl, phenyl, phenylcarbonyl, pyrazolylC 1-6 alkyl, pyridinyl, pyrimidinyl, pyrimidinylamino, pyrimidinyl(C 1-6 alkyl)amino, pyrimidinyloxy, pyrimidinyloxyC 1-6 alkyl, pyrrolidinylcarbonyl and thiazolyl; heteroaryl, said heteroaryl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 1-6 alkyl, haloC 1-6 alkyl, hydroxy C 1-6 alkyl and C 1-6 alkoxyC 1-6 alkyl; phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl, haloC 1-6 alkoxy and haloC 1-6 alkyl; or C 3-7 cycloalkyl; R 2< and R 3< are independently selected from hydrogen and C 1-6 alkyl; R 4< is heteroaryl, said heteroaryl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl and (C 1-6 alkyl) 2 amino; aryl, said aryl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 3-7 cycloalkyl, C 1-6 alkyl, C 2-6 alkynyl, C 1-6 alkoxy, haloC 1-6 alkyl and haloC 1-6 alkoxy; phenylC 1-6 alkyl, said phenylC 1-6 alkyl being unsubstituted or substituted with one, two or three halogen; or C 3-7 cycloalkyl; Y and Q are independently selected from CH and N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0010] Objects of the present invention are novel compounds of formula (I), their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula (I) as HBV inhibitors and for the treatment or prophylaxis of HBV infection.DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS

[0011] The term "C 1-6 alkyl" denotes a monovalent linear or branched saturated hydrocarbon group of 1 to 6 carbon atoms. In particular embodiments, C 1-6 alkyl has 1 to 6 carbon atoms, and in more particular embodiments 1 to 4 carbon atoms. Examples of C 1-6 alkyl include methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, sec-butyl or tert-butyl.

[0012] The term "halo" or "halogen" are used interchangeably herein and denote fluoro, chloro, bromo or iodo.

[0013] The term "haloC 1-6 alkyl" denotes a C 1-6 alkyl group wherein at least one of the hydrogen atoms of the C 1-6 alkyl group has been replaced by same or different halogen atoms, particularly fluoro atoms. Examples of haloC 1-6 alkyl include monofluoro-, difluoro- or trifluoro-methyl,-ethyl or -propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, trifluoroethyl, fluoromethyl, difluoromethyl, difluoroethyl or trifluoromethyl.

[0014] The term "haloC 1-6 alkoxy" denotes a C 1-6 alkoxy group wherein at least one of the hydrogen atoms of the C 1-6 alkoxy group has been replaced by same or different halogen atoms, particularly fluoro atoms. Examples of haloC 1-6 alkoxy include monofluoro-, difluoro- or trifluoro-methoxy, -ethoxy or -propoxy, for example 3,3,3-trifluoropropoxy, 2-fluoroethoxy, trifluoroethoxy, fluoromethoxy, difluoromethoxy, difluoroethoxy or trifluoromethoxy.

[0015] The term "halopyridinyl" denotes a pyridinyl substituted once, twice or three times by halogen. Examples of halopyridinyl include, but not limited to, bromopyridinyl, chloropyridinyl, difluoropyridinyl, fluoropyridinyl and fluorochloropyridinyl.

[0016] The term "halopyrimidinyl" denotes a pyrimidinyl substituted once, twice or three times by halogen. Examples of halopyrimidinyl include, but not limited to, fluoropyrimidinyl.

[0017] The term "halopyrrolidinyl" denotes a pyrrolidinyl substituted once, twice or three times by halogen. Examples of halopyrrolidinyl include, but not limited to, difluoropyrrolidinyl.

[0018] The term "halopiperidinyl" denotes a piperidinyl substituted once, twice or three times by halogen. Examples of halopiperidinyl include, but not limited to, difluoropiperidinyl.

[0019] The term "pyrimidinyloxy" denotes pyrimidinyl-O-.

[0020] The term "halopyrimidinyloxy" denotes halopyrimidinyl-O-, wherein halopyrimidinyl is defined above. Examples of halopyrimidinyloxy include, but not limited to, fluoropyrimidinyloxy.

[0021] The term "oxo" denotes a divalent oxygen atom =O.

[0022] The term "heteroaryl" denotes a monovalent aromatic heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms, comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Examples of heteroaryl moieties include, but not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzooxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl. Heteroaryl can be further substituted by halogen, C 1-6 alkyl, haloC 1-6 alkyl, cyano, C 3-7 cycloalkyl, (C 1-6 alkyl) 2 amino, C 1-6 alkoxy. Example of heteroaryl include, but not limited to, chloropyridinyl, chlorothiazolyl, cyanopyrazolyl, cyanopyridinyl, fluorochloropyridinyl, fluoropyrazolyl, fluoropyridinyl, fluoropyrimidinyl, hydroxymethylpyrazolyl, methoxymethylpyrazolyl, methylfluoropyridinyl, methylfluoropyrimidinyl, methylpyrazolyl, trifluoromethylpyridinyl and trifluoromethylthiazolyl.

[0023] The term "aryl" denotes a monovalent aromatic carbocyclic mono- or bicyclic ring system comprising 6 to 10 carbon ring atoms. Example of monocyclic aryl include, but not limited to, phenyl; and examples of the bicyclic aryl include, but not limited to, indanyl and bicyclo[4.2.0]octa-1(6),2,4-trienyl.

[0024] The term "heterocyclyl" denotes a monovalent saturated or partly unsaturated mono or bicyclic ring system of 3 to 10 ring atoms, comprising 1 to 5 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon. In particular embodiments, heterocyclyl is a monovalent saturated monocyclic ring system of 4 to 7 ring atoms, comprising 1, 2, or 3 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Examples for monocyclic saturated heterocyclyl are aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, oxazepanyl, and lactam include, but not limited to, oxopyrrolidinyl, oxomorpholinyl, oxooxazolidinyl and oxooxazinanyl; monocyclic saturated heterocyclyl can be further substituted by (C 1-6 alkyl) 2 aminocarbonyl, (C 1-6 alkyl) 2 morpholinylcarbonyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkyl, C 1-6 alkyl, C 1-6 alkyl(C 1-6 alkylsulfonyl)amino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylmorpholinylcarbonyl, C 1-6 alkyloxadiazolyl, C 1-6 alkyloazolyl, C 1-6 alkylpyrazolyl, C 1-6 alkylsulfonyl, C 1-6 alkylsulfonylamino, C 1-6 alkylsulfonylC 1-6 alkyl, cyano, dioxopyrrolidinyl, haloC 1-6 alkyl, haloC 1-6 alkyloxadiazolyl, halopiperidinylcarbonyl, halopyrimidinylamino, halopyrimidinyloxy, halopyrrolidinylcarbonyl, hydroxy, hydroxyazetidinylcarbonyl, hydroxyC 1-6 alkyl, hydroxyC 1-6 alkyl, hydroxyC 1-6 alkyl(C 1-6 alkyl)aminocarbonyl, hydroxyC 1-6 alkylaminocarbonyl, hydroxypyrrolidinylcarbonyl, morpholinylcarbonyl, oxadiazolyl, oxazolyl, oxazolylaminocarbonyl, oxazolyl(C 1-6 alkyl)aminocarbonyl, oxazolylcarbonyl(C 1-6 alkyl)amino, oxomorpholinyl, oxooxazolidinyl, oxopyrrolidinyl, phenyl, pyrazolylC 1-6 alkyl, pyridinyl, pyrimidinyl, pyrimidinylamino, pyrimidinylC 1-6 alkylamino, pyrimidinyloxy, pyrimidinyloxyC 1-6 alkyl, pyrrolidinylcarbonyl and thiazolyl. Examples for substituted monocyclic saturated heterocyclyl include, but not limited to difluoropiperidinyl, methyloxooxazinanyl, dimethyloxooxazinanyl, methoxyoxooxazinanyl, morpholinylcarbonyl(methyl)oxooxazinanyl, dimethyloxopyrrolidinyl, oxazolyloxopyrrolidinyl, dimethylmorpholinyl, methyloxomorpholinyl, hydroxypiperidinyl, cyanooxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, hydroxyoxopyrrolidinyl, acetylpiperidinyl, methylaminocarbonyloxopyrrolidinyl, methoxyoxopyrrolidinyl, dimethyloxooxazolidinyl, phenyl(hydroxy)oxopyrrolidinyl, pyrimidinylo xyo xopyrro lidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, pyrimidinyloxy(hydroxy)(methyl)oxopyrrolidinyl and pyrimidinylaminohydroxyoxopyrrolidinyl. Examples for bicyclic saturated heterocyclic ring are azabicyclo[3.2.1]octyl, quinuclidinyl, oxaazabicyclo[3.2.1]octanyl, azabicyclo[3.3.1]nonanyl, oxaaza-bicyclo[3.3.1]nonanyl, azabicyclo[3.1.0]hexanyl, oxodiazaspiro[3.4]octanyl, acetyloxodiazaspiro[3.4]octanyl, thiaazabicyclo[3.3.1]nonanyl, oxoazaspiro[2.4]heptanyl, oxoazaspiro[3.4]octanyl, oxoazabicyclo[3.1.0]hexanyl and dioxotetrahydropyrrolo[1,2-a]pyrazinyl. Examples for partly unsaturated heterocyclyl include dihydrofuryl, imidazolinyl, dihydrooxazolyl, tetrahydropyridinyl, dioxopiperazinyl, oxoimidazolidinyl, trioxothiazinanyl and dihydropyranyl; partly unsaturated heterocyclyl can be further substituted by halogen, C 1-6 alkyl, C 1-6 alkylsulfonyl, examples for substituted partly unsaturated heterocyclyl include, but not limited to, methylimidazolidinyl, methylsulfonyloxoimidazolidinyl and dimethyloxooxazolidinyl.

[0025] The term "lactam" denotes a cyclic amide containing from 3 to 10 ring atoms which can comprise one, two or three atoms selected from nitrogen, oxygen and / or sulfur. Lactam can be mono-cyclic ring or bi-cyclic ring which can be further substituted by (C 1-6 alkyl) 2 aminocarbonyl, (C 1-6 alkyl) 2 morpholinylcarbonyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkyl, C 1-6 alkyl, C 1-6 alkyl(C 1-6 alkylsulfonyl)amino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylmorpholinylcarbonyl, C 1-6 alkyloxadiazolyl, C 1-6 alkyloazolyl, C 1-6 alkylpyrazolyl, C 1-6 alkylsulfonyl, C 1-6 alkylsulfonylamino, C 1-6 alkylsulfonylC 1-6 alkyl, cyano, dioxopyrrolidinyl, haloC 1-6 alkyl, haloC 1-6 alkyloxadiazolyl, halopiperidinylcarbonyl, halopyrimidinylamino, halopyrimidinyloxy, halopyrrolidinylcarbonyl, hydroxy, hydroxyazetidinylcarbonyl, hydroxyC 1-6 alkyl, hydroxyC 1-6 alkyl, hydroxyC 1-6 alkyl(C 1-6 alkyl)aminocarbonyl, hydroxyC 1-6 alkylaminocarbonyl, hydroxypyrrolidinylcarbonyl, morpholinylcarbonyl, oxadiazolyl, oxazolyl, oxazolylaminocarbonyl, oxazo lyl(C 1-6 alkyl)aminocarbonyl, oxazolylcarbonyl(C 1-6 alkyl)amino, oxomorpholinyl, oxooxazolidinyl, oxopyrrolidinyl, phenyl, pyrazolylC 1-6 alkyl, pyridinyl, pyrimidinyl, pyrimidinylamino, pyrimidinylC 1-6 alkylamino, pyrimidinyloxy, pyrimidinyloxyC 1-6 alkyl, pyrrolidinylcarbonyl and thiazolyl . Examples of lactam include, but not limited to, oxooxazinanyl, methyloxooxazinanyl, dimethyloxooxazinanyl, oxopyrrolidinyl, dimethyloxopyrrolidinyl, cyanooxopyrrolidinyl, hydroxyoxopyrrolidinyl, methoxyoxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, oxazo lyloxopyrrolidinyl, oxoazabicyclo[3.1.0]hexanyl, oxomorpholinyl, methyloxomorpholinyl, difluoropyrrolidinyloxopyrro lidinyl, dimethyloxooxazolidinyl, phenyl(hydroxy)oxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, pyrimidinyloxy(hydroxy)(methyl)oxopyrro lidinyl and pyrimidinylaminohydro xyoxopyrrolidinyl.

[0026] The term "diastereomer" denotes a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, activities and reactivities.

[0027] The term "enantiomers" denotes two stereoisomers of a compound which are non-superimposable mirror images of one another.

[0028] The term "pharmaceutically acceptable salts" denotes salts which are not biologically or otherwise undesirable. Pharmaceutically acceptable salts include both acid and base addition salts.

[0029] The term "pharmaceutically acceptable acid addition salt" denotes those pharmaceutically acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and organic acids selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, maloneic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicyclic acid.

[0030] The term "pharmaceutically acceptable base addition salt" denotes those pharmaceutically acceptable salts formed with an organic or inorganic base. Examples of acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Salts derived from pharmaceutically acceptable organic nontoxic bases includes salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, and polyamine resins.

[0031] Compounds of the general formula (I) which contain one or several chiral centers can either be present as racemates, diastereomeric mixtures, or optically active single isomers. The racemates can be separated according to known methods into the enantiomers. Particularly, diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid.INHIBITOR OF HBV

[0032] The present invention provides (i) novel compounds having the general formula (I), wherein R 1< is heterocyclyl, said heterocyclyl being unsubstituted or substituted with one, two or three substituents independently selected from (C 1-6 alkyl) 2 aminocarbonyl, (C 1-6 alkyl) 2 morpholinylcarbonyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkoxycarbonyl, C 1-6 alkyl, C 1-6 alkyl(C 1-6 alkylsulfonyl)amino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylimidazolyl, C 1-6 alkylmorpholinylcarbonyl, C 1-6 alkyloxadiazolyl, C 1-6 alkyloxazolyl, C 1-6 alkylpyrazolyl, C 1-6 alkylsulfonyl, C 1-6 alkylsulfonylamino, C 1-6 alkylsulfonylC 1-6 alkyl, carbamoyl, cyano, dioxopyrrolidinyl, haloC 1-6 alkyl, haloC 1-6 alkyloxadiazolyl, halogen, halopiperidinylcarbonyl, halopyridinyl, halopyrimidinylamino, halopyrimidinyloxy, halopyrrolidinylcarbonyl, hydroxy, hydroxyazetidinylcarbonyl, hydroxyC 1-6 alkyl, hydroxyC 1-6 alkyl(C 1-6 alkyl)aminocarbonyl, hydroxyC 1-6 alkylaminocarbonyl, hydroxypyrrolidinylcarbonyl, morpholinylcarbonyl, oxadiazolyl, oxazolyl, oxazolylaminocarbonyl, oxazolyl(C 1-6 alkyl)aminocarbonyl, oxazolylcarbonyl, oxazolylcarbonyl(C 1-6 alkyl)amino, oxomorpholinyl, oxooxazolidinyl, oxopyrrolidinyl, phenyl, phenylcarbonyl, pyrazolylC 1-6 alkyl, pyridinyl, pyrimidinyl, pyrimidinylamino, pyrimidinyl(C 1-6 alkyl)amino, pyrimidinyloxy, pyrimidinyloxyC 1-6 alkyl, pyrrolidinylcarbonyl and thiazolyl; heteroaryl, said heteroaryl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 1-6 alkyl ,haloC 1-6 alkyl, hydroxy C 1-6 alkyl and C 1-6 alkoxyC 1-6 alkyl; phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl, haloC 1-6 alkoxy and haloC 1-6 alkyl; or C 3-7 cycloalkyl; R 2< and R 3< are independently selected from hydrogen and C 1-6 alkyl; R 4< is heteroaryl, said heteroaryl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl and (C 1-6 alkyl) 2 amino; aryl, said aryl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 3-7 cycloalkyl, C 1-6 alkyl, C 2-6 alkynyl, C 1-6 alkoxy, haloC 1-6 alkyl and haloC 1-6 alkoxy; phenylC 1-6 alkyl, said phenylC 1-6 alkyl being unsubstituted or substituted with one, two or three halogen; or C 3-7 cycloalkyl; Y and Qare independently selected from CH and N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0033] A further embodiment of the present invention is (ii) a compound of formula (I), wherein R 1< is azabicyclo[3.1.0]hexanyl; dioxopiperazinyl; dioxopyrimidinyl; dioxotetrahydropyrrolo [1,2-a]pyrazinyl; morpholinyl, said morpholinyl being unsubstituted or substituted with one, two or three C 1-6 alkyl; oxaazabicyclo[3.2.1]octanyl; oxoazabicyclo[3.1.0]hexanyl; oxoazaspiro[2.4]heptanyl, said oxoazaspiro[2.4]heptanyl being unsubstituted or substituted with hydroxy; oxoazaspiro[4.4]nonanyl; oxoazaspiro[3.4]octanyl, said oxoazaspiro[3.4]octanyl being unsubstituted or substituted with hydroxy; oxodiazaspiro[3.4]octanyl, said oxodiazaspiro[3.4]octanyl being unsubstituted or substituted with one, two or three substituents independently selected from C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, oxazolylcarbonyl and pyrimidinyl; oxodihydropyrazolo[1,5-a]pyrazinyl; oxohexahydropyrimidinyl; oxoimidazolidinyl, said oxoimidazolidinyl being unsubstituted or substituted with one, two or three substituents independently selected from C 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, phenyl, phenylcarbonyl and pyrimidinyl; oxoindolinyl; oxoisoindolinyl; oxomorpholinyl, said oxomorpholinyl being unsubstituted or substituted with one, two or three substituents independently selected from C 1-6 alkyl and oxazolyl; oxooxaazaspiro[2.4]heptanyl; oxooxaazaspiro[3.4]octanyl; oxooxaazaspiro[4.4]nonanyl; oxooxaazaspiro[4.5] decanyl; oxooxazinanyl, said oxooxazinanyl being unsubstituted or substituted with one, two or three substituents independently selected from C 1-6 alkyl, C 1-6 alkoxy and morpholinylcarbonyl; oxooxazolidinyl, said oxooxazolidinyl being unsubstituted or substituted with one, two or three substituents independently selected from C 1-6 alkyl, phenyl, pyridinyl, halopyridinyl, oxazolyl, C 1-6 alkylimidazolyl and C 1-6 alkyloxadiazolyl; oxopiperidyl, said oxopiperidyl being unsubstituted or substituted with one, two or three substituents independently selected from C 1-6 alkyl and hydroxy; oxopyrrolidinyl, said oxopyrrolidinyl being unsubstituted or substituted with one, two or three substituents independently selected from (C 1-6 alkyl) 2 aminocarbonyl, (C 1-6 alkyl) 2 morpholinylcarbonyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkyl, C 1-6 alkyl(C 1-6 alkylsulfonyl)amino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylmorpholinylcarbonyl, C 1-6 alkyloxadiazolyl, C 1-6 alkyloazolyl, C 1-6 alkylpyrazolyl, C 1-6 alkylsulfonyl, C 1-6 alkylsulfonylamino, C 1-6 alkylsulfonylC 1-6 alkyl, cyano, dioxopyrrolidinyl, haloC 1-6 alkyl, haloC 1-6 alkyloxadiazolyl, halopiperidinylcarbonyl, halopyrimidinylamino, halopyrimidinyloxy, halopyrrolidinylcarbonyl, hydroxy, hydroxyazetidinylcarbonyl, hydroxyC 1-6 alkyl, hydroxyC 1-6 alkyl(C 1- alkyl)aminocarbonyl, hydroxyC 1-6 alkylaminocarbonyl, hydroxypyrrolidinylcarbonyl, morpholinylcarbonyl, oxadiazolyl, oxazolyl, oxazolylaminocarbonyl, oxazolyl(C 1-6 alkyl)aminocarbonyl, oxazolylcarbonyl(C 1-6 alkyl)amino, oxomorpholinyl, oxooxazolidinyl, oxopyrrolidinyl, phenyl, pyrazolylC 1-6 alkyl, pyridinyl, pyrimidinyl, pyrimidinylamino, pyrimidinylC 1-6 alkylamino, pyrimidinyloxy, pyrimidinyloxyC 1-6 alkyl, pyrrolidinylcarbonyl and thiazolyl; oxopyrrolo[3,2-c]pyridinyl; oxopyrrolo[3,4-b]pyridinyl; oxotetrahydrofuro[3,4-c]pyrrolyl; oxotetrahydroimidazo[5,1-c][1,4]oxazinyl; piperidinyl, said piperidinyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, hydroxy and C 1-6 alkylcarbonyl; pyrazolyl, said pyrazolyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 1-6 alkyl, hydroxyC 1-6 alkyl and C 1-6 alkoxyC 1-6 alkyl; pyridinyl, said pyridinyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 1-6 alkyl and haloC 1-6 alkyl; pyrimidinyl, said pyrimidinyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen and C 1-6 alkyl; pyrrolidinyl, said pyrrolidinyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, hydroxy, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy and C 1-6 alkoxyC 1-6 alkyl; tetrahydrofuranyl; thiazolyl, said thiazolyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen and haloC 1-6 alkyl; phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, hydroxy, C 3-7 cycloalkyl, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl and haloC 1-6 alkoxy;or C 3-7 cycloalkyl; R 2< and R 3< are independently selected from hydrogen and C 1-6 alkyl; R 4< is benzofuranyl; benzothiophenyl; benzoxazolyl; indolyl; C 1-6 alkylbenzothiazolyl; pyridinyl, said pyridinyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy, haloC 1-6 alkyl and (C 1-6 alkyl) 2 amino; bicyclo[4.2.0]octa-1(6),2,4-trienyl; indanyl; phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 3-7 cycloalkyl, C 1-6 alkyl, C 2-6 alkynyl, C 1-6 alkoxy, haloC 1-6 alkyl and haloC 1-6 alkoxy; phenylC 1-6 alkyl, said phenylC 1-6 alkyl being unsubstituted or substituted with one, two or three halogen; or C 3-7 cycloalkyl; Y and Qare independently selected from CH and N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Afurther embodiment of the present invention is (iii) a compound of formula (I), wherein R 1< is pyrazolyl substituted by halogen, cyano, C 1-6 alkyl, hydroxyC 1-6 alkyl or C 1-6 alkoxyC 1-6 alkyl; pyridinyl, said pyridinyl being unsubstituted or substituted with one or two substituents independently selected from halogen, cyano, C 1-6 alkyl and haloC 1-6 alkyl; pyrimidinyl substituted with one or two substituents independently selected from halogen and C 1-6 alkyl; thiazolyl, said thiazolyl being unsubstituted or substituted by halogen or haloC 1-6 alkyl; phenyl, said phenyl being unsubstituted or substituted with one or two substituents independently selected from halogen, cyano, hydroxy, C 3-7 cycloalkyl, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl and haloC 1-6 alkoxy; R 2< and R 3< are independently selected from hydrogen and C 1-6 alkyl with the proviso that R 2< and R 3< are not C 1-6 alkyl simultaneously; R 4< is benzothiophenyl; benzoxazolyl; indolyl; benzothiazolyl substituted by C 1-6 alkyl; pyridinyl, said pyridinyl being unsubstituted or substituted with one or two substituents independently selected from halogen, cyano, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy, haloC 1-6 alkyl and (C 1-6 alkyl) 2 amino; bicyclo[4.2.0]octa-1(6),2,4-trienyl; phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 3-7 cycloalkyl, C 1-6 alkyl, C 2-6 alkynyl, C 1-6 alkoxy, haloC 1-6 alkyl and haloC 1-6 alkoxy; phenylC 1-6 alkyl, said phenylC 1-6 alkyl being unsubstituted or substituted with one or two halogen; or C 3-7 cycloalkyl; Y and Qare independently selected from CH and N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Afurther embodiment of the present invention is (iv) a compound of formula (I), wherein R 1< is fluorophenyl, phenyl, chlorophenyl, trifluoromethylphenyl, cyanophenyl, methoxyphenyl, methylphenyl, difluorophenyl, fluorochlorophenyl, difluoromethylphenyl, methylfluorophenyl, cyclopropylphenyl, hydroxyphenyl, trifluoromethoxyphenyl, bromophenyl, methylpyrazolyl, cyanopyrazolyl, fluoropyrazolyl, hydroxymethylpyrazolyl, methoxymethylpyrazolyl, trifluoromethylpyridinyl, cyanopyridinyl, methylfluoropyridinyl, pyridinyl, chloropyridinyl, fluoropyridinyl, fluorochloropyridinyl, fluoropyrimidinyl, methylfluoropyrimidinyl, thiazolyl, trifluoromethylthiazolyl or chlorothiazolyl; R 2< and R 3< are independently selected from hydrogen and methyl with the proviso that R 2< and R 3< are not methyl simultaneously; R 4< is phenyl, trifluoromethylphenyl, fluorochlorophenyl, fluorophenyl, chlorophenyl, cyanophenyl, pyridinyl, methylfluoropyridinyl, fluorotrifluoromethylphenyl, trifluorophenyl, fluorochlorobenzyl, dichlorobenzyl, methylchloropyridinyl, methylbenzothiazolyl, benzothiophenyl, trifluoromethylpyridinyl, difluorophenyl, fluorocyanophenyl, indolyl, methylfluorophenyl, chloropyridinyl, cyanopyridinyl, chloromethoxypyridinyl, methyltrifluoromethylphenyl, chlorotrifluoromethylphenyl, chlorocyanophenyl, ethylphenyl, ethynylphenyl, isopropylphenyl, methoxyphenyl, ethynylfluorophenyl, dimethylpyridinyl, fluorobromophenyl, difluoromethoxyphenyl, fluorotrifluoromethoxyphenyl, difluoromethylphenyl, methylphenyl, difluorocyanophenyl, fluorochloropyridinyl, cyclopropylphenyl, methyldifluorophenyl, difluorochlorophenyl, cyclopropyldifluorophenyl, difluoroethylphenyl, cyclopropylfluorophenyl, methoxydifluorophenyl, benzyl, fluoropyridinyl, benzoxazolyl, methylpyridinyl, difluoropyridinyl, cyclopentyl, cyclohexyl, bicyclo[4.2.0]octa-1(6),2,4-trienyl, bromopyridinyl, cyclopropylpyridinyl, dimethylaminopyridinyl or difluoromethylpyridinyl; Y and Qare independently selected from CH and N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0034] A further embodiment of the present invention is (v) a compound of formula (I), wherein R 1< is phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, hydroxy, C 3-7 cycloalkyl, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl and haloC 1-6 alkoxy; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0035] A further embodiment of the present invention is (vi) a compound of formula (I), wherein R 1< is phenyl, bromophenyl, chlorophenyl, cyanophenyl, cyclopropylphenyl, difluorophenyl, difluoromethylphenyl, fluorophenyl, fluorochlorophenyl, fluoromethylphenyl, hydroxyphenyl, methoxyphenyl, methylphenyl, trifluoromethoxyphenyl or trifluoromethylphenyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0036] A further embodiment of the present invention is (vii) a compound of formula (I), wherein R 4< is phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C 3-7 cycloalkyl, C 1-6 alkyl, C 2-6 alkynyl, C 1-6 alkoxy, haloC 1-6 alkyl and haloC 1-6 alkoxy; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0037] A further embodiment of the present invention is (viii) a compound of formula (I), wherein R 4< is phenyl, chlorophenyl, chlorocyanophenyl, chlorotrifluoromethylphenyl, cyanophenyl, cyclopropylphenyl, difluorophenyl, difluoroethylphenyl, difluoromethoxyphenyl, difluoromethylphenyl, ethylphenyl, ethynylphenyl, fluorophenyl, fluorobromophenyl, fluorochlorophenyl, fluorocyanophenyl, fluorocyclopropylphenyl, fluoroethynylphenyl, difluorochlorophenyl, difluorocyanophenyl, difluorocyclopropylphenyl, methoxydifluorophenyl, methyldifluorophenyl, methylfluorophenyl, fluorotrifluoromethoxyphenyl, fluorotrifluoromethylphenyl, isopropylphenyl, methoxyphenyl, methylphenyl, methyltrifluoromethylphenyl, trifluorophenyl or trifluoromethylphenyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. A further embodiment of the present invention is (ix) a compound of formula (I), wherein R 1< is pyrazolyl substituted by halogen or hydroxyC 1-6 alkyl; pyridinyl substituted by halogen; pyrimidinyl substituted by halogen; phenyl substituted once or twice by halogen; R 1< is H; R 3< is H or C 1-6 alkyl; R 4< is pyridinyl substituted by haloC 1-5 alkyl; or phenyl substituted with one, two or three substituents independently selected from halogen and cyano; Y and Q are independently selected from CH and N, with proviso that Y and Q are not CH simultaneously; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. A further embodiment of the present invention is (x) a compound of formula (I), wherein R 1< is fluoropyrazolyl, hydroxymethylpyroazolyl, fluoropyridinyl, fluoropyrimidinyl, fluorophenyl or difluorophenyl; R 2< is H; R 3< is H or methyl; R 4< is difluoromethylpyridinyl, fluorochlorophenyl, fluorocyanophenyl or trifluorophenyl; Y and Q are independently selected from CH and N, with proviso that Y and Q are not CH simultaneously; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0038] In another embodiment of the present invention, particular compounds of the present invention are (xi) selected from: N-(3-cyano-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-fluoro-2-pyridyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 1-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluoropyrazol-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[2-(difluoromethyl)-4-pyridyl]-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5-fluoropyrimidin-2-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazo lo [1,5 -a]pyrazine-5 -carboxamide; and (6S)-3-[4-(hydroxymethyl)pyrazol-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0039] Another embodiment of present invention is (xii) a compound of formula (I), wherein R 1< is azabicyclo[3.1.0]hexanyl; morpholinyl, said morpholinyl being unsubstituted or substituted twice by C 1-6 alkyl; oxaazabicyclo[3.2.1]octanyl; piperidinyl, said piperidinyl being unsubstituted or substituted with one or two substituents independently selected from halogen, hydroxy and C 1-6 alkylcarbonyl; pyrrolidinyl, said pyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from halogen, cyano, hydroxy, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy and C 1-6 alkoxyC 1-6 alkyl; tetrahydrofuranyl; or C 3-7 cycloalkyl; R 1< is H; R 3< is H or C 1-6 alkyl; R 4< is benzofuranyl; pyridinyl, said pyridinyl being substituted with one or two substituents independently selected from halogen and haloC 1-6 alkyl; indanyl; phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano and C 1-6 alkyl; or phenylC 1-6 alkyl; Yis CH when Q is N; or Y is N when Q is CH; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Afurther embodiment of present invention is (xiii) a compound of formula (I), wherein R 1< is azabicyclo[3.1.0]hexanyl, cyclohexyl, cyclopentyl, morpholinyl, dimethylmorpholinyl, oxaazabicyclo[3.2.1]octanyl, piperidinyl, difluoropiperidinyl, hydroxypiperidinyl, acetylpiperidinyl, pyrrolidinyl, methylpyrrolidinyl, methoxymethylpyrrolidinyl, methoxypyrrolidinyl, trifluoromethylpyrrolidinyl, cyanopyrrolidinyl, methylhydroxypyrrolidinyl, difluoropyrrolidinyl or tetrahydrofuranyl; R 1< is H; R 3< is H or methyl; R 4< is benzofuranyl, indanyl, benzyl, phenyl, fluorochlorophenyl, fluorocyanophenyl, trifluorophenyl, methyldifluorophenyl, chloropyridinyl, fluorochloropyridinyl or trifluoromethylpyridinyl; Yis CH when Q is N; or Y is N when Q is CH; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0040] Another embodiment of present invention is (xiv) a compound of formula (I), wherein R 1< is dioxopiperazinyl; dioxopyrimidinyl dioxotetrahydropyrrolo[1,2-a]pyrazinyl; oxoazabicyclo[3 .1.0]hexanyl; oxoazaspiro[2.4]heptanyl, said oxoazaspiro[2.4]heptanyl being unsubstituted or substituted with hydroxy; oxoazaspiro[4.4]nonanyl; oxoazaspiro[3.4]octanyl, said oxoazaspiro[3.4]octanyl being unsubstituted or substituted with hydroxy; oxodiazaspiro[3.4]octanyl, said oxodiazaspiro[3.4]octanyl being substituted by C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, oxazolylcarbonyl or pyrimidinyl; oxodihydropyrazolo[1,5-a]pyrazinyl; oxohexahydropyrimidinyl; oxoimidazolidinyl, said oxoimidazolidinyl being unsubstituted or substituted with one or two substituents independently selected from C 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkylsulfonyl, phenyl, phenylcarbonyl and pyrimidinyl; oxoindolinyl; oxomorpholinyl, said oxomorpholinyl being unsubstituted or substituted with one or two substituents independently selected from C 1-6 alkyl and oxazolyl; oxooxaazaspiro[2.4]heptanyl; oxooxaazaspiro[3.4]octanyl; oxooxaazaspiro[4.4]nonanyl; oxooxaazaspiro[4.5]decanyl; oxooxazinanyl, said oxooxazinanyl being unsubstituted or substituted with one or two substituents independently selected from C 1-6 alkyl, C 1-6 alkoxy and morpholinylcarbonyl; oxooxazolidinyl, said oxooxazolidinyl being unsubstituted or substituted with one or two substituents independently selected from C 1-6 alkyl, phenyl, pyridinyl, halopyridinyl, oxazolyl, C 1-6 alkylimidazolyl and C 1-6 alkyloxadiazolyl; oxopiperidyl substituted by C 1-6 alkyl or hydroxy; oxopyrrolidinyl, said oxopyrrolidinyl being unsubstituted or substituted with one, two or three substituents independently selected from (C 1-6 alkyl) 2 aminocarbonyl, (C 1-6 alkyl) 2 morpholinylcarbonyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkyl, C 1-6 alkyl(C 1-6 alkylsulfonyl)amino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylmorpholinylcarbonyl, C 1-6 alkyloxadiazolyl, C 1-6 alkyloazolyl, C 1-6 alkylpyrazolyl, C 1-6 alkylsulfonyl, C 1-6 alkylsulfonylamino, C 1-6 alkylsulfonylC 1-6 alkyl, cyano, dioxopyrrolidinyl, haloC 1-6 alkyl, haloC 1-6 alkyloxadiazolyl, halopiperidinylcarbonyl, halopyrimidinylamino, halopyrimidinyloxy, halopyrrolidinylcarbonyl, hydroxy, hydroxyazetidinylcarbonyl, hydroxyC 1-6 alkyl, hydroxyC 1-6 alkyl, hydroxyC 1-6 alkyl(C 1-6 alkyl)aminocarbonyl, hydroxyC 1-6 alkylaminocarbonyl, hydroxypyrrolidinylcarbonyl, morpholinylcarbonyl, oxadiazolyl, oxazolyl, oxazolylaminocarbonyl, oxazolyl(C 1-6 alkyl)aminocarbonyl, oxazolylcarbonyl(C 1-6 alkyl)amino, oxomorpholinyl, oxooxazolidinyl, oxopyrrolidinyl, phenyl, pyrazolylC 1-6 alkyl, pyridinyl, pyrimidinyl, pyrimidinylamino, pyrimidinyl(C 1-6 alkyl)amino, pyrimidinyloxy, pyrimidinyloxyC 1-6 alkyl, pyrrolidinylcarbonyl and thiazolyl; oxopyrrolo[3,2-c]pyridinyl; oxopyrrolo[3,4-b]pyridinyl; oxotetrahydrofuro [3 ,4-c]pyrro lyl; oxotetrahydroimidazo[5,1-c][1,4]oxazinyl; R 2< and R 3< are independently selected from hydrogen and C 1-6 alkyl with the proviso that R 2< is not C 1-6 alkyl when R 3< is H; R 4< is pyridinyl substituted with one or two substituents independently selected from halogen and haloC 1-6 alkyl; phenyl substituted with one, two or three substituents independently selected from halogen and haloC 1-6 alkyl; Yis CH; Qis N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Afurther embodiment of present invention is (xv) a compound of formula (I), wherein R 1< is dioxopiperazinyl, dioxopyrimidinyl, dioxotetrahydropyrrolo[1,2-a]pyrazinyl, oxoazabicyclo[3.1.0]hexanyl, oxoazaspiro[2.4]heptanyl, hydroxy oxoazaspiro[2.4]heptanyl, oxoazaspiro[4.4]nonanyl, oxoazaspiro[3.4]octanyl, hydroxyoxoazaspiro[3.4]octanyl, acetyloxodiazaspiro[3.4]octanyl, methoxycarbonyloxodiazaspiro [3.4]octanyl, ethoxycarbonyloxodiazaspiro [3.4]octanyl, oxazolylcarbonyloxodiazaspiro[3.4]octanyl, pyrimidinyloxodiazaspiro[3.4]octanyl, oxodihydropyrazolo[1,5-a]pyrazinyl, oxohexahydropyrimidinyl, oxoimidazolidinyl, acetyloxoimidazolidinyl, benzoyloxoimidazolidinyl, dimethyloxoimidazolidinyl, methyloxoimidazolidinyl, methylsulfonyloxoimidazolidinyl, phenyloxoimidazolidinyl, pyrimidinyloxoimidazolidinyl, oxoindolinyl, oxoisoindolinyl, oxomorpholinyl, methyloxomorpholinyl, dimethyloxomorpholinyl, oxazolyloxomorpholinyl, oxooxaazaspiro[4.5]decanyl, oxooxaazaspiro[4.4]nonanyl, oxooxaazaspiro[2.4]heptanyl, oxooxaazaspiro[3.4]octanyl, oxooxazinanyl, methyloxooxazinanyl, dimethyloxooxazinanyl, methoxyoxooxazinanyl, morpholinylcarbonyl(methyl)oxooxazinanyl, oxooxazolidinyl, dimethyloxooxazolidinyl, chloropyridinyloxooxazolidinyl, fluoropyridinyloxooxazolidinyl, methyloxooxazolidinyl, methylimidazolyloxooxazolidinyl, methyloxadiazolyloxooxazolidinyl, oxazolyloxooxazolidinyl, phenyloxooxazolidinyl, pyridinyloxooxazolidinyl, hydroxyoxopiperidyl, methyloxopiperidyl, oxopyrrolidinyl, acetylaminooxopyrrolidinyl, cyanooxopyrrolidinyl, difluoropiperidinylcarbonyl(methyl)oxopyrrolidinyl, difluoropyrrolidinylcarbonyloxopyrrolidinyl, difluoropyrrolidinylcarbonyl(methyl)oxopyrrolidinyl, dihydroxyoxopyrrolidinyl, dimethyloxopyrrolidinyl,dimethylaminocarbonyloxopyrrolidinyl, dimethylmorpholinylcarbonyloxopyrrolidinyl, dioxopyrrolidinyloxopyrrolidinyl, ethyloxopyrrolidinyl, fluoropyrimidinylaminooxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, hydroxyoxopyrrolidinyl, hydroxyazetidinylcarbonyloxopyrrolidinyl, hydroxyethyl(methyl)aminocarbonyloxopyrrolidinyl, hydroxy(dimethyl)oxopyrrolidinyl, hydroxydimethylethylaminooxopyrrolidinyl, hydroxymethyloxopyrrolidinyl, hydroxy(methyl)cyanooxopyrrolidinyl, hydroxymethyl(cyano)oxopyrrolidinyl, hydroxymethylethyloxopyrrolidinyl, hydroxypyrrolidinylcarbonyloxopyrrolidinyl, methoxyoxopyrrolidinyl, methoxymethyloxopyrrolidinyl, methyloxopyrrolidinyl, methyl(methylsulfonyl)aminooxopyrrolidinyl, methylaminocarbonyloxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, methylmorpholinylcarbonyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, methyloxadiazolyl(methyl)oxopyrrolidinyl, methyloxazolyloxopyrrolidinyl, methylpyrazolyloxopyrrolidinyl, methylsulfonyloxopyrrolidinyl, methylsulfonylaminooxopyrrolidinyl, methylsulfonylmethyloxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, morpholinylcarbonyl(methyl)oxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, oxadiazolyl(methyl)oxopyrrolidinyl, oxazolyloxopyrrolidinyl, oxazolylaminocarbonyloxopyrrolidinyl, oxazolylcarbonyl(methyl)aminooxopyrrolidinyl, oxazo lyl(methyl)aminocarbonyloxopyrrolidinyl, oxomorpholinyloxopyrrolidinyl, oxooxazolidinyloxopyrrolidinyl, oxopyrrolidinyloxopyrrolidinyl, phenyloxopyrrolidinyl, phenyl(hydroxy)oxopyrrolidinyl, pyrazolylmethyloxopyrrolidinyl, pyridinyloxopyrrolidinyl, pyrimidinyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, pyrimidinyl(methyl)aminooxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, pyrimidinyloxy(hydroxy)(methyl)oxopyrrolidinyl, pyrimidinyloxymethyloxopyrrolidinyl, pyrrolidinylcarbonyloxopyrrolidinyl, thiazolyloxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, trifluoromethyloxadiazolyloxopyrrolidinyl, oxotetrahydrofuro[3,4-c]pyrrolyl, oxotetrahydroimidazo[5,1-c][1,4]oxazinyl, oxopyrrolo[3,4-b]pyridinyl or oxopyrrolo[3,2-c]pyridinyl; R 2< and R 3< are independently selected from hydrogen and methyl with the proviso that R 2< is not methyl when R 3< is H; R 4< is chloropyridinyl, difluoromethylpyridinyl, fluorochloropyridinyl, fluorodifluoromethylpyridinyl, trifluoromethylpyridinyl, difluorochlorophenyl, difluorodifluoromethylphenyl, fluorochlorophenyl, fluorotrifluoromethylphenyl, trifluorophenyl; Yis CH; Qis N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0041] A further embodiment of present invention is (xvi) a compound of formula (I), wherein R 1< is oxoazabicyclo[3.1.0]hexanyl; oxodiazaspiro[3.4]octanyl substituted by C 1-6 alkoxycarbonyl or pyrimidinyl; oxoimidazolidinyl; oxoindolinyl; oxomorpholinyl, said oxomorpholinyl being unsubstituted or substituted once or twice by C 1-6 alkyl; oxooxaazaspiro[2.4]heptanyl; oxooxaazaspiro[4.5]decanyl; oxooxazinanyl, said oxooxazinanyl being unsubstituted or substituted once or twice by C 1-6 alkyl; oxooxazolidinyl, said oxooxazolidinyl being unsubstituted or substituted twice by C 1-6 alkyl; oxopyrrolidinyl said oxopyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyloxadiazolyl, cyano, halopyrimidinyloxy, haloC 1-6 alkyl, hydroxy, hydroxyC 1-6 alkyl, morpholinylcarbonyl, oxadiazolyl, pyrimidinylamino, pyrimidinyloxy and pyrrolidinylcarbonyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0042] A further embodiment of present invention is (xvii) a compound of formula (I), wherein R 1< is oxoazabicyclo[3.1.0]hexanyl, methoxycarbonyloxodiazaspiro[3.4]octanyl, ethoxycarbonyloxodiazaspiro[3.4]octanyl, pyrimidinyloxodiazaspiro[3.4]octanyl, oxoimidazolidinyl, oxoindolinyl, oxomorpholinyl, dimethyloxomorpholinyl, oxooxaazaspiro[4.5]decanyl, oxooxaazaspiro[2.4]heptanyl, oxooxazinanyl, methyloxooxazinanyl, dimethyloxooxazinanyl, oxooxazolidinyl, dimethyloxooxazolidinyl, oxopyrrolidinyl, cyanooxopyrrolidinyl, hydroxyoxopyrrolidinyl, methoxyoxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, hydroxymethylcyanooxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, dimethylaminocarbonyloxopyrrolidinyl or pyrrolidinylcarbonyloxopyrrolidinyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0043] A further embodiment of present invention is (xviii) a compound of formula (I), wherein R 4< is pyridinyl substituted by haloC 1-6 alkyl; or phenyl substituted with two or three substituents independently selected from halogen and haloC 1-6 alkyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0044] A further embodiment of present invention is (xix) a compound of formula (I), wherein R 4< is difluoromethylpyridinyl, fluorochlorophenyl, difluorodifluoromethylphenyl or trifluorophenyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Afurther embodiment of present invention is (xx) a compound of formula (I), wherein R 1< is oxoazabicyclo[3.1.0]hexanyl; oxodiazaspiro[3.4]octanyl substituted with C 1-6 alkoxycarbonyl or pyrimidinyl; oxoimidazolidinyl; oxoindolinyl; oxomorpholinyl, said oxomorpholinyl being unsubstituted or substituted once or twice by C 1-6 alkyl; oxooxaazaspiro[2.4]heptanyl; oxooxaazaspiro[4.5]decanyl; oxooxazinanyl, said oxooxazinanyl being unsubstituted or substituted once ro twice by C 1-6 alkyl; oxooxazolidinyl, said oxooxazolidinyl being unsubstituted or substituted once or twice by C 1-6 alkyl; oxopyrrolidinyl said oxopyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyloxadiazolyl, cyano, halopyrimidinyloxy, haloC 1-6 alkyl, hydroxy, hydroxyC 1-6 alkyl, morpholinylcarbonyl, oxadiazolyl, pyrimidinylamino, pyrimidinyloxy and pyrrolidinylcarbonyl; R 2< is H; R 3< is H or C 1-6 alkyl; R 4< is pyridinyl substituted by haloC 1-6 alkyl; or phenyl substituted with two or three substituents independently selected from halogen and haloC 1-6 alkyl; Yis CH; Qis N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Afurther embodiment of present invention is (xxi) a compound of formula (I), wherein R 1< is oxoazabicyclo[3.1.0]hexanyl, methoxycarbonyloxodiazaspiro[3.4]octanyl, ethoxycarbonyloxodiazaspiro[3.4]octanyl, pyrimidinyloxodiazaspiro[3.4]octanyl, oxoimidazolidinyl, oxoindolinyl, oxomorpholinyl, dimethyloxomorpholinyl, oxooxaazaspiro[4.5]decanyl, oxooxaazaspiro[2.4]heptanyl, oxooxazinanyl, methyloxooxazinanyl, dimethyloxooxazinanyl, oxooxazolidinyl, dimethyloxooxazolidinyl, oxopyrrolidinyl, cyanooxopyrrolidinyl, hydroxyoxopyrrolidinyl, methoxyoxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, hydroxymethylcyanooxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, dimethylaminocarbonyloxopyrrolidinyl or pyrrolidinylcarbonyloxopyrrolidinyl; R 2< is H; R 3< is H or methyl; R 4< is difluoromethylpyridinyl, fluorochlorophenyl, difluorodifluoromethylphenyl or trifluorophenyl; Yis CH; Qis N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0045] In another embodiment of the present invention, particular compounds of the present invention are (xxii) selected from: N-(3-chloro-4-fluoro-phenyl)-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-hydroxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(3-oxomorpholin-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxooxazolidin-3-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-methoxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-3-azabicyclo[3.1.0]hexan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrimidin-2-ylamino)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-methyl-2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5,5-dimethyl-2-oxo-1,3-oxazinan-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-oxo-8-oxa-2-azaspiro[4.5]decan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-oxo-4-oxa-6-azaspiro[2.4]heptan-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; methyl 6-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate; ethyl 6-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate; (6S)-6-methyl-3-(7-oxo-2-pyrimidin-2-yl-2,6-diazaspiro[3.4]octan-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxoindolin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-cyano-4-(hydroxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-4-methyl-2-oxo-pyrrolidin-1-yl)-N-[3-(difluoromethyl)-4,5-difluorophenyl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(hydroxymethyl)-4-methyl-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(2,2-dimethyl-5-oxo-morpholin-4-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(2-oxoimidazolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4S)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-(5-fluoropyrimidin-2-yl)oxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(dimethylcarbamoyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrrolidine-1-carbonyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4R)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-cyano-2-methyl-5-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5-hydroxy-2-oxo-1,3-oxazinan-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; and (6S)-3-[(3S,4R)-3-hydroxy-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0046] Another embodiment of present invention is (xxiii) a compound of formula (I), wherein R 1< is oxopyrrolidinyl, said oxopyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from (C 1-6 alkyl) 2 aminocarbonyl, (C 1-6 alkyl) 2 morpholinylcarbonyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkyl, C 1-6 alkyl(C 1-6 alkylsulfonyl)amino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylmorpholinylcarbonyl, C 1-6 alkyloxadiazolyl, C 1-6 alkyloxazolyl, C 1-6 alkylpyrazolyl, C 1-6 alkylsulfonyl, C 1-6 alkylsulfonylamino, C 1-6 alkylsulfonylC 1-6 alkyl, cyano, dioxopyrrolidinyl, haloC 1-6 alkyl, haloC 1-6 alkyloxadiazolyl, halopiperidinylcarbonyl, halopyrimidinylamino, halopyrimidinyloxy, halopyrrolidinylcarbonyl, hydroxy, hydroxyazetidinylcarbonyl, hydroxyC 1-6 alkyl, hydroxyC 1-6 alkyl(C 1-6 alkyl)aminocarbonyl, hydroxyC 1-6 alkylaminocarbonyl, hydroxypyrrolidinylcarbonyl, morpholinylcarbonyl, oxadiazolyl, oxazolyl, oxazolylaminocarbonyl, oxazolyl(C 1-6 alkyl)aminocarbonyl, oxazolylcarbonyl(C 1-6 alkyl)amino, oxomorpholinyl, oxooxazolidinyl, oxopyrrolidinyl, phenyl, pyrazolylC 1-6 alkyl, pyridinyl, pyrimidinyl, pyrimidinylamino, pyrimidinyl(C 1-6 alkyl)amino, pyrimidinyloxy, pyrimidinyloxyC 1-6 alkyl, pyrrolidinylcarbonyl and thiazolyl; R 2< and R 3< are independently selected from hydrogen and C 1-6 alkyl with the proviso that R 2< is not C 1-6 alkyl when R 3< is H; R 4< is pyridinyl substituted with one or two substituents independently selected from halogen and haloC 1-6 alkyl; phenyl substituted with one, two or three substituents independently selected from halogen and haloC 1-6 alkyl; Yis CH; Qis N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0047] A further embodiment of present invention is (xxiv) a compound of formula (I), wherein R 1< is oxopyrrolidinyl, acetylaminooxopyrrolidinyl, cyanooxopyrrolidinyl, difluoropiperidinylcarbonyl(methyl)oxopyrrolidinyl, difluoropyrro lidinylcarbonylo xopyrro lidinyl, difluoropyrrolidinylcarbonyl(methyl)oxopyrrolidinyl, dihydroxyoxopyrrolidinyl, dimethyloxopyrrolidinyl, dimethylaminocarbonyloxopyrrolidinyl, dimethylmorpholinylcarbonyloxopyrrolidinyl, dioxopyrrolidinyloxopyrrolidinyl, ethyloxopyrrolidinyl, fluoropyrimidinylaminooxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, hydroxyoxopyrrolidinyl, hydroxyazetidinylcarbonyloxopyrrolidinyl, hydroxyethyl(methyl)aminocarbonyloxopyrrolidinyl, hydroxy(dimethyl)oxopyrrolidinyl, hydroxydimethylethylaminooxopyrrolidinyl, hydroxymethyloxopyrrolidinyl, hydroxy(methyl)cyanooxopyrrolidinyl, hydroxymethyl(cyano)oxopyrrolidinyl, hydroxymethylethyloxopyrrolidinyl, hydroxypyrrolidinylcarbonyloxopyrrolidinyl, methoxyoxopyrrolidinyl, methoxymethyloxopyrrolidinyl, methyloxopyrrolidinyl, methyl(methylsulfonyl)aminooxopyrrolidinyl, methylaminocarbonyloxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, methylmorpholinylcarbonyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, methyloxadiazolyl(methyl)oxopyrrolidinyl, methyloxazolyloxopyrrolidinyl, methylpyrazolyloxopyrrolidinyl, methylsulfonyloxopyrrolidinyl, methylsulfonylaminooxopyrrolidinyl, methylsulfonylmethyloxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, morpholinylcarbonyl(methyl)oxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, oxadiazolyl(methyl)oxopyrrolidinyl, oxazolyloxopyrrolidinyl, oxazolylaminocarbonyloxopyrrolidinyl, oxazolylcarbonyl(methyl)aminooxopyrrolidinyl, oxazolyl(methyl)aminocarbonyloxopyrrolidinyl, oxomorpholinyloxopyrrolidinyl, oxooxazolidinyloxopyrrolidinyl, oxopyrrolidinyloxopyrrolidinyl, phenyloxopyrrolidinyl, phenyl(hydroxy)oxopyrrolidinyl, pyrazolylmethyloxopyrrolidinyl, pyridinyloxopyrrolidinyl, pyrimidinyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, pyrimidinyl(methyl)aminooxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, pyrimidinyloxy(hydroxy)(methyl)oxopyrrolidinyl, pyrimidinyloxymethyloxopyrrolidinyl, pyrrolidinylcarbonyloxopyrrolidinyl, thiazolyloxopyrrolidinyl, trifluoromethyloxopyrrolidinyl or trifluoromethylo xadiazo lylo xopyrro lidinyl; R 2< and R 3< are independently selected from hydrogen and methyl with the proviso that R 2< is not methyl when R 3< is H; R 4< is chloropyridinyl, difluoromethylpyridinyl, fluorochloropyridinyl, trifluoromethylpyridinyl, difluorochlorophenyl, difluorodifluoromethylphenyl, fluorochlorophenyl, fluorotrifluoromethylphenyl or trifluorophenyl; Yis CH; Qis N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0048] A further embodiment of present invention is (xxv) a compound of formula (I), wherein R 1< is oxopyrrolidinyl, said oxopyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkoxy, C 1-6 alkyl, C 1-6 alkyloxadiazolyl, cyano, haloC 1-6 alkyl, halopyrimidinyloxy, hydroxy, hydroxyC 1-6 alkyl, morpholinylcarbonyl, oxadiazolyl, pyrimidinylamino, pyrimidinyloxy and pyrrolidinylcarbonyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0049] A further embodiment of present invention is (xxvi) a compound of formula (I), wherein R 1< is oxopyrrolidinyl, cyanooxopyrrolidinyl, hydroxyoxopyrrolidinyl, methoxyoxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, hydroxymethylcyanooxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, dimethylaminocarbonyloxopyrrolidinyl or pyrrolidinylcarbonyloxopyrrolidinyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0050] A further embodiment of present invention is (xxvii) a compound of formula (I), wherein R 2< is H; R 3< is H or C 1-6 alkyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0051] A further embodiment of present invention is (xxviii) a compound of formula (I), wherein R 2< is H; R 3< is H or methyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0052] A further embodiment of present invention is (xxix) a compound of formula (I), wherein R 4< is pyridinyl substituted by haloC 1-6 alkyl; or phenyl substituted with one, two or three substituents independently selected from halogen and haloC 1-6 alkyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0053] A further embodiment of present invention is (xxx) a compound of formula (I), wherein R 4< is difluoromethylpyridinyl, fluorochlorophenyl, difluorodifluoromethylphenyl or trifluorophenyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Afurther embodiment of present invention is (xxxi) a compound of formula (I), wherein R 1< is oxopyrrolidinyl, said oxopyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkoxy, C 1-6 alkyl, C 1-6 alkyloxadiazolyl, cyano, haloC 1-6 alkyl, halopyrimidinyloxy, hydroxy, hydroxyC 1-6 alkyl, morpholinylcarbonyl, oxadiazolyl, pyrimidinylamino, pyrimidinyloxy and pyrrolidinylcarbonyl; R 1< is H; R 3< is H or C 1-6 alkyl; R 4< is pyridinyl substituted by haloC 1-6 alkyl; or phenyl substituted with one, two or three substituents independently selected from halogen and haloC 1-6 alkyl; Yis CH; Qis N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0054] A further embodiment of present invention is (xxxii) a compound of formula (I), wherein R 1< is oxopyrrolidinyl, cyanooxopyrrolidinyl, hydroxyoxopyrrolidinyl, methoxyoxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, hydroxymethylcyanooxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, dimethylaminocarbonyloxopyrrolidinyl or pyrrolidinylcarbonyloxopyrrolidinyl; R 1< is H; R 3< is H or C 1-6 alkyl; R 4< is difluoromethylpyridinyl, fluorochlorophenyl, difluorodifluoromethylphenyl or trifluorophenyl; Yis CH; Qis N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0055] In another embodiment of the present invention, particular compounds of the present invention are (xxxiii) selected from: N-(3-chloro-4-fluoro-phenyl)-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-hydroxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-methoxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrimidin-2-ylamino)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-cyano-4-(hydroxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-4-methyl-2-oxo-pyrrolidin-1-yl)-N-[3-(difluoromethyl)-4,5-difluorophenyl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(hydroxymethyl)-4-methyl-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4S)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-(5-fluoropyrimidin-2-yl)oxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(morpholine-4-carbonyl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(dimethylcarbamoyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrrolidine-1-carbonyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4R)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-cyano-2-methyl-5-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; and (6S)-3-[(3S,4R)-3-hydroxy-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0056] The present invention provides (xxxiv) novel compounds having the general formula (I), wherein R 1< is heterocyclyl, said heterocyclyl being unsubstituted or substituted with one to three substituents independently selected from C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkylaminocarbonyl, C 1-6 alkylsulfonyl, halogen, cyano, hydroxy, oxadiazolyl and oxazolyl; heteroaryl, said heteroaryl being unsubstituted or substituted with one to three substituents independently selected from halogen, cyano, C 1-6 alkyl and haloC 1-6 alkyl; phenyl, said phenyl being unsubstituted or substituted with one to three substituents independently selected from halogen, cyano, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl, haloC 1-6 alkoxy and haloC 1-6 alkyl; or C 3-7 cycloalkyl; R 2< and R 3< are independently selected from hydrogen and C 1-6 alkyl; R 4< is heterocyclyl, said heterocyclyl being unsubstituted or substituted with one to three substituents independently selected from halogen and C 1-6 alkyl; heteroaryl, said heteroaryl being unsubstituted or substituted with one to three substituents independently selected from halogen, cyano, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl and (C 1-6 alkyl) 2 amino; aryl, said aryl being unsubstituted or substituted with one to three substituents independently selected from halogen, cyano, C 3-7 cycloalkyl, C 1-6 alkyl, C 2-6 alkynyl, C 1-6 alkoxy, haloC 1-6 alkyl and haloC 1-6 alkoxy; phenylC 1-6 alkyl, said phenylC 1-6 alkyl being unsubstituted or substituted with halogen; or C 3-7 cycloalkyl; Y and Qare independently selected from CH and N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0057] A further embodiment of the present invention is (xxxv) a compound of formula (I), wherein R 1< is heterocyclyl, said heterocyclyl being unsubstituted or substituted with one to three substituents independently selected from C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl, cyano, hydroxy, C 1-6 alkylsulfonyl and oxazolyl; heteroaryl, said heteroaryl being unsubstituted or substituted with one to three substituents independently selected from halogen, cyano, haloC 1-6 alkyl and C 1-6 alkyl; phenyl, said phenyl being unsubstituted or substituted with one to three halogen; or C 3-7 cycloalkyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0058] A further embodiment of the present invention is (xxxvi) a compound of formula (I), wherein R 1< is oxopyrrolidinyl, dimethyloxopyrrolidinyl, cyanooxopyrrolidinyl, hydroxyo xopyrro lidinyl, methoxyo xopyrro lidinyl, trifluoromethylo xopyrro lidinyl, oxazolyloxopyrrolidinyl, azabicyclo[3.1.0]hexanyl, oxoazabicyclo[3.1.0]hexanyl, oxomorpholinyl, methyloxomorpholinyl, oxooxazolidinyl, dimethyloxooxazolidinyl, dimethyloxoimidazolidinyl, methylsulfonyloxoimidazolidinyl, trioxothiazinanyl, fluoropyrimidinyl, trifluoromethylpyridinyl, methylfluoropyridinyl, fluoropyridinyl, methylpyrazolyl, cyanopyrazolyl, fluoropyrazolyl, fluorophenyl, difluorophenyl, cyclopentyl or cyclohexyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0059] A further embodiment of the present invention is (xxxvii) a compound of formula (I), wherein R 4< is phenyl, said phenyl being unsubstituted or substituted with one to three substituents independently selected from halogen, cyano, C 3-7 cycloalkyl, C 1-6 alkyl, haloC 1-6 alkyl and C 2-6 alkynyl; or pyridinyl, said pyridinyl being unsubstituted or substituted with one to three substituents independently selected from halogen, C 1-6 alkyl and haloC 1-6 alkyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0060] A further embodiment of the present invention is (xxxviii) a compound of formula (I), wherein R 4< is fluorophenyl, chlorophenyl, fluorochlorophenyl, fluorotrifluoromethylphenyl, trifluorophenyl, fluorocyanophenyl, methylfluorophenyl, ethynylfluorophenyl, cyclopropylfluorophenyl, methyldifluorophenyl, difluorochlorophenyl, difluoromethyldifluorophenyl, fluoropyridinyl, chloropyridinyl, methylpyridinyl or difluoromethylpyridinyl;or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0061] Another embodiment of the present invention is (xxxix) a compound of formula (I), wherein Y and Q are independently selected from CH and N, provided that Y and Q are not CH simultaneously;or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0062] Another embodiment of the present invention is (xl) a compound of formula (I), wherein R 1< is oxopyrrolidinyl, oxomorpholinyl or oxooxazolidinyl, said oxopyrrolidinyl, oxomorpholinyl and oxooxazolidinyl being unsubstituted or substituted with one to three substituents independently selected from C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, cyano, oxazolyl and hydroxy; pyridinyl, pyrimidinyl or pyrazolyl, said pyridinyl, pyrimidinyl or pyrazolyl being unsubstituted or substituted with one to three substituents independently selected from halogen and cyano; phenyl, said phenyl being unsubstituted or substituted with halogen; or C 3-7 cycloalkyl; R 2< and R 3< are independently selected from hydrogen and C 1-6 alkyl; R 4< is phenyl or pyridinyl, said phenyl or pyridinyl being unsubstituted or substituted with one to three substituents independently selected from halogen, cyano and haloC 1-6 alkyl; or C 3-7 cycloalkyl; Y and Q are independently selected from CH and N, provided that Y and Q are not CH simultaneously; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0063] Another embodiment of the present invention is (xli) a compound of formula (I), wherein R 1< is oxopyrrolidinyl, cyanooxopyrrolidinyl, hydroxyoxopyrrolidinyl, methoxyoxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, oxomorpholinyl, methyloxomorpholinyl, oxazolyloxopyrrolidinyl, oxooxazolidinyl, fluoropyrimidinyl, fluoropyridinyl, cyanopyrazolyl, fluoropyrazolyl, fluorophenyl, difluorophenyl or cyclopentyl; R 2< and R 3< are independently selected from hydrogen and methyl; R 4< is fluorochlorophenyl, fluorocyanophenyl, trifluorophenyl, difluoromethyldifluorophenyl, difluoromethylpyridinyl; Y and Q are independently selected from CH and N, provided that Y and Q are not CH simultaneously; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

[0064] In another embodiment, the present invention provides novel compounds having the general formula (I), wherein R 1< is heterocyclyl, said heterocyclyl being unsubstituted or substituted with cyano; heteroaryl, said heteroaryl being unsubstituted or substituted independently with one, two or three halogen; phenyl, said phenyl being unsubstituted or substituted independently with one, two or three halogen; or lactam, said lactam being unsubstituted or substituted with cyano; R 2< and R 3< are independently selected from hydrogen and C 1-6 alkyl; R 4< is phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen and cyano; or pyridinyl, said pyridinyl being unsubstituted or substituted with haloC 1-6 alkyl; Y and Q are independently selected from C and N; or pharmaceutically acceptable salts, enantiomers or diastereomers thereof.

[0065] Another embodiment of present invention is a compound of formula (I), wherein R 1< is fluorophenyl, difluorophenyl, fluoropyrimidinyl, morpholinyl, oxopyrrolidinyl, cyanooxopyrrolidinyl or oxomorpholinyl; R 2< and R 3< are independently selected from hydrogen and methyl; R 4< is fluorochlorophenyl, cyanofluorophenyl, trifluorophenyl or difluoromethylpyridinyl; Y and Q are independently selected from C and N; or pharmaceutically acceptable salts, enantiomers or diastereomers thereof.

[0066] A further embodiment of present invention is a compound of formula (I), wherein R 1< is phenyl, said phenyl being unsubstituted or substituted independently with one, two or three halogen; pyrimidinyl, said pyrimidinyl being unsubstituted or substituted independently with one, two or three halogen; morpholinyl; or lactam, said lactam being unsubstituted or substituted with cyano; or pharmaceutically acceptable salts, enantiomers or diastereomers thereof.

[0067] In another embodiment of the present invention, compounds of the present invention are selected from: 3-(4-fluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N,3-diphenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-fluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-chlorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-fluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-chlorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[2-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 1-(4-fluorophenyl)-N-phenyl-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 3-(4-fluorophenyl)-N-phenyl-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-[3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-8-(4-fluorophenyl)-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carboxamide; N-(2-fluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N,3-bis(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chlorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyanophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(4-chlorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-cyanophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-fluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(4-chloro-3-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(4-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(4-cyanophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-methoxyphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-cyclopentyl-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-methoxyphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-cyano-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chlorophenyl)-3-(2-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chlorophenyl)-3-(o-tolyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(5-fluoro-6-methyl-2-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-fluorophenyl)-N-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chlorophenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chlorophenyl)-3-(2,3-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-cyano-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-chloro-2-fluoro-phenyl)-N-(3-chlorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-chloro-2-fluoro-phenyl)-N-(3-chlorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chlorophenyl)-3-(2,5-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-[3-(difluoromethyl)phenyl]-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-fluoro-6-methyl-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-fluoro-4-methyl-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-(2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide+H31; N-phenyl-3-thiazol-2-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[4-(trifluoromethyl)thiazol-2-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-chlorothiazol-2-yl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3,4-difluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(6-chloro-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluoro-3-methyl-phenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[(3-chloro-4-fluoro-phenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[(3,5-dichlorophenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(4-chloro-5-methyl-2-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-chloro-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[(2-chloro-3-fluoro-phenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[(2,6-dichlorophenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-(5-fluoro-6-methyl-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(2-methyl-1,3-benzothiazol-5-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(benzothiophen-3-yl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-cyclopropylphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-hydroxyphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-4-methyl-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-[4-(trifluoromethyl)-2-pyridyl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N,3-bis(3-chloro-4-fluoro-phenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-cyclohexyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(5-fluoro-4-methyl-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-fluoro-2-pyridyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(1H-indol-6-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(4-fluoro-3-methyl-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-cyclopentyl-N-indan-5-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-cyclopentyl-N-indan-1-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-benzyl-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-pyrrolidin-1-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-6-methyl-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4,4-difluoro-1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-thiazol-2-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3,3-difluoro-1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-3-cyclopentyl-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-cyano-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-6-methoxy-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-fluoro-2-pyridyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6R)-N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(benzofuran-6-yl)-3-cyclopentyl-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-5-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[3-chloro-5-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3,4-difluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-cyano-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3,5-difluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[4-chloro-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-ethylphenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-ethynylphenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(3-isopropylphenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(3-methoxyphenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[2-(trifluoromethoxy)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-chloro-4-fluoro-phenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(m-tolyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-bromophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-ethynyl-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-5-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2,6-dimethyl-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-1-(4-fluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-bromo-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[3-(difluoromethoxy)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[3-(difluoromethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(m-tolyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[3-(trifluoromethoxy)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 1-(2,4-difluorophenyl)-N-(3-ethynyl-4-fluoro-phenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-chloro-4-fluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-cyano-4-fluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-cyano-4,5-difluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 1-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 3-(2,4-difluorophenyl)-N-(3-ethynyl-4-fluoro-phenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(6-chloro-5-fluoro-2-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyclopropylphenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(6-chloro-5-fluoro-2-pyridyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3,4-difluoro-5-methyl-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4,5-difluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyclopropyl-4,5-difluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[3-(1,1-difluoroethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-chloro-5-fluoro-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2-chloro-5-fluoro-4-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyclopropyl-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 1-(2,4-difluorophenyl)-N-[2-(trifluoromethyl)-4-pyridyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide; N-(6-chloro-5-fluoro-2-pyridyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide; N-(3,4-difluoro-5-methyl-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyclopropyl-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4,5-difluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3,4-difluoro-5-methoxy-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyclopropyl-4,5-difluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(6-chloro-5-fluoro-2-pyridyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-1-cyclopentyl-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 1-cyclopentyl-N-(3,4,5-trifluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 1-cyclopentyl-N-(3,4-difluoro-5-methyl-phenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-cyclopropyl-4,5-difluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3,4-difluoro-5-methoxy-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3,4-difluoro-5-methyl-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2-methylpyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-morpholino-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-methylpyrazol-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-benzyl-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(2-fluoro-4-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-(2-fluoro-4-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(1,3-benzoxazol-6-yl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(2-methyl-4-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2,6-difluoro-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-(5-fluoro-4-methyl-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-cyclopentyl-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-cyclohexyl-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-tetrahydrofuran-3-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(4-bicyclo[4.2.0]octa-1(6),2,4-trienyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoropyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-4-methyl-pyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-6-methyl-N-(2-methyl-4-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-methylpyrazol-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-6-methyl-3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-bromo-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-2-methyl-4-pyridyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-(5-fluoro-2-methyl-4-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(5-chloro-2-methyl-4-pyridyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[(2-chloro-3-fluoro-phenyl)methyl]-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-(5-fluoro-6-methyl-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5-fluoro-2-pyridyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(4-methylpyrazol-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-cyanopyrazol-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluoropyrazol-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[4-fluoro-3-(trifluoromethyl)phenyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-cyclopentyl-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-cyclopentyl-6-methyl-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(6-chloro-5-fluoro-2-pyridyl)-3-cyclopentyl-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-cyclopropyl-4-pyridyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-[2-(dimethylamino)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-[2-(methoxymethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-[3-(methoxymethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3-methoxypyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4,4-dimethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-[3-(trifluoromethyl)pyrrolidm-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3-cyanopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-azabicyclo[3.1.0]hexan-3-yl)-N-(3-chloro-4-fluoro-phenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3-hydroxy-3-methyl-pyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,2-dimethylmorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[2-(difluoromethyl)-4-pyridyl]-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3-methyl-5-oxo-morpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(3,3-difluoropyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-[trans-2,6-dimethylmorpholin-4-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-[cis-2,6-dimethylmorpholin-4-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-hydroxy-1-piperidyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-methyl-2-oxo-imidazolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-7-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4,5-difluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-hydroxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(3-oxomorpholin-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(1-acetyl-4-piperidyl)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4,5-difluoro-phenyl)-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-[4-(methylcarbamoyl)-2-oxo-pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxooxazolidin-3-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-methoxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(2-acetyl-7-oxo-2,6-diazaspiro[3.4]octan-6-yl)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-methyl-5-oxo-morpholin-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,5-dioxopiperazin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4,4-dimethyl-2-oxo-imidazolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(3,6-dioxo-4,7,8,8a-tetrahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(4-oxazol-5-yl-2-oxo-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(3-methylsulfonyl-5-oxo-imidazolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S,7S)-6,7-dimethyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(6-oxo-5-azaspiro[2.4]heptan-5-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-3-azabicyclo[3.1.0]hexan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(4-methyl-2-oxo-pyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(3-hydroxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4,4-dimethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-(4,4-dimethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(2-chloro-4-pyridyl)-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S,7R)-6,7-dimethyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(3S)-3-hydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(6-chloro-5-fluoro-2-pyridyl)-3-(4,4-dimethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(3R)-3-hydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[6-(difluoromethyl)-5-fluoro-2-pyridyl]-6-methyl-3-(3-oxo-2-azaspiro[4.4]nonan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-(3-oxo-2-azaspiro[4.4]nonan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrimidin-2-yloxymethyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrazol-1-ylmethyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrimidin-2-ylamino)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[(5-fluoropyrimidin-4-yl)amino]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S,7S)-6,7-dimethyl-3-(2-oxoimidazolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S,7S)-6,7-dimethyl-3-(3-oxomorpholin-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-benzoyl-5-oxo-imidazolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[6-(difluoromethyl)-5-fluoro-2-pyridyl]-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-methyl-2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(2,4-dioxo-1H-pyrimidin-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(2,4-dioxopyrimidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-oxo-3-pyrimidin-2-yl-imidazolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-(5-fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[5-(1-methylimidazol-2-yl)-2-oxo-oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-thiazol-5-yl-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-thiazol-2-yl-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxohexahydropyrimidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5,5-dimethyl-2-oxo-1,3-oxazinan-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-[4-(methoxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-oxo-8-oxa-2-azaspiro[4.5]decan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-methyl-2-oxo-pyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-[4-(hydroxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(methoxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(methoxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(4-oxo-3,3a,6,6a-tetrahydro-1H-furo[3,4-c]pyrrol-5-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-ethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(8-oxo-2-oxa-7-azaspiro[4.4]nonan-7-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(4-methylsulfonyl-2-oxo-pyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-hydroxy-2-oxo-1-piperidyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(methylsulfonylmethyl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-[[methyl(methylsulfonyl)amino]methyl]-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxopyrrolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-phenyl-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(1-hydroxy-1-methyl-ethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-acetamido-2-oxo-pyrrolidin-1-yl)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-[4-(methanesulfonamido)-2-oxo-pyrrolidin-1-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-[4-[methyl(methylsulfonyl)amino]-2-oxo-pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(2,5-dioxopyrrolidin-1-yl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(2-oxopyrrolidin-1-yl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-methyl-N-[1-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-5-oxo-pyrrolidin-3-yl]oxazole-5-carboxamide; N-methyl-N-[1-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-5-oxo-pyrrolidin-3-yl]oxazole-4-carboxamide; N-methyl-N-[1-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-5-oxo-pyrrolidin-3-yl]oxazole-2-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(2-oxooxazolidin-3-yl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(3-oxomorpholin-4-yl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(5-methyl-2-oxo-oxazolidin-3-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[5,1-c][1,4]oxazin-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[5,1-c][1,4]oxazin-2-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(2-chloro-4-pyridyl)-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(4-methyl-2-oxo-imidazolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4R)-2-oxo-4-phenyl-oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4S)-2-oxo-4-phenyl-oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-phenyl-imidazolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4,4-dimethyl-2-oxo-imidazolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-oxo-4-oxa-6-azaspiro[2.4]heptan-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(6-oxo-5-oxa-7-azaspiro[3.4]octan-7-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; methyl 6-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate; ethyl 6-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate; (6S)-6-methyl-3-(5-methyl-2-oxo-pyrrolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-(oxazole-2-carbonyl)-7-oxo-2,6-diazaspiro[3.4]octan-6-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(7-oxo-2-pyrimidin-2-yl-2,6-diazaspiro[3.4]octan-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxoindolin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(1-oxoisoindolin-2-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-oxo-7H-pyrrolo[3,4-b]pyridin-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5-fluoropyrimidin-2-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(hydroxymethyl)pyrazol-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(methoxymethyl)pyrazol-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-5-phenyl-oxazolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-5-(2-pyridyl)oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-5-(4-pyridyl)oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-5-(3-pyridyl)oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-oxazol-4-yl-2-oxo-oxazolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(2-methyloxazol-5-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(2-methyloxazol-4-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(3-pyridyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(4-oxazol-4-yl-2-oxo-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(2-pyridyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(4-pyridyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-methyl-2-oxo-1-piperidyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-cyano-4-(hydroxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-4-methyl-2-oxo-pyrrolidin-1-yl)-N-[3-(difluoromethyl)-4,5-difluorophenyl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(hydroxymethyl)-4-methyl-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-[methyl(pyrimidin-2-yl)amino]-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxooxazolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(2-chloro-4-pyridyl)-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxoimidazolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(2,2-dimethyl-5-oxo-morpholin-4-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(3S)-3-methyl-5-oxo-morpholin-4-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(2-oxoimidazolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-acetyl-5-oxo-imidazolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-(2,2-dimethyl-5-oxo-morpholin-4-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-hydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-hydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-[(4S)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4S)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-(5-fluoropyrimidin-2-yl)oxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[2-hydroxyethyl(methyl)carbamoyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[(2-hydroxy-1,1-dimethyl-ethyl)carbamoyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(morpholine-4-carbonyl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[(3S)-3-hydroxypyrrolidine-1-carbonyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[(3R)-3-hydroxypyrrolidine-1-carbonyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(3-hydroxyazetidine-1-carbonyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(dimethylcarbamoyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrrolidine-1-carbonyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(oxazol-2-ylcarbamoyl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(2,2-dimethylmorpholine-4-carbonyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-[(2R)-2-methylmorpholine-4-carbonyl]-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-[(2S)-2-methylmorpholine-4-carbonyl]-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[trans-2,6-dimethylmorpholine-4-carbonyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[cis-2,6-dimethylmorpholine-4-carbonyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(3,3-difluoropyrrolidine-1-carbonyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-[methyl(oxazol-2-yl)carbamoyl]-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(3,3-difluoropyrrolidine-1-carbonyl)-4-methyl-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(4,4-difluoropiperidine-1-carbonyl)-4-methyl-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-methyl-4-(morpholine-4-carbonyl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-methyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-methyl-4-(1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-methyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(2S)-2-oxazol-5-yl-5-oxo-morpholin-4-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[5-(6-chloro-3-pyridyl)-2-oxo-oxazolidin-3-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[5-(5-fluoro-2-pyridyl)-2-oxo-oxazolidin-3-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[5-(6-fluoro-2-pyridyl)-2-oxo-oxazolidin-3-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(1-methylpyrazol-4-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-pyrimidin-5-yl-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[(5-fluoropyrimidin-2-yl)amino]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4R)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(3R,4R)-3,4-dihydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-hydroxy-4,4-dimethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-3H-pyrrolo[3,2-c]pyridin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(6-oxo-4,7-dihydropyrazolo[1,5-a]pyrazin-5-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-cyano-2-methyl-5-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5-hydroxy-2-oxo-1,3-oxazinan-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(7-oxo-6-azaspiro[3.4]octan-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(8-hydroxy-7-oxo-6-azaspiro[3.4]octan-6-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(7-hydroxy-6-oxo-5-azaspiro[2.4]heptan-5-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(6-methyl-2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(4-methyl-2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(3S,4R)-3,4-dihydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(3S,4R)-3-hydroxy-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[5-methyl-5-(morpholine-4-carbonyl)-2-oxo-1,3-oxazinan-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(2R,3R,4S)-4-hydroxy-2-methyl-5-oxo-3-pyrimidin-2-yloxy-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-pyrimidin-2-yl-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-hydroxy-2-oxo-4-phenyl-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(5S)-5-methoxy-2-oxo-1,3-oxazinan-3-yl]-6-methyl-N-(3,4,5trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; and (6S)-3-[(5R)-5-methoxy-2-oxo-1,3-oxazinan-3-yl]-6-methyl-N-(3,4,5trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.SYNTHESIS

[0068] The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R 1< to R 4< are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.

[0069] R 5< and R 6< are independently selected from H, C 1-6 alkyl, heterocyclyl, C 3-7 cycloalkyl, C 1-6 alkylcarbonyl, heterocyclylcarbonyl and C 3-7 cycloalkylcarbonyl; or R 5< and R 6< together with the nitrogen atom they are attached to form a 3-7 membered heterocyclyl, such as, but not limited to, pyrrolidinyl, piperidinyl, oxopyrrolidinyl, morpholinyl and oxomorpholinyl. R 7< is aryl or heteroaryl.

[0070] As depicted in Scheme 1, the synthesis of compounds of the present invention started from bicycle II, which was treated with iodinating reagents, such as N-iodosuccinimide, to give iodide III. Bicycle II was brominated with suitable brominating reagents, such as NBS, to give corresponding bromide, which was used in following reactions exemplified with iodide III. Palladium catalyzed Suzuki-Miyaura reaction between iodide III and boronic acid R 7< -B(OH) 2 affords intermediate V (Buchwald, S. L. et al. Acc Chem Res. 2008, 41, 1461). Intermediated V was prepared from boronic acid pinacol ester IV and desired halide, R 1< -halide, while boronic acid pinacol ester IV was prepared according to a known procedure (Bethel, P. A. et al. Tetrahedron 2012, 68, 5434) by reacting iodide III with Grignard reagent, such as iPrMgCl, and boronic ester, such as iPrOBPin. Deprotection of intermediate V in acidic conditions, such as HCl in EtOAc and TFA in DCM, followed by urea formation with amine R 4< NH 2 in the presence of a phosgene equivalent, such as triphosgene and carbonyldiimidazole, affords final compound VI. In the aforementioned urea formation reaction, a suitable isocyanate or phenyl carbamate was used (Padiya, K. J. et al. Org Lett. 2012, 14, 2814 and references cited therein). On the other hand, copper catalyzed coupling reaction of iodide III with amine or amide R 5< R 6< NH afforded intermediate VII, which is then converted into final compound VIII by employing suitable urea formation methods mentioned above.

[0071] R 7< is aryl or heteroaryl.

[0072] Alternatively, compound VI was prepared according to synthetic route depicted in Scheme 2. That is, iodide III is first converted into urea IX by employing suitable urea formation methods mentioned above. Urea IX then reacted with boronic acid R 7< -B(OH) 2 to give compound VI in the presence of palladium catalyst, or was converted to boronic ester X by known procedure mentioned above. Suzuki-Miyaura reaction of X with desired halide afforded compound VI.

[0073] This invention also relates to a process for the preparation of a compound of formula (I) comprising the reaction of: (a) the reaction of a compound of formula (V), with an acid followed by urea formation with amine R 4< NH 2 in the presence of a phosgene equivalent; (b) the reaction of a compound of formula (VII), with an acid followed by urea formation with amine R 4< NH 2 in the presence of a phosgene equivalent; (c) the reaction of a compound of formula (IX), with R 7< -B(OH) 2; (d) the reaction of a compound of formula (X), with halide via Suzuki-Miyaura reaction; or wherein R2, R3, R4 are defined above; R5 and R6 are independently selected from H, C1-6alkyl, C1-6heteroalkyl, C3-6cycloalkyl, C1-6alkylcarbonyl, C1-6heteroalkylcarbonyl, C3-6cycloalkylcarbonyl and C3-6heterocycloalkylcarbonyl; or R5 and R6 together with the nitrogen atom they are attached to form a 3-7 membered heterocyclyl, such as, but not limited to, pyrrolidinyl, piperidinyl, oxopyrrolidinyl, morpholinyl and oxomorpholinyl; R7 is aryl or heteroaryl.

[0074] In step (a) and (b), the acid can be for example HCl in EtOAc and TFA in DCM; phosgene equivalent can be for example triphosgene and carbonyldiimidazole.

[0075] In step (d), the halide can be R 7< -halide.

[0076] A compound of formula (I) when manufactured according to the above process is also an object of the invention.PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION

[0077] Another embodiment provides pharmaceutical compositions or medicaments containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments. In one example, compounds of formula (I) may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form. The pH of the formulation depends mainly on the particular use and the concentration of compound, but preferably ranges anywhere from about 3 to about 8. In one example, a compound of formula (I) is formulated in an acetate buffer, at pH 5. In another embodiment, the compounds of formula (I) are sterile. The compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.

[0078] Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The "effective amount" of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to the suppression of serum HBV DNA levels, or HBeAg seroconversion to HBeAb, or HBsAg loss, or normalization of alanine aminotransferase levels and improvement in liver histology. For example, such amount may be below the amount that is toxic to normal cells, or the mammal as a whole.

[0079] In one example, the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.01 to 100 mg / kg, alternatively about 0.1 to 20 mg / kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg / kg / day. In another embodiment, oral unit dosage forms, such as tablets and capsules, contain from about 0.1 to about 1000 mg of the compound of the invention.

[0080] The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.

[0081] The compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.

[0082] A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C., et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).

[0083] An example of a suitable oral dosage form is a tablet containing about 0.1 mg to 1000 mg of the compound of the invention compounded with about 30 mg to 90 mg anhydrous lactose, about 5 mg to 40 mg sodium croscarmellose, about 5 mg to 30 mg polyvinylpyrrolidone (PVP) K30, and about 1 mg to 10 mg magnesium stearate. The powdered ingredients are first mixed together and then mixed with a solution of the PVP. The resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment. An example of an aerosol formulation can be prepared by dissolving the compound, for example 5 mg to 400 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired. The solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants.

[0084] An embodiment, therefore, includes a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. In a further embodiment includes a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.INDICATIONS AND METHODS OF TREATMENT

[0085] The compounds of the invention can inhibit HBV's DNA synthesis and reduce HBV DNA levels. Accordingly, the compounds of the invention are useful for the treatment or prophylaxis of HBV infection.

[0086] The invention relates to the use of a compound of formula (I) for the treatment or prophylaxis of HBV infection.

[0087] The use of a compound of formula (I) for the preparation of medicaments useful in the treatment or prophylaxis diseases that are related to HBV infection is an object of the invention.

[0088] The invention relates in particular to the use of a compound of formula (I) for the preparation of a medicament for the treatment or prophylaxis of HBV infection.

[0089] Another embodiment includes a method for the treatment or prophylaxis of HBV infection which method comprises administering an effective amount of a compound of formula (I), a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof.EXAMPLES

[0090] The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.

[0091] Abbreviations used herein are as follows: DIPEA:N,N-diisopropylethylamine DCM:dichloromethane EA or EtOAc:ethyl acetate EC 50 :half maximal effective concentration EDCI:1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HATU:1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate HOBT:hydroxybenzotriazole HPLC:high performance liquid chromatography iPrOBPin:2-isopropyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane LCMSliquid chromatography-mass spectrometry min(s):minute(s) MS:mass spectrometry MsCl:methanesulfonyl chloride NBS:N-bromosuccinimide NIS:N-iodosuccinimide PE:petroleum ether prep-HPLC:preparative high performance liquid chromatography prep-TLC:preparative thin layer chromatography SFC:supercritical fluid chromatography TEA:triethylamine pgRNA:pre-genomic RNA qPCR:quantitative polymerase chain reaction v / vvolume ratio General Experimental Conditions

[0092] Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SP1 system and the Quad 12 / 25 Cartridge module, ii) ISCO combi-flash chromatography instrument. Silica gel brand and pore size: i) KP-SIL 60 Å, particle size: 40-60 µm ; ii) CAS registry NO: Silica Gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore: 200-300 or 300-400.

[0093] Intermediates and final compounds were purified by preparative HPLC on reversed phase column using XBridge™ Prep-C18 (5 µm, OBDTM 30 × 100 mm) column or SunFire™ Prep-C18 (5 µm, OBD™ 30 × 100 mm) column. Waters AutoP purification System (Column: XBridge™ Prep-C18, 30 × 100 mm, Sample Manager 2767, Pump 2525, Detector: Micromass ZQ and UV 2487, solvent system: acetonitrile and 0.1% ammonium hydroxide in water). For SFC chiral separation, intermediates were separated by chiral column (Daicel chiralpak IC, 5 µm, 30 × 250 mm) using Mettler Toledo SFC-Multigram III system, solvent system: 95% CO 2 and 5% IPA (0.5% TEA in IPA), back pressure 100bar, detection UV@ 254nm.

[0094] LC / MS spectra of compounds were obtained using a LC / MS (Waters™ Alliance 2795-Micromass ZQ), LC / MS conditions were as follows (running time 6 mins): Acidic condition: A: 0.1% ibrmic acid in H 2 O; B: 0.1% formic acid in acetonitrile; Basic condition: A: 0.1% NH 3 H 2 O in H 2 O; B: acetonitrile; Neutral condition: A: H 2 O; B: acetonitrile.

[0095] Mass spectra (MS): generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion (MH) +< .

[0096] NMR Spectra were obtained using Bruker Avance 400 MHz.

[0097] The microwave assisted reactions were carried out in a Biotage Initiator Sixty microwave synthesizer.

[0098] All reactions involving air-sensitive reagents were performed under an argon atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted.

[0099] The following examples are intended to illustrate the meaning of the present invention but should by no means represent a limitation within the meaning of the present invention:PREPARATIVE EXAMPLES

[0100] The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.Example 1: 3-(4-fluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0101]

[0102] The title compound was prepared according to the following scheme: Step 1: preparation of tert-butyl N-(2-hydroxyethyl)-N-(1H-pyrazol-5-ylmethyl)carbamate (compound 1b)

[0103] To a solution of 1H-pyrazole-5-carbaldehyde (compound 1a, 54.0 g, 562.5 mmol) in MeOH (300 mL) was added 2-aminoethanol (41.2 g, 675 mmol), and the reaction mixture was stirred at 25 °C for 1 hour. NaBH 4 (25.9 g, 675.0 mmol) was then added at 0 °C and the reaction mixture was stirred for another 1 hour. H 2 O (300 mL) and Boc 2 O (147.1 g, 675.0 mmol) were added to the reaction mixture, then the resulting mixture was stirred at room temperature for 12 hours, and extracted with EtOAc (600 mL). The organic layer was dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by column chromatography (eluting with 20%∼50% EtOAc in petroleum ether) to afford compound 1b (80 g) as a colorless oil. LCMS (M+H +< ): 320.Step 2: preparation of 2-[tert-butoxycarbonyl(1H-pyrazol-5-ylmethyl)amino]ethyl methanesulfonate (compound 1c)

[0104] To a solution of tert-butyl N-(2-hydroxyethyl)-N-(1H-pyrazol-5-ylmethyl)carbamate (compound 1b, 80.0 g, 117.2 mmol) and Et 3 N (100.5 g, 995.6 mmol) in DCM (800 mL) was added MsCl (57.3 g, 497.8 mmol) slowly at 0 °C. The resulting mixture was stirred at room temperature for 2 hours, washed with water (500 mL), brine (500 mL) and dried over Na 2 SO 4 . The organic layer was concentrated to afford compound 1c (100 g, crude), which was used directly in next step.Step 3: preparation of tert-butyl 6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 1d)

[0105] To a solution of 2-[tert-butoxycarbonyl(1H-pyrazol-5-ylmethyl)amino]ethyl methanesulfonate (compound 1c, 100.0 g, 313.4 mmol) in DMF (1000 mL) was added NaH (15.0 g, 376.2 mmol) in portions at 0 °C. The resulting mixture was stirred at room temperature for 12 hours, poured into water (2000 mL) and extracted with EtOAc (1000 mL) twice. The combined organic layer was dried over Na 2 SO 4 , and then concentrated to afford compound Id (18.0 g). LCMS (M+H +< ): 224.Step 4: preparation of tert-butyl 3-iodo-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 1e)

[0106] To a solution of tert-butyl 6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 1d, 3.3 g, 14.8 mmol) in CH 3 CN (40 mL) was added NIS (5.0 g, 22.1 mmol) slowly. The reaction mixture was stirred at room temperature for 16 hours and then diluted with EtOAc (50 mL), and washed with brine (50 mL). The organic layer was dried over Na 2 SO 4 and concentrated. The residue was purified by column chromatography (eluting with 10%∼80% EtOAc in petroleum ether) to afford compound 1e (4.8 g) as a white solid. LCMS (M+H +< ): 350. 1< H NMR (400 MHz, chloroform-d) δ ppm 7.53 (s, 1 H), 4.53 (br, 2 H), 4.20 (t, J = 5.27 Hz, 2 H), 3.89 (t, J=5.14 Hz, 2 H), 1.53 (s, 9 H).Step 5: preparation of 3-iodo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 1f)

[0107] A solution of tert-butyl 3-iodo-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 1e, 4.2 g, 12 mmol) in HCl / MeOH (30 mL) was stirred at room temperature for 3 hours. The reaction mixture was concentrated to afford compound 1f (4 g) in HCl salt as a slight yellow solid. LCMS (M+H +< ): 250.Step 6: preparation of 3-iodo-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (compound 1h)

[0108] To a solution of 3-iodo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 1f, 4 g, 14 mmol) in DCM (40 mL) was added isocyanatobenzene (2.5 g, 21 mmol) and Et 3 N (4.25 g, 42 mmol). The reaction mixture was stirred at room temperature for 1 hour, and then concentrated in vacuo. The residue was purified by column chromatography (eluting with 20%∼50% EtOAc in petroleum ether) to afford compound 1h as a white solid (4.8 g). LCMS (M+H +< ): 369.Step 7: preparation of 3-(4-fluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 1):

[0109] To a solution of 3-iodo-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (compound 1h, 0.1 g, 0.3 mmol) in dioxane / water (10 mL, 10:1, v / v) were added (4-fluorophenyl)boronic acid (40 mg, 0.3 mmol), Pd(PPh 3 ) 4 (10 mg, 0.1 mmol) and Cs 2 CO 3 (195 mg, 0.6 mmol). The reaction mixture was stirred at 70 °C for 16 hours under nitrogen and then concentrated in vacuo to afford the crude product, which was purified by prep-HPLC to afford Example 1 as a white solid. LCMS (M+H +< ): 337. 1< H NMR (400MHz, chloroform-d) δ ppm 7.70 (s, 1H), 7.40 - 7.30 (m, 6H), 7.17 - 7.08 (m, 3H), 6.45 (br. s, 1H), 4.88 (s, 2H), 4.37 (t, J=5.3 Hz, 2H), 4.05 (t, J=5.4 Hz, 2H).Example 2: N,3-diphenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0110] Preparation of Example 2:

[0111] The title compound was prepared in analogy to the preparation of Example 1 by using phenylboronic acid instead of (4-fluorophenyl)boronic acid. Example 2 was obtained as a white solid (30 mg). LCMS (M+H +< ): 319. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.90 (s, 1H), 7.85 (s, 1H), 7.51-7.38 (m, 6H), 7.30-7.20 (m, 3H), 6.97 (m, 1H), 4.95 (s, 2H), 4.24 (m, 2H), 4.01 (m, 2H).Example 3: 3-(3-fluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0112] Preparation of Example 3:

[0113] The title compound was prepared in analogy to the preparation of Example 1 by using (3-fluorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 3 was obtained as a white solid. LCMS (M+H +< ): 337. 1H NMR (400MHz, chloroform-d) δ ppm 7.75 (s, 1H), 7.46 - 7.31 (m, 5H), 7.18 - 6.97 (m, 4H), 6.47 (s, 1H), 4.91 (s, 2H), 4.37 (t, J=5.3 Hz, 2H), 4.06 (t, J=5.4 Hz, 2H).Example 4: 3-(3-chlorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0114] Preparation of Example 4:

[0115] The title compound was prepared in analogy to the preparation of Example 1 by using (3-chlorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 4 was obtained as a white solid. LCMS (M+H +< ): 353. 1< H NMR (400MHz, chloroform-d) δ ppm 7.75 (s, 1H), 7.41 - 7.29 (m, 7H), 7.25 (d, J=7.5 Hz, 1H), 7.13 (d, J=6.8 Hz, 1H), 6.48 (s, 1H), 4.91 (s, 2H), 4.38 (t, J=5.3 Hz, 2H), 4.06 (t, J=5.4 Hz, 2H).Example 5: N-phenyl-3-[3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0116] Preparation of Example 5:

[0117] The title compound was prepared in analogy to the preparation of Example 1 by using (3-trifluorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 5 was obtained as a white solid. LCMS (M+H +< ): 387. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.89 (s, 1H), 7.79 - 7.71 (m, 2H), 7.69 - 7.56 (m, 2H), 7.38 (d, J=8.0 Hz, 2H), 7.29 (t, J=7.9 Hz, 2H), 7.11 - 7.03 (m, 1H), 6.47 (s, 1H), 5.03 (s, 2H), 4.33 (t, J=5.4 Hz, 2H), 4.12 (t, J=5.3 Hz, 2H).Example 6: 3-(2-fluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0118] Preparation of Example 6:

[0119] The title compound was prepared in analogy to the preparation of Example 1 by using (2-fluorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 6 was obtained as a white solid. LCMS (M+H +< ): 337. 1< H NMR (400MHz, chloroform-d) ppm 7.76 (s, 1H), 7.35 (m, 6H), 7.26 - 7.16 (m, 2H), 7.11 (t, J=6.9 Hz, 1H), 6.47 (s, 1H), 4.81 (s, 2H), 4.40 (t, J=5.4 Hz, 2H), 4.09 (t, J=5.4 Hz, 2H).Example 7: 3-(2-chlorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0120] Preparation of Example 7:

[0121] The title compound was prepared in analogy to the preparation of Example 1 by using (2-chlorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 7 was obtained as a white solid . LCMS (M+H +< ): 353. 1< H NMR (400MHz, chloroform-d) δ ppm 7.70 (s, 1H), 7.55 - 7.49 (m, 1H), 7.38 - 7.29 (m, 7H), 7.11 (d, J=5.8 Hz, 1H), 6.45 (br. s, 1H), 4.74 (s, 2H), 4.42 (t, J=5.3 Hz, 2H), 4.09 (t, J=5.3 Hz, 2H).Example 8: N-phenyl-3-[2-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0122] Preparation of Example 8:

[0123] The title compound was prepared in analogy to the preparation of Example 1 by using (2-trifluorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 8 was obtained as a white solid . LCMS (M+H +< ): 387. 1< H NMR (400MHz, chloroform-d) δ ppm 7.81 (d, J=7.5 Hz, 1H), 7.64 - 7.50 (m, 3H), 7.36 - 7.29 (m, 5H), 7.10 (s, 1H), 6.33 (s, 1H), 4.59 (s, 2H), 4.39 (t, J=5.4 Hz, 2H), 4.06 (t, J=5.5 Hz, 2H).Example 9: 1-(4-fluorophenyl)-N-phenyl-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide

[0124]

[0125] The title compound was prepared according to the following scheme: Step 1: preparation of tert-butyl 6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxylate (compound 9b)

[0126] To a solution of 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 9a, 3.7 g, 30 mmol) and DIPEA (11.6 g, 90 mmol) in DCM (50 mL) was added Boc 2 O (7.2 g, 33 mmol) at 0 °C. The resulting mixture was stirred at room temperature for 12 hours, and then concentrated and purified by column chromatography (eluting with 30%∼100% EtOAc in petroleum ether) to afford compound 9b (4.7 g) as a white solid. LCMS (M+H +< ): 224.Step 2: preparation of tert-butyl 1-iodo-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxylate (compound 9c)

[0127] To a solution of tert-butyl 6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxylate a]pyrazine (compound 9b, 4.6 g, 21 mmol) in CH 3 CN (50 mL) was added NIS (5.6 g, 2.5 mmol) and then the reaction mixture was stirred at room temperature for 48 hours and then concentrated and the residue was purified by column chromatography (eluting with 10%∼80% EtOAc in petroleum ether) to afford compound 9c (5 g) as a yellow solid. LCMS (M+H +< ): 350.Step 3: preparation of tert-butyl 1-(4-fluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxylate (compound 9d)

[0128] To a mixture of tert-butyl 1-iodo-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxylate (compound 9c, 1.1 g, 3 mmol), (4-fluorophenyl)boronic acid (630 mg, 4.5 mmol) and K 2 CO 3 (1.2 g, 9 mmol) in dioxane / water (10 mL, 5:1, v / v) was added Pd(PPh 3 ) 4 (150 mg, 0.015 mmol) under N 2 . The reaction mixture was stirred at 80 °C for 12 hours, and then concentrated. The residue was purified by column chromatography (eluting with 10%∼50% EtOAc in petroleum ether) to afford compound 9d (550 mg). LCMS (M+H +< ): 318.Step 4: preparation of 1-(4-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 9e)

[0129] A solution of tert-butyl 1-(4-fluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxylate (compound 9d, 550 mg, 1.7 mmol) in HCl / MeOH (20 mL) was stirred at room temperature for 2 hours. Then the reaction mixture was concentrated in vacuo to afford compound 9e (400 mg) as a slight yellow solid, which was used directly without further purification in next step. LCMS (M+H +< ): 236.Step 5: preparation of 1-(4-fluorophenyl)-N-phenyl-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide (Example 9)

[0130] To a solution of 1 -(4-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 9e, 88 mg, 0.4 mmol) and Et 3 N (204 mg, 2.0 mmol) in DCM (5 mL) was added isocyanatobenzene (96 mg, 0.8 mmol) and then the reaction mixture was stirred at room temperature for 30 min. The solvent was removed in vacuo and the residue was purified by prep-HPLC to afford 1-(4-fluorophenyl)-N-phenyl-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide (Example 9, 20 mg) as a white solid. LCMS (M+H +< ): 337. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.85 (s, 1H), 7.75 (s, 1H), 7.71 - 7.62 (m, 2H), 7.48 - 7.44 (m, 2H), 7.29 - 7.22 (m, 4H), 7.04 - 6.92 (m, 1H), 4.95 (s, 2H), 4.18 - 4.14 (m, 2H), 3.92 - 3.88 (m, 2H).Example 10: 3-(4-fluorophenyl)-N-phenyl-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide

[0131]

[0132] The title compound was prepared according to the following scheme: Step 1: preparation of tert-butyl 6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxylate (compound 10b)

[0133] To a solution of 4,5,6,7-tetrahydrotriazolo[1,5-a]pyrazine (compound 10a, 3.7 g, 30 mmol) and DIPEA (11.6 g, 90 mmol) in DCM (50 mL) was added Boc 2 O (7.2 g, 33 mmol) at 0 °C, and the reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was concentrated and the residue purified by column chromatography (eluting with 30%∼100% EtOAc in petroleum ether) to afford compound 10b (4.7 g) as a white solid. LCMS (M+H +< ): 225.Step 2: preparation of tert-butyl 3-bromo-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxylate (compound 10c)

[0134] To a solution of tert-butyl 6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxylate (compound 10b, 4.6 g, 21 mmol) in CH 3 CN (50 mL) was added N-bromosuccinimide (NBS, 5.6 g, 2.5 mmol) and then the reaction mixture was stirred at room temperature for 48 hours. The reaction mixture was concentrated and the residue was purified by column chromatography (eluting with 10%∼80% EtOAc in petroleum ether) to afford compound 10c (5 g) as a yellow solid. LCMS (M+H +< ): 351.Step 3: preparation of tert-butyl 3-(4-fluorophenyl)-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxylate (compound 10d)

[0135] To a mixture of tert-butyl 3-bromo-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxylate (compound 10c, 1.1 g, 3 mmol), (4-fluorophenyl)boronic acid (630 mg, 4.5 mmol) and K 2 CO 3 (1.2 g, 9 mmol) in dioxane / water (10 mL, 5:1, v / v) was added Pd(PPh 3 ) 4 (150 mg) under N 2 . The reaction mixture was stirred at 80 °C for 16 hours. Then the reaction was concentrated and the residue was purified by column chromatography (eluting with 10%∼50% EtOAc in petroleum ether) to afford compound 10d (550 mg). LCMS (M+H +< ): 319.Step 4: preparation of 3-(4-fluorophenyl)-4,5,6,7-tetrahydrotriazolo[1,5-a]pyrazine (compound 10e)

[0136] A solution of tert-butyl 3-(4-fluorophenyl)-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxylate (compound 10d, 550 mg, 1.7 mmol) in HCl / MeOH (20 mL) was stirred at room temperature for 2 hours. Then the reaction mixture was concentrated in vacuo to afford compound 10e (400 mg) as a slight yellow solid. LCMS (M+H +< ): 219.Step 5: preparation of 3-(4-fluorophenyl)-N-phenyl-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide (Example 10)

[0137] The title compound was prepared in analogy to the preparation of Example 9 by using 3-(4-fluorophenyl)-4,5,6,7-tetrahydrotriazolo[1,5-a]pyrazine (compound 10e ) instead of 1-(4-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 9e ). Example 10 was obtained as a white solid (45 mg). LCMS (M+H +< ): 338. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.92 (s, 1H), 7.83 - 7.76 (m, 2H), 7.46 (d, J=7.5 Hz, 2H), 7.36 (t, J=8.8 Hz, 2H), 7.27 (t, J=7.9 Hz, 2H), 7.03 - 6.96 (m, 1H), 5.05 (s, 2H), 4.51 (t, J=5.3 Hz, 2H), 4.03 (t, J=5.3 Hz, 2H).Example 11: 3-(4-fluorophenyl)-N-[3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0138]

[0139] The title compound was prepared according to the following scheme: Step 1: preparation of tert-butyl 3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 11a)

[0140] To a mixture of tert-butyl 3-iodo-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 1e, 1.1 g, 3 mmol), (4-fluorophenyl)boronic acid (630 mg, 4.5 mmol) and K 2 CO 3 (1.2 g, 9 mmol) in and dioxane / water (10 mL, 5:1, v / v) was added Pd(PPh 3 ) 4 (150 mg) under N 2 . The reaction mixture was stirred at 80 °C for 2 hours. Then the reaction was concentrated and the residue was purified by column chromatography to afford compound 11a (550 mg) as a slight yellow solid. LCMS (M+H +< ): 318.Step 2: preparation of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b)

[0141] A solution of tert-butyl 3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 11a, 550 mg, 1.7 mmol) in HCl / MeOH (20 mL) was stirred at room temperature for 2 hours. Then the reaction mixture was concentrated in vacuo to afford compound 11b (400 mg) as a slight yellow solid. LCMS (M+H +< ): 218.Step 3: preparation of N-(2-fluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 11)

[0142] To a mixture of 3-(trifluoromethyl)aniline (64 mg) and DIPEA (0.1 mL) in DCM (5 mL) was added triphosgene (36 mg). After stirring for 10 min at room temperature, 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b, 50 mg) was added to the reaction mixture. The resulting mixture was stirred at room temperature for 12 hours, then diluted with EtOAc (10 mL), washed with water (5 mL) and brine (5 mL). The organic layer was concentrated and the residue was purified by prep-HPLC to afford Example 11 (50 mg) as a white solid. LCMS (M+H +< ): 405. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.21 (s, 1H), 7.90 (s, 1H), 7.84 (s, 1H), 7.74 (d, J=8.0 Hz, 1H), 7.54 - 7.46 (m, 3H), 7.35 - 7.22 (m, 3H), 4.95 (s, 2H), 4.24 (t, J=5.0 Hz, 2H), 4.02 (t, J=5.1 Hz, 2H).Example 12: N-(3-chloro-4-fluoro-phenyl)-8-(4-fluorophenyl)-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carboxamide

[0143]

[0144] The title compound was prepared according to the following scheme: Step 1: preparation of 3-(4-fluorophenyl)-1H-pyrrole-2-carboxylic acid (compound 12b):

[0145] To a solution of 8-(4-fluorophenyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine (compound 12a, 2.9 g, 12.4 mmol) (for its synthesis, refer to: Liu, J. et al, Angew Chem Int. Ed., 2013, 52, 6953) in MeOH (13.5 mL) were added sequentially H 2 O (4.5 mL) and NaOH (750 mg, 18.6 mmol). The reaction mixture was stirred at 75 °C for 5 hours, then cooled down, quenched by adding ice-water, neutralized to pH 6.0 with 1.0 N HCl solution in methanol, extracted with EtOAc / THF (60 mL, 5 / 2, v / v). The organic layer was dried over Na 2 SO 4 , filtered and concentrated to give compound 12b (2.5 g) as a crude product, which was used directly in next step. LCMS (M+H +< ): 206.Step 2: preparation of N-benzyl-3-(4-fluorophenyl)-N-(2-hydroxyethyl)-1H-pyrrole-2-carboxamide (compound 12c):

[0146] To a solution of 3-(4-fluorophenyl)-1H-pyrrole-2-carboxylic acid (compound 12b, 2.5 g, 12.4 mmol) in DMF (10 mL) were added 2-(benzylamino)ethanol (2.3 g, 15.0 mmol), EDCI (3.1 g, 16.1 mmol), HOBt (0.5 g, 3.7 mmol) and DIPEA (3.0 mL). The reaction mixture was stirred at room temperature overnight, quenched by adding ice-water, then extracted with EtOAc (60 mL). The organic layer was dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by column chromatography (eluting with 40%∼60% EtOAc in petroleum ether) to afford compound 12c (3.0 g) as a white solid. LCMS (M+H +< ): 339.Step 3: preparation of N-benzyl-N-(2-chloroethyl)-3-(4-fluorophenyl)-1H-pyrrole-2-carboxamide (compound 12d):

[0147] To a solution of N-benzyl-3-(4-fluorophenyl)-N-(2-hydroxyethyl)-1H-pyrrole-2-carboxamide (compound 12c, 676 mg, 2.0 mmol) in dioxane (8.0 mL) was added dropwise thionyl chloride (435 µL, 6.0 mmol). The resulting mixture was stirred at room temperature for 2 hours, and then quenched by adding ice-water, extracted with EtOAc / petroleum ether (50 mL, 1 / 1, v / v) twice. The organic layer was dried over Na 2 SO 4 , filtered and concentrated to give crude compound 12d (712 mg) which was used directly in next step. LCMS (M+H +< ): 357.Step 4: preparation of 2-benzyl-8-(4-fluorophenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1-one (compound 12e):

[0148] To a solution of N-benzyl-N-(2-chloroethyl)-3-(4-fluorophenyl)-1H-pyrrole-2-carboxamide (compound 12d, 712 mg, 2.0 mmol) in dry THF (10 mL) was added sodium hydride (60% dispersion in mineral oil, 120 mg, 3.0 mmol). The reaction mixture was stirred at room temperature for 1 hour, diluted with THF (50 mL), and quenched with sodium sulfate decahydrate. The resulting mixture was stirred at room temperature for 1 hour, then filtered and concentrated. The residue was purified by column chromatography (eluting with 25%∼35% EtOAc in petroleum ether) to afford compound 12e (512 mg) as a white solid. LCMS (M+H +< ): 321.Step 5: preparation of 2-benzyl-8-(4-fluorophenyl)-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine (compound 12f):

[0149] A solution of 2-benzyl-8-(4-fluorophenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1-one (compound 12e, 96 mg, 0.3 mmol) in THF (2.0 mL) was added lithium aluminum hydride (12 mg, 0.3 mmol) and stirred at room temperature for 1 hour. The reaction mixture was diluted with THF (30 mL), quenched by adding sodium sulfate decahydrate. The resulting mixture was stirred at room temperature for 1 hour, then filtered and concentrated to give crude compound 12f (92 mg) which was used directly in next step. LCMS (M+H +< ): 307.Step 6: preparation of 8-(4-fluorophenyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine (compound 12h):

[0150] To a solution of 2-benzyl-8-(4-fluorophenyl)-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine (compound 12f, 640 mg, 2.0 mmol) in EtOH (20 mL) was added palladium hydroxide (20% on carbon, wetted with ca. 50% water, 0.5 g). The reaction mixture was heated to reflux under 1 atm. H 2 overnight. After cooled to room temperature, the reaction mixture was filtered and concentrated to give crude compound 12h (432 mg) which was used directly in next step. LCMS (M+H +< ): 217.Step 7: preparation of N-(3-chloro-4-fluoro-phenyl)-8-(4-fluorophenyl)-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carboxamide (Example 12):

[0151] To a solution of 8-(4-fluorophenyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine (compound 12h, 54 mg, 0. 25 mmol) in DCM (2.0 mL) was added DIPEA (0.1 mL), phenyl N-(3-chloro-4-fluoro-phenyl)carbamate (compound 12i, 80 mg, 0.3 mmol) (for its synthesis, refer to: Sheng, C. et al, Eur. J. Med. Chem. 2011, 46, 5276). The reaction mixture was stirred at 40 °C for 3 hours. The reaction mixture was concentrated in vacuo to give the crude product, which was purified by prep-HPLC to afford Example 12 (10 mg). LCMS (M+H +< ): 388. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.59 (dd, J=2.5, 6.8 Hz, 1H), 7.43 - 7.35 (m, 2H), 7.33 - 7.27 (m, 1H), 7.18 - 7.07 (m, 3H), 6.75 (d, J=2.8 Hz, 1H), 6.33 (d, J=2.8 Hz, 1H), 4.88 (s, 2H), 4.12 (d, J=4.5 Hz, 2H), 3.94 (d, J=5.8 Hz, 2H).Example 13: N-(2-fluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0152] Preparation of Example 13:

[0153] The title compound was prepared in analogy to the preparation of Example 9 by using 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b, 50mg) instead of 1-(4-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 9e ), and 1-fluoro-2-isocyanato-benzene (44 mg) instead of isocyanatobenzene. Example 13 was obtained as a white solid (40 mg). LCMS (M+H +< ): 355. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.92 (s, 1H), 7.83 (s, 1H), 7.53 - 7.42 (m, 4H), 7.27 (t, J=8.9 Hz, 2H), 7.14 - 7.06 (m, 2H), 4.92 (s, 2H), 4.22 (t, J=5.3 Hz, 2H), 4.04 - 3.96 (m, 2H).Example 14: N,3-bis(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0154] Preparation of Example 14:

[0155] The title compound was prepared in analogy to the preparation of Example 11 by using 4-fluoroaniline instead of 3-(trifluoromethyl)aniline. Example 14 was obtained as a white solid (20 mg). LCMS (M+H +< ): 355. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.92 (s, 1H), 7.83 (s, 1H), 7.54 - 7.40 (m, 4H), 7.27 (t, J=8.9 Hz, 2H), 7.16 - 7.04 (m, 2H), 4.92 (s, 2H), 4.22 (t, J=5.3 Hz, 2H), 4.04 - 3.95 (m, 2H).Example 15: N-(3-chlorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0156] Preparation of Example 15:

[0157] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloroaniline instead of 3-(trifluoromethyl)aniline. Example 15 was obtained as a white solid . LCMS (M+H +< ): 371. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.06 (s, 1H), 7.84 (s, 1H), 7.63 (s, 1H), 7.53 - 7.45 (m, 2H), 7.41 (d, J=8.3 Hz, 1H), 7.33 - 7.23 (m, 3H), 7.02 (d, J=7.8 Hz, 1H), 4.94 (s, 2H), 4.23 (m, 2H), 4.00 (m, 2H).Example 16: N-(3-cyanophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0158] Preparation of Example 16:

[0159] The title compound was prepared in analogy to the preparation of Example 11 by using 3-aminobenzonitrile instead of 2-fluoroaniline. Example 16 was obtained as a white solid (30 mg). LCMS (M+H +< ): 362. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.21 (s, 1H), 7.92 (s, 1H), 7.84 (s, 1H), 7.76 (d, J=8.0 Hz, 1H), 7.54 - 7.39 (m, 4H), 7.32 - 7.22 (m, 2H), 4.95 (s, 2H), 4.24 (m, 2H), 4.02 (m, 2H).Example 17: N-(4-chlorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0160] Preparation of Example 17:

[0161] The title compound was prepared in analogy to the preparation of Example 11 by using 4-chloroaniline instead of 3-(trifluoromethyl)aniline. Example 17 was obtained as a white solid (30 mg). LCMS (M+H +< ): 371. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.00 (s, 1H), 7.83 (s, 1H), 7.49 (d, J=8.3 Hz, 4H), 7.37 - 7.22 (m, 4H), 4.93 (s, 2H), 4.27 - 4.17 (m, 2H), 4.01 (d, J=4.8 Hz, 2H).Example 18: 3-(2-cyanophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0162] Preparation of Example 18:

[0163] The title compound was prepared in analogy to the preparation of Example 1 by using (2-cyanophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 18 was obtained as a white solid (20 mg). LCMS (M+H +< ): 344. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.86 (s, 1H), 7.94 (d, J=7.5 Hz, 1H), 7.84 (s, 1H), 7.78 (t, J=7.5 Hz, 1H), 7.59 - 7.40 (m, 4H), 7.29 - 7.20 (m, 2H), 7.01 - 6.92 (m, 1H), 4.84 (s, 2H), 4.28 (t, J=5.0 Hz, 2H), 4.03 (t, J=5.1 Hz, 2H).Example 19: N-(3-fluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0164] Preparation of Example 19:

[0165] The title compound was prepared in analogy to the preparation of Example 11 by using 3-fluoroaniline instead of 2-fluoroaniline. Example 19 was obtained as a white solid (30 mg). LCMS (M+H +< ): 355. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.14 - 9.01 (m, 1H), 7.83 (s, 1H), 7.50 (dd, J=5.6, 8.2 Hz, 2H), 7.42 (d, J=12.0 Hz, 1H), 7.35 - 7.18 (m, 4H), 6.78 (t, J=7.8 Hz, 1H), 4.93 (s, 2H), 4.28 - 4.17 (m, 2H), 4.01 (d, J=5.3 Hz, 2H).Example 20: N-(4-chloro-3-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0166] Preparation of Example 20:

[0167] The title compound was prepared in analogy to the preparation of Example 11 by using 4-chloro-3-fluoro-aniline instead of 3-(trifluoromethyl)aniline. Example 20 was obtained as a white solid. LCMS (M+H +< ): 389. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.20 (s, 1H), 7.83 (s, 1H), 7.70 - 7.57 (m, 1H), 7.53 - 7.40 (m, 3H), 7.35 - 7.21 (m, 3H), 4.93 (s, 2H), 4.30 - 4.15 (m, 2H), 4.01 (d, J=4.8 Hz, 2H).Example 21: N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5- a]pyrazine-5-carboxamide

[0168] Preparation of Example 21:

[0169] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoro-aniline instead of 3-(trifluoromethyl)aniline. Example 21 was obtained as a white solid (32 mg). LCMS (M+H +< ): 389. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.05 (s, 1H), 7.83 (s, 1H), 7.72 (dd, J=2.3, 6.8 Hz, 1H), 7.49 (dd, J=5.5, 8.5 Hz, 2H), 7.44 - 7.38 (m, 1H), 7.30 (td, J=9.0, 18.2 Hz, 3H), 4.93 (s, 2H), 4.22 (t, J=5.0 Hz, 2H), 4.06 - 3.95 (m, 2H).Example 22: 3-(4-fluorophenyl)-N-(4-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0170] Preparation of Example 22:

[0171] The title compound was prepared in analogy to the preparation of Example 11 by using 4-amino-pyridine instead of 3-(trifluoromethyl)aniline. Example 22 was obtained as a white solid (30 mg). LCMS (M+H +< ): 338. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.31 (s, 1H), 8.34 (d, J=6.3 Hz, 2H), 7.83 (s, 1H), 7.56 - 7.42 (m, 4H), 7.33 - 7.21 (m, 2H), 4.95 (s, 2H), 4.23 (t, J=5.1 Hz, 2H), 4.11 - 3.98 (m, 2H).Example 23: N-(4-cyanophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0172] Preparation of Example 23:

[0173] The title compound was prepared in analogy to the preparation of Example 11 by using 4-aminobenzonitrile instead of 3-(trifluoromethyl)aniline. Example 23 was obtained as a white solid (35 mg). LCMS (M+H +< ): 362. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.35 (s, 1H), 7.83 (s, 1H), 7.75 - 7.63 (m, 4H), 7.49 (dd, J=5.5, 8.5 Hz, 2H), 7.27 (t, J=8.8 Hz, 2H), 4.95 (s, 2H), 4.24 (t, J=5.3 Hz, 2H), 4.02 (t, J=5.3 Hz, 2H).Example 24: N-(3-chloro-4-fluoro-phenyl)-3-(2-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0174]

[0175] The title compound was prepared according to the following scheme: Preparation of 3-(2-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 24b):

[0176] The compound 24b was prepared in analogy to compound 11b by using (2-fluorophenyl) boronic acid instead of (4-fluorophenyl)boronic acid. Compound 24b was obtained as a white solid (250 mg). LCMS (M+H +< ): 218.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-(2-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 24):

[0177] Example 24 was prepared in analogy to the preparation of Example 11 by using 3-choloro-4-fluoroaniline and 3-(2-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 24b ). Example 24 was obtained as a white solid (10 mg). LCMS (M+H +< ): 389. 1< H NMR (400MHz, chloroform-d) ppm 7.77 (s, 1H), 7.50 (dd, J=2.6, 6.5 Hz, 1H), 7.39 - 7.31 (m, 2H), 7.27 - 7.16 (m, 3H), 7.12 - 7.04 (m, 1H), 6.57 (s, 1H), 4.79 (s, 2H), 4.40 (t, J=5.5 Hz, 2H), 4.07 (t, J=5.4 Hz, 2H).Example 25: 3-(3-methoxyphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0178] Preparation of Example 25:

[0179] The title compound was prepared in analogy to the preparation of Example 1 by using (3-methoxylphenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 25 was obtained as a white solid. LCMS (M+H +< ): 349. 1< H NMR (400MHz, DMSO-d 6 ) ppm 8.91 (s, 1H), 7.86 (s, 1H), 7.44 (d, J=7.8 Hz, 2H), 7.35 (t, J=7.9 Hz, 1H), 7.25 (t, J=7.8 Hz, 2H), 7.07 - 6.94 (m, 3H), 6.85 (d, J=8.3 Hz, 1H), 4.95 (s, 2H), 4.22 (t, J=5.0 Hz, 2H), 4.01 (d, J=5.3 Hz, 2H), 3.81 (s, 3H).Example 26: 3-cyclopentyl-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0180]

[0181] The title compound was prepared according to the following scheme: Step 1: preparation of tert-butyl 3-(cyclopenten-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 26a)

[0182] A mixture of cyclopenten-1-ylboronic acid (144 mg 1.2 mmol), Pd (PPh 3 ) 4 (240 mg, 0.03 mmol), Cs 2 CO 3 (800 mg, 2.2 mmol) and tert-butyl 3-iodo-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 1e, 400 mg, 1.1 mmol) in dioxane / H 2 O (30 mL, 4:1, v / v) was refluxed for 12 hours under N 2 . The reaction mixture was diluted with EtOAc (30 mL), washed with water (10 mL) and brine (10 mL). The organic layer was concentrated. The residue was purified by column chromatography to afford compound 26a (275 mg) as a white solid. LCMS (M+H +< ): 290.Step 2: preparation of tert-butyl 3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 26b)

[0183] To a solution of tert-butyl 3-(cyclopenten-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 26a, 275 mg, 0.9 mmol) in MeOH (20 mL) was added Pd / C (80mg) under N 2 , and the reaction mixture was stirred at room temperature for 12 hours under H 2 . Then the solid was filtered off, the filtrate was concentrated to afford compound 26b (270 mg) as a colorless oil. LCMS (M+H +< ): 292.Step 3: preparation of 3-cyclopentyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 26c)

[0184] A solution of tert-butyl 3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 26b, 270 mg, 0.9 mmol) in HCl / MeOH (20 mL) was stirred at room temperature for 2 hours. Then the reaction mixture was concentrated in vacuo to afford compound 26c (230 mg) as a slight yellow solid. LCMS (M+H +< ): 192.Step 4: preparation of 3-cyclopentyl-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 26)

[0185] The title compound was prepared in analogy to the preparation of Example 11 by using aniline and 3-cyclopentyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 26c ) instead of 3-(trifluoromethyl)aniline and 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine, respectively. Example 26 was obtained as a white solid. LCMS (M+H +< ): 311. 1< H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.81 (br. s, 1H), 7.46 (d, J=7.8 Hz, 2H), 7.35 - 7.19 (m, 3H), 6.98 (t, J=7.3 Hz, 1H), 4.69 (s, 2H), 4.15 - 4.04 (m, 2H), 3.93 (t, J=5.4 Hz, 2H), 2.88 - 2.76 (m, 1H), 2.26 - 1.21 (m, 8H).Example 27: 3-(2-methoxyphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0186] Preparation of Example 27:

[0187] The title compound was prepared in analogy to the preparation of Example 1 by using (2-methoxylphenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 27 was obtained as a white solid. LCMS (M+H +< ): 349. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.84 (s, 1H), 7.63 - 7.61 (m, 1H), 7.43 (d, J=7.8 Hz, 2H), 7.34 - 7.21 (m, 4H), 7.09 (d, J=8.3 Hz, 1H), 6.98 (td, J=7.3, 19.0 Hz, 2H), 4.72 (s, 2H), 4.21 (t, J=5.3 Hz, 2H), 4.01 (t, J=5.4 Hz, 2H), 3.81 (s, 3H).Example 28: N-phenyl-3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0188] Preparation of Example 28:

[0189] Step 1: preparation of N-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (compound 28a)

[0190] To a solution of 3-iodo-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (compound 1h, 500 mg, 1.4 mmol) in THF (15 mL) was added isopropyl magnesium chloride (1.7 mL, 3.4 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 hours, then 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (380 mg, 2 mmol) in THF (5 mL) was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. The reaction was quenched with saturated aqueous ammonium chloride solution (20 mL) slowly and extracted with EtOAc (30 mL). The organic layer was washed with brine, and concentrated to afford compound 28a (450 mg) as a white solid. LCMS (M+H +< ): 369.Step 2: preparation of N-phenyl-3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 28)

[0191] To a mixture of N-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (compound 28a, 100 mg, 0.3 mmol), 2-chloro-4-(trifluoromethyl)pyridine (108 mg, 0.6 mmol) and K 2 CO 3 (83 mg, 0.6 mmol) in DMSO / H 2 O (10:1, 2 mL, v / v) was added Pd(dppf)Cl 2 (15 mg) under N 2 . The resulting mixture was stirred at 80 °C for 12 hours. After cooled down, then the reaction mixture was filtered, and concentrated. The residue was purified by prep-HPLC to afford Example 28 (19 mg) as a white solid. LCMS (M+H +< ): 388. 1< H NMR (400MHz, chloroform-d) δ ppm 8.77 (d, J=5.1 Hz, 1H), 8.06 (s, 1H), 7.73 (s, 1H), 7.42 - 7.33 (m, 5H), 7.16 - 7.11 (m, 1H), 6.79 (s, 1H), 5.18 (s, 2H), 4.39 (t, J=5.3 Hz, 2H), 4.10 (t, J=5.3 Hz, 2H).Example 29: 3-(4-cyano-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0192] Preparation of Example 29:

[0193] The title compound was prepared in analogy to the preparation of Example 28 by using 2-chloropyridine-4-carbonitrile instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 29 was obtained as a white solid (11 mg). LCMS (M+H +< ): 345. 1< H NMR (400MHz, DMSO-d6) δ ppm 8.75 (d, J=4.8 Hz, 1H), 7.98 (s, 1H), 7.74 (s, 1H), 7.42 - 7.32 (m, 5H), 7.31 - 7.12 (m, 1H), 6.65 (br. s, 1H), 5.14 (s, 2H), 4.37 (t, J=5.3 Hz, 2H), 4.09 (t, J=5.4 Hz, 2H).Example 30: N-(3-chlorophenyl)-3-(2-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0194] Preparation of Example 30:

[0195] Step 1: preparation of N-(3-chlorophenyl)-3-iodo-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (compound 30a)

[0196] Compound 30a was prepared in analogy to compound 1h by using 1-chloro-3-isocyanato-benzene (500 mg) instead of isocyanatobenzene. Compound 30a was obtained as a white solid (500 mg). LCMS (M+H +< ): 403.Step 2: preparation of N-(3-chlorophenyl)-3-(2-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 30)

[0197] To a solution of N-(3-chlorophenyl)-3-(2-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (compound 30a, 0.1 g, 0.3 mmol) in dioxane / water (10 mL, 10:1, v / v) was added (2-fluorophenyl)boronic acid (40 mg, 0.33 mmol), Pd(PPh 3 ) 4 (10 mg, 0.09 mmol) and Cs 2 CO 3 (195 mg, 0.6 mmol). The reaction mixture was stirred at 70 °C for 16 hours under nitrogen. The reaction mixture was concentrated and the residue was purified by prep-HPLC to afford Example 30 (5 mg) as a white solid. LCMS (M+H +< ): 371. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.15 (br. s, 1H), 7.78 - 7.57 (m, 2H), 7.52 - 7.15 (m, 6H), 7.00 (d, J=7.3 Hz, 1H), 4.91 - 4.74 (m, 2H), 4.24 (br. s, 2H), 4.04 (br. s, 2H).Example 31: N-(3-chlorophenyl)-3-(o-tolyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0198] Preparation of Example 31:

[0199] The title compound was prepared in analogy to the preparation of Example 30 by using (2-methylphenyl)boronic acid instead of (2-fluorophenyl)boronic acid. Example 31 was obtained as a white solid (10 mg). LCMS (M+H +< ): 367. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.04 (s, 1H), 7.59 (d, J=12.8 Hz, 2H), 7.38 (d, J=8.0 Hz, 1H), 7.34 - 7.15 (m, 5H), 7.00 (d, J=7.9 Hz, 1H), 4.68 (s, 2H), 4.24 (br. s, 2H), 4.02 (br. s, 2H), 2.27 (s, 3H).Example 32: N-(5-fluoro-6-methyl-2-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0200] Preparation of Example 32:

[0201]

[0202] To a mixture of 5-fluoro-6-methyl-pyridin-2-amine (40 mg, 0.32 mmol) and Et 3 N (65 mg, 0.64 mmol) in THF (5 mL) was added phenyl chloroformate (50 mg, 0.12 mmol) slowly at 0 °C. The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with EtOAc (20 mL), washed with saturated aqueous NaHCO 3 (20 mL) and brine (30 mL), and dried over anhydrous sodium sulfate. The solvents were removed in vacuo. The residue was dissolved in DMF (2 mL), to which 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ) (41 mg, 0.32 mmol) and DIPEA (0.2 mL) was added. Then the reaction mixture was stirred at 80 °C for 1 hour. The reaction mixture was subjected to prep-HPLC to afford Example 32 as a white solid. LCMS (M+H +< ): 370. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.70 (s, 1H), 7.83 (s, 1H), 7.69 - 7.62 (m, 1H), 7.59 - 7.53 (m, 1H), 7.50 (dd, J=5.5, 8.7 Hz, 2H), 7.27 (t, J=8.8 Hz, 2H), 4.95 (s, 2H), 4.20 (t, J=5.3 Hz, 2H), 4.04 - 3.96 (m, 2H), 2.37 (d, J=2.8 Hz, 3H).Example 33: 3-(2-fluorophenyl)-N-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0203] Preparation of Example 33:

[0204] The title compound was prepared in analogy to the preparation of Example 24 by using 4-fluoroaniline instead of 3-choloro-4-fluoroaniline. Example 33 was obtained as a white solid (45 mg). LCMS (M+H +< ): 355. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.01 - 8.77 (m, 1H), 7.73 (d, J=1.9 Hz, 1H), 7.49 - 7.41 (m, 3H), 7.39 - 7.25 (m, 3H), 7.09 (t, J=8.9 Hz, 2H), 4.82 (s, 2H), 4.24 (t, J=5.4 Hz, 2H), 4.08 - 3.97 (m, 2H).Example 34: 3-(2-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0205] Preparation of Example 34:

[0206] The title compound was prepared in analogy to the preparation of Example 24 by using 3-trifluoro-4-fluoroaniline instead of 3-choloro-4-fluoroaniline. Example 34 was obtained as a white solid (21 mg). LCMS (M+H +< ): 423. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.18 (s, 1H), 7.89 (dd, J=2.6, 6.3 Hz, 1H), 7.82 - 7.64 (m, 2H), 7.52 - 7.21 (m, 5H), 4.84 (s, 2H), 4.26 (t, J=5.4 Hz, 2H), 4.09 - 3.96 (m, 2H).Example 35: N-(3-chlorophenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H -pyrazolo[1,5-a]pyrazine-5-carboxamide

[0207] Preparation of Example 35:

[0208] The title compound was prepared in analogy to the preparation of Example 30 by using (3,4-difluorophenyl)boronic acid instead of (2-fluorophenyl)boronic acid. Example 35 was obtained as a white solid (15 mg). LCMS (M+H +< ): 389. 1H NMR (400MHz, chloroform-d) δ ppm 7.67 (s, 1H), 7.46 (s, 1H), 7.37 - 7.27 (m, 1H), 7.25 - 7.20 (m, 2H), 7.10 - 7.04 (m, 1H), 7.01 - 6.92 (m, 2H), 6.56 (s, 1H), 4.75 (s, 2H), 4.36 (t, J=5.5 Hz, 2H), 4.12 - 3.98 (m, 2H).Example 36: N-(3-chlorophenyl)-3-(2,3-difluorophenyl)-6,7-dihydro-4H -pyrazolo[1,5-a]pyrazine-5-carboxamide

[0209] Preparation of Example 36:

[0210] The title compound was prepared in analogy to the preparation of Example 30 by using (3,4-difluorophenyl)boronic acid instead of (2-fluorophenyl)boronic acid. Example 36 was obtained as a white solid (23 mg). LCMS (M+H +< ): 389. 1< H NMR (400MHz, chloroform-d) δ ppm 7.73 (s, 1H), 7.46 (d, J=1.3 Hz, 1H), 7.26 - 7.20 (m, 2H), 7.19 - 7.00 (m, 4H), 6.60 (s, 1H), 4.79 (s, 2H), 4.36 (t, J=5.5 Hz, 2H), 4.07 (t, J=5.5 Hz, 2H).Example 37: 3-(3-cyano-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0211] Preparation of Example 37:

[0212] The title compound was prepared in analogy to the preparation of Example 28 by using 2-chloropyridine-3-carbonitrile instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 37 was obtained as a white solid (15 mg). LCMS (M+H +< ): 345. 1< H NMR (400MHz, DMSO-d6) δ ppm 8.89 (s, 2H), 8.37 - 8.32 (m, 1H), 8.28 (s, 1H), 7.43 (s, 3H), 7.31 - 7.22 (m, 2H), 7.03 - 6.92 (m, 1H), 5.04 (s, 2H), 4.31 - 4.27 (m, 2H), 4.06 - 4.01 (m, 2H).Example 38: 3-(3-chloro-2-fluoro-phenyl)-N-(3-chlorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0213] Preparation of Example 38:

[0214] The title compound was prepared in analogy to the preparation of Example 30 by using (2-fluoro-3-chlorophenyl)boronic acid instead of (2-fluorophenyl)boronic acid. Example 38 was obtained as a white solid (41 mg). LCMS (M+H +< ): 405. 1< H NMR (400MHz, chloroform-d) δ ppm 7.76 (s, 1H), 7.47 - 7.37 (m, 2H), 7.28 - 7.21 (m, 3H), 7.20 - 7.15 (m, 1H), 7.10 - 7.05 (m, 1H), 6.64 (s, 1H), 4.79 (s, 2H), 4.41 (t, J=5.5 Hz,2H), 4.07 (t, J=5.5 Hz, 2H).Example 39: 3-(5-chloro-2-fluoro-phenyl)-N-(3-chlorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0215] Preparation of Example 39:

[0216] The title compound was prepared in analogy to the preparation of Example 30 by using (2-fluoro-5-chlorophenyl)boronic acid instead of (2-fluorophenyl)boronic acid. Example 39 was obtained as a white solid (40 mg). LCMS (M+H +< ): 405. 1< H NMR (400MHz, chloroform-d) δ ppm 7.71 (d, J=0.6 Hz, 1H), 7.46 (s, 1H), 7.33 (dd, J=2.6, 6.5 Hz, 1H), 7.30 - 7.25 (m, 1H), 7.25 - 7.22 (m, 2H), 7.13 (dd, J=8.8, 9.9 Hz, 1H), 7.09 - 7.04 (m, 1H), 6.59 (s, 1H), 4.78 (s, 2H), 4.36 (t, J=5.5 Hz, 2H), 4.06 (t, J=5.5 Hz, 2H).Example 40: N-(3-chlorophenyl)-3-(2,5-difluorophenyl)-6,7-dihydro-4H -pyrazolo[1,5-a]pyrazine-5-carboxamide

[0217] Preparation of Example 40:

[0218] The title compound was prepared in analogy to the preparation of Example 30 by using (2,5-difluorophenyl)boronic acid instead of (2-fluorophenyl)boronic acid. Example 40 was obtained as a white solid (23 mg). LCMS (M+H +< ): 389. 1< H NMR (400MHz, chloroform-d) δ ppm 7.76 (s, 1H), 7.42 (s, 1H), 7.25 - 7.19 (m, 2H), 7.14 (dt, J=4.6, 9.3 Hz, 1H), 7.10 - 6.95 (m, 3H), 6.74 (s, 1H), 4.79 (s, 2H), 4.38 (t, J=5.4 Hz, 2H), 4.05 (t, J=5.5 Hz, 2H).Example 41: 3-[3-(difluoromethyl)phenyl]-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0219] Preparation of Example 41:

[0220] The title compound was prepared in analogy to the preparation of Example 28 by using 1-bromo-3-(difluoromethyl)benzene instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 41 was obtained as a white solid. LCMS (M+H +< ): 369. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.91 (s, 1H), 7.90 (s, 1H), 7.67 - 7.54 (m, 3H), 7.49 - 7.39 (m, 3H), 7.25 (t, J=7.8 Hz, 2H), 7.05 - 6.97 (m, 2H), 4.96 (s, 2H), 4.22 (d, J=5.0 Hz, 2H), 4.01 (t, J=5.0 Hz, 2H).Example 42: 3-(5-fluoro-6-methyl-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0221] Preparation of Example 42:

[0222] The title compound was prepared in analogy to the preparation of Example 28 by using 6-chloro-3-fluoro-2-methyl-pyridine instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 42 was obtained as a white solid. LCMS (M+H +< ): 352. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.92 (s, 1H), 8.04 (s, 1H), 7.66 - 7.53 (m, 2H), 7.44 (d, J=8.0 Hz, 2H), 7.26 (t, J=7.8 Hz, 2H), 6.97 (t, J=7.3 Hz, 1H), 5.04 (s, 2H), 4.22 (t, J=4.9 Hz, 2H), 4.00 (t, J=5.1 Hz, 2H), 2.3 (s, 3H).Example 43: 3-(5-fluoro-4-methyl-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0223] Preparation of Example 43:

[0224] The title compound was prepared in analogy to the preparation of Example 28 by using 2-chloro-5-fluoro-4-methyl-pyridine instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 43 was obtained as a white solid. LCMS (M+H +< ): 352. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.91 (s, 1H), 8.43 (s, 1H), 8.04 (s, 1H), 7.68 (d, J=6.0 Hz, 1H), 7.43 (d, J=7.8 Hz, 2H), 7.25 (t, J=7.8 Hz, 2H), 7.01 - 6.89 (m, 1H), 5.02 (s, 2H), 4.26 - 4.15 (m, 2H), 3.99 (t, J=5.0 Hz, 2H), 2.31 (s, 3H).Example 44: N-phenyl-3-(2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0225] Preparation of Example 44:

[0226] The title compound was prepared in analogy to the preparation of Example 28 by using 2-chloropyridine instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 44 was obtained as a white solid (30 mg). LCMS (M+H +< ): 320. 1< H NMR (400MHz, methanol-d 4 ) δ ppm 8.68 (d, J=5.1 Hz, 1H), 8.30 (br. s, 1H), 8.15 (s, 1H), 7.91 (d, J=8.2 Hz, 1H), 7.63 (s, 1H), 7.43 - 7.39 (m, 2H), 7.33 - 7.28 (m, 2H), 7.09 - 7.05 (m, 1H), 5.15 (s, 2H), 4.37 (t, J=5.4 Hz, 2H), 4.13 (d, J=5.6 Hz, 2H).Example 45: N-phenyl-3-thiazol-2-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0227] Preparation of Example 45:

[0228] The title compound was prepared in analogy to the preparation of Example 28 by using 2-bromothiazole instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 45 was obtained as a white solid (12 mg). LCMS (M+H +< ): 326. 1< H NMR (400MHz, methanol-d 4 ) δ ppm 8.01 (s, 1H), 7.84 (d, J=3.3 Hz, 1H), 7.53 (d, J=3.4 Hz, 1H), 7.44 - 7.40 (m, 2H), 7.30 (t, J=7.9 Hz, 2H), 7.10 - 7.03 (m, 1H), 5.11 (s, 2H), 4.35 - 4.31 (m, 2H), 4.10 (t, J=5.3 Hz, 2H).Example 46: N-phenyl-3-[4-(trifluoromethyl)thiazol-2-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0229] Preparation of Example 46:

[0230] The title compound was prepared in analogy to the preparation of Example 28 by using 4-trifluoromethy-2-bromothiazole instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 46 was obtained as a white solid (12 mg). LCMS (M+H +< ): 394. 1< H NMR (400MHz, methanol-d 4 ) δ ppm 8.06 (s, 2H), 7.42 - 7.38 (m, 2H), 7.34 - 7.24 (m, 2H), 7.11 - 7.02 (m, 1H), 5.12 (s, 2H), 4.37 - 4.32 (m, 2H), 4.10 (s, 2H).Example 47: 3-(5-chlorothiazol-2-yl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0231] Preparation of Example 47:

[0232] The title compound was prepared in analogy to the preparation of Example 28 by using 5-chloro-2-bromothiazole instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 47 was obtained as a white solid (17 mg). LCMS (M+H +< ): 360. 1< H NMR (400MHz, methanol-d 4 ) δ ppm 7.95 (s, 1H), 7.67 (s, 1H), 7.44 - 7.39 (m, 2H), 7.34 - 7.25 (m, 2H), 7.10 - 7.02 (m, 1H), 5.07 (s, 2H), 4.37 - 4.27 (m, 2H), 4.10 - 4.06 (m, 2H).Example 48: 3-(3,4-difluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0233] Preparation of Example 48:

[0234] The title compound was prepared in analogy to the preparation of Example 1 by using (3,4-difulorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 48 was obtained as a white solid (10 mg). LCMS (M+H +< ): 355. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.90 (s, 1H), 7.89 (s, 1H), 7.64 - 7.41 (m, 4H), 7.32 - 7.17 (m, 3H), 7.05 - 6.94 (m, 1H), 4.94 (s, 2H), 4.22 (t, J=5.3 Hz, 2H), 4.08 - 3.88 (m, 2H).Example 49: 3-(6-chloro-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0235] Preparation of Example 49:

[0236] The title compound was prepared in analogy to the preparation of Example 28 by using 2,6-dichloropyridine instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 49 was obtained as a white solid. LCMS (M+H +< ): 354. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.92 (s, 1H), 8.14 (s, 1H), 7.88 - 7.83 (m, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.46 (d, J=7.8 Hz, 2H), 7.31 - 7.22 (m, 3H), 7.00 - 6.95 (m, 1H), 5.04 (s, 2H), 4.25 (t, J=5.1 Hz, 2H), 4.02 (t, J=5.1 Hz, 2H).Example 50: N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0237]

[0238] The title compound was prepared according to the following scheme: Preparation of 3-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (50b)

[0239] The compound 50b was prepared in analogy to compound 11b by using (2,4-difluorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Compound 50b was obtained as a white solid (250 mg). LCMS (M+H +< ): 236.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 50)

[0240] The title compound was prepared in analogy to the preparation of Example 11 by using 3-choloro-4-fluoroaniline instead of 3-trifluoromethyaniline and 3-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 50b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 50 was obtained as a white solid (10 mg). LCMS (M+H +< ): 407. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.15 (s, 1H), 7.80 - 7.61 (m, 2H), 7.59 - 7.24 (m, 4H), 7.24 - 7.12 (m, 1H), 4.79 (s, 2H), 4.24 (t, J=5.1 Hz, 2H), 4.07 - 3.93 (m, 2H).Example 51: 3-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0241] Preparation of Example 51:

[0242] The title compound was prepared in analogy to the preparation of Example 11 by using 3,4,5-trifluoroaniline instead of 3-trifluoromethylaniline and 3-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 50b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 51 was obtained as a white solid (22 mg). LCMS (M+H +< ): 409. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.31 (d, J=10.0 Hz, 1H), 7.70 (d, J=1.9 Hz, 1H), 7.55 - 7.29 (m, 4H), 7.19 (dt, J=2.4, 8.5 Hz, 1H), 4.80 (s, 2H), 4.24 (t, J=5.3 Hz, 2H), 4.12 - 3.93 (m, 2H).Example 52: 3-(4-fluoro-3-methyl-phenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0243] Preparation of Example 52:

[0244] The title compound was prepared in analogy to the preparation of Example 1 by using (3-methyl-4-fluorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 52 was obtained as a white solid (26 mg). LCMS (M+H +< ): 351. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.89 (s, 1H), 7.80 (s, 1H), 7.45 (d, J=7.7 Hz, 2H), 7.40 - 7.35 (m, 1H), 7.31 - 7.12 (m, 4H), 7.03 - 6.91 (m, 1H), 4.92 (s, 2H), 4.22 (t, J=5.3 Hz, 2H), 4.07 - 3.92 (m, 2H), 2.29 (d, J=1.5 Hz, 3H).Example 53: 3-(4-fluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0245]

[0246] The title compound was prepared according to the following scheme: Step 1: preparation of tert-butyl N-(2-hydroxy-1-methyl-ethyl)-N-(1H-pyrazol-5-ylmethyl)carbamate (compound 53a)

[0247] To a solution of 1H-pyrazole-5-carbaldehyde (compound 1a, 54.0 g, 562.5 mmol) in MeOH (300 mL) was added 2-aminopropan-1-ol (41.2 g, 675 mmol) and the reaction mixture was stirred at 25 °C for 1 hour. NaBH 4 (25.9 g, 675.0 mmol) was added at 0 °C and the reaction mixture was stirred for another 1 hour followed by the addition of H 2 O (300 mL) and Boc 2 O (147.1 g, 675.0 mmol). The resulting mixture was stirred at room temperature for 12 hours, and extracted with EtOAc (600 mL). The organic layer was dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by column chromatography (eluting with 0%∼5% MeOH in DCM) to afford compound 53a (80 g) as a colorless oil. LCMS (M+H +< ): 334. 1< H NMR (400MHz, chloroform-d) δ ppm 7.55 - 7.46 (m, 1H), 6.30 - 6.07 (m, 1H), 4.62 - 4.37 (m, 2H), 4.33 - 3.99 (m, 1H), 3.74 - 3.47 (m, 2H), 1.54 - 1.27 (m, 9H), 1.12 (d, J=7.0 Hz, 3H).Step 2: preparation of 2-[tert-butoxycarbonyl(1H-pyrazol-5-ylmethyl)amino]propyl methanesulfonate (compound 53b)

[0248] To a mixture of tert-butyl N-(2-hydroxy-1-methyl-ethyl)-N-(1H-pyrazol-5-ylmethyl)carbamate (compound 53a, 80.0 g, 117.2 mmol) and Et 3 N (100.5 g, 995.6 mmol) in DCM (800 mL) was added MsCl (57.3 g, 497.8 mmol) slowly at 0 °C. The resulting mixture was stirred at room temperature for 2 hours, then washed with water (500 mL), brine (500 mL), and dried over Na 2 SO 4 . The organic layer was concentrated to afford compound 53b (100 g, crude), which was used directly in next step.Step 3: preparation of tert-butyl 6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 53c)

[0249] To a solution of 2-[tert-butoxycarbonyl(1H-pyrazol-5-ylmethyl)amino]propyl methanesulfonate (compound 53b, 100.0 g, 313.4 mmol) in DMF (1000 mL) was added NaH (15.0 g, 376.2 mmol) in portions at 0 °C. The reaction mixture was then stirred at room temperature for 12 hours, poured into water (2000 mL) and extracted with EtOAc (1000 mL) twice. The organic layers were combined and concentrated. The residue was purified by column chromatography (eluting with 10%∼80% EtOAc in petroleum ether) to afford compound 53c (18.0 g) as a colorless oil. LCMS (M+H +< ): 238. 1< H NMR (400MHz, chloroform-d) δ ppm 7.55 - 7.46 (m, 1H), 6.20 (s, 1H), 4.98 - 4.91 (m, 1H), 4.85 - 4.76 (m, 1H), 4.45 - 4.33 (m, 1H), 4.26 - 4.18 (m, 1H), 4.16 - 4.08 (m, 1H), 1.53 (s, 9H), 1.23 - 1.10 (m, 3H).Step 4: preparation of tert-butyl 3-iodo-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 53d)

[0250] To a solution of tert-butyl 6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 53c, 3.3 g, 14.8 mmol) in CH 3 CN (40 mL) was added NIS (5.0 g, 22.1 mmol) slowly. The reaction mixture was stirred at room temperature for 16 hours and then extracted with EtOAc (50 mL), washed with brine (50 mL). The organic layer was dried over Na 2 SO 4 and concentrated, and the residue was purified by column chromatography (eluting with 10%∼80% EtOAc in petroleum ether) to afford compound 53d (4.8 g) as a white solid.Step 5: preparation of tert-butyl 3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 53e)

[0251] To a mixture of tert-butyl 3-iodo-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 53d, 1.1 g, 3 mmol), (4-fluorophenyl)boronic acid (630 mg, 4.5 mmol) and K 2 CO 3 (1.2 g, 9 mmol) in and dioxane / water (10 mL, 5:1, v / v) was added Pd(PPh 3 ) 4 (150 mg) under N 2 . The reaction mixture was stirred at 80 °C for 2 hours. The reaction was concentrated and the residue was purified by column chromatography to afford compound 53e (550 mg) a slight yellow solid. LCMS (M+H +< ): 332.Step 6: preparation of 3-(4-fluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 53f)

[0252] A solution of tert-butyl 3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 53e, 550 mg, 1.7 mmol) in HCl / MeOH (20 mL) was stirred at room temperature for 2 hours. Then the reaction mixture was concentrated in vacuo to afford compound 53f (400 mg) as a slight yellow solid. LCMS (M+H +< ): 232.Step 7: preparation of 3-(4-fluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 53):

[0253] The title compound was prepared in analogy to the preparation of Example 11 by using 3,4,5-trifluoroaniline instead of 3-trifluoromethylaniline and 3-(4-fluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 53f ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 53 was obtained as a white solid (16 mg). LCMS (M+H +< ): 405. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.12 (s, 1H), 7.86 (s, 1H), 7.55 (dd, J=5.4, 8.8 Hz, 2H), 7.43 (dd, J=6.5, 10.7 Hz, 2H), 7.27 (t, J=8.8 Hz, 2H), 5.19 (d, J=16.7 Hz, 1H), 4.95 - 4.87 (m, 1H), 4.66 (d, J=16.6 Hz, 1H), 4.28 - 4.17 (m, 1H), 3.54 (s, 1H), 1.18 (d, J=6.9 Hz, 3H).Example 54: N-[(3-chloro-4-fluoro-phenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0254] Preparation of Example 54:

[0255] The title compound was prepared in analogy to the preparation of Example 11 by using (3-chloro-4-fluoro-phenyl)methanamine instead of 3-(trifluoromethyl)aniline. Example 54 was obtained as a white solid (27 mg). LCMS (M+H +< ): 403. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 7.81 (s, 1H), 7.55 (t, J=5.6 Hz, 1H), 7.50 - 7.46 (m, 3H), 7.35 - 7.25 (m, 4H), 4.81 (s, 2H), 4.25 (d, J=5.5 Hz, 2H), 4.14 (t, J=5.6 Hz, 2H), 3.89 (t, J=5.6 Hz, 2H).Example 55: N-[(3,5-dichlorophenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0256] Preparation of Example 55:

[0257] The title compound was prepared in analogy to the preparation of Example 11 by using (3,5-dichloro-phenyl)methanamine instead of 3-(trifluoromethyl)aniline. Example 55 was obtained as a white solid. LCMS (M+H +< ): 419. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 7.86 - 7.74 (m, 1H), 7.59 (t, J=5.7 Hz, 1H), 7.52 - 7.40 (m, 3H), 7.31 (d, J=1.9 Hz, 2H), 7.29 - 7.14 (m, 2H), 4.82 (s, 2H), 4.26 (d, J=5.8 Hz, 2H), 4.15 (t, J=5.3 Hz, 2H), 3.89 (t, J=5.3 Hz, 2H).Example 56: N-(4-chloro-5-methyl-2-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0258] Preparation of Example 56:

[0259] The title compound was prepared in analogy to the preparation of Example 32 by using 4-chloro-5-methyl-pyridin-2-amine instead of 5-fluoro-6-methyl-pyridin-2-amine. Example 56 was obtaineded as a white solid (21 mg). LCMS (M+H +< ): 386. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.85 (s, 1H), 8.21 (s, 1H), 7.91 (s, 1H), 7.83 (s, 1H), 7.50 (dd, J=5.5, 8.8 Hz, 2H), 7.34 - 7.19 (m, 2H), 4.96 (s, 2H), 4.25 - 4.16 (m, 2H), 4.05 - 3.97 (m, 2H), 2.25 (s, 3H).Example 57: 3-(4-chloro-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0260] Preparation of Example 57:

[0261] The title compound was prepared in analogy to the preparation of Example 28 by using 2,4-dichloropyridine instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 57 was obtained as a white solid. LCMS (M+H +< ): 354. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.07 (s, 1H), 8.55 (d, J=5.5 Hz, 1H), 8.22 (s, 1H), 7.89 (d, J=1.8 Hz, 1H), 7.49 (d, J=7.8 Hz, 2H), 7.31 (dd, J=1.9, 5.4 Hz, 1H), 7.25 (t, J=7.9 Hz, 2H), 6.96 (t, J=7.4 Hz, 1H), 5.05 (s, 2H), 4.24 (t, J=5.1 Hz, 2H), 4.03 (t, J=5.1 Hz, 2H).Example 58: N-[(2-chloro-3-fluoro-phenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0262] Preparation of Example 58:

[0263] The title compound was prepared in analogy to the preparation of Example 11 by using (2-chloro-3fluoro-phenyl)methanamine instead of 3-(trifluoromethyl)aniline. Example 58 was obtained as a white solid (26 mg). LCMS (M+H +< ): 403. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 7.82 (s, 1H), 7.57 (t, J=5.5 Hz, 1H), 7.48 (dd, J=5.4, 8.7 Hz, 2H), 7.38 - 7.15 (m, 5H), 4.84 (s, 2H), 4.37 (d, J=5.5 Hz, 2H), 4.17 (t, J=5.1 Hz, 2H), 3.92 (d, J=5.3 Hz, 2H).Example 59: N-[(2,6-dichlorophenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0264] Preparation of Example 59:

[0265] The title compound was prepared in analogy to the preparation of Example 11 by using (2,5-dichloro-phenyl)methanamine instead of 3-(trifluoromethyl)aniline. Example 59 was obtained as a white solid (21 mg). LCMS (M+H +< ): 419. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 7.78 (s, 1H), 7.53 - 7.41 (m, 4H), 7.39 - 7.31 (m, 1H), 7.28 - 7.17 (m, 2H), 7.09 (br. s, 1H), 4.76 (s, 2H), 4.49 (d, J=4.3 Hz, 2H), 4.10 (d, J=5.3 Hz, 2H), 3.87 (d, J=5.0 Hz, 2H).Example 60: 3-(2,4-difluorophenyl)-N-(5-fluoro-6-methyl-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0266] Preparation of Example 60:

[0267] To a mixture of 5-fluoro-6-methyl-pyridin-2-amine (40 mg, 0.32 mmol) and Et 3 N (65 mg, 0.64 mmol) in THF (5 mL) was added phenyl chloroformate (50 mg, 0.12 mmol) at 0 °C. After stirred at room temperature for 12 hours, the reaction mixture was diluted with EtOAc (20 mL), washed with saturated aqueous NaHCO 3 (20 mL). The separated organic layer was washed with brine (30 mL), dried over anhydrous sodium sulfate. The solvent was removed in vacuo. The residue was dissolved in DMF (2 mL), to which were added 3-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 50b, 44 mg, 0.32 mmol) and DIPEA (0.2 mL). The resulting mixture was stirred at 80 °C for 1 hour, then subjected to purification by prep-HPLC to afford Example 60 (16 mg) as a white solid. LCMS (M+H +< ): 388. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.63 (br. s, 1H), 8.43 (br. s, 1H), 7.66 - 7.61 (m, 1H), 7.59 - 7.45 (m, 2H), 7.41 - 7.30 (m, 1H), 7.23 - 7.11 (m, 1H), 4.81 (s, 2H), 4.21 (d, J=5.0 Hz, 2H), 4.02 (s, 2H), 2.36 (d, J=2.5 Hz, 3H).Example 61: N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0268] Preparation of Example 61:

[0269] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-trifluoromethylaniline and 3-(4-fluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 53f ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 61 was obtained as a white solid (27 mg). LCMS (M+H +< ): 403. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.96 (s, 1H), 7.86 (s, 1H), 7.74 (dd, J=2.5, 6.9 Hz, 1H), 7.55 (dd, J=5.5, 8.8 Hz, 2H), 7.45 - 7.40 (m, 1H), 7.36 - 7.30 (m, 1H), 7.27 (t, J=8.8 Hz, 2H), 5.20 (d, J=16.7 Hz, 1H), 4.96 - 4.87 (m, 1H), 4.65 (d, J=16.7 Hz, 1H), 4.29 - 4.22 (m, 1H), 4.21 - 4.14 (m, 1H), 1.18 (d, J=6.8 Hz, 3H).Example 62: 3-(4-fluorophenyl)-N-(2-methyl-1,3-benzothiazol-5-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0270] Preparation of Example 62:

[0271] The title compound was prepared in analogy to the preparation of Example 11 by using 2-methyl-1,3-benzothiazol-5-amine instead of 3-(trifluoromethyl)aniline. Example 62 was obtained as a white solid (33 mg). LCMS (M+H +< ): 408. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.06 (s, 1H), 8.07 (d, J=1.8 Hz, 1H), 7.92 - 7.82 (m, 2H), 7.56 - 7.44 (m, 3H), 7.33 - 7.21 (m, 2H), 4.97 (s, 2H), 4.25 (t, J=5.3 Hz, 2H), 4.04 (t, J=5.1 Hz, 2H), 2.81 - 2.73 (m, 3H).Example 63: N-(benzothiophen-3-yl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0272] Preparation of Example 63:

[0273] The title compound was prepared in analogy to the preparation of Example 11 by using 2-methyl-1,3-benzothiazol-5-amine instead of 3-(trifluoromethyl)aniline. Example 63 was obtained as a white solid (24 mg). LCMS (M+H +< ): 393. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.04 (s, 1H), 7.96 - 7.91 (m, 1H), 7.88 - 7.84 (m, 2H), 7.58 (s, 1H), 7.55 - 7.49 (m, 2H), 7.44 - 7.37 (m, 2H), 7.28 (t, J=8.8 Hz, 2H), 5.00 (s, 2H), 4.26 (t, J=5.2 Hz, 2H), 4.07 (t, J=5.4 Hz, 2H).Example 64: 3-(2,4-difluorophenyl)-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0274] Preparation of Example 64:

[0275] The title compound was prepared in analogy to the preparation of Example 11 by using 2-(trifluoromethyl)pyridin-4-amine instead of 3-trifluoromethylaniline and 3-(2, 4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 64 was afforded as a white solid (10 mg). LCMS (M+H +< ): 424. 1< H NMR (400MHz, DMSO-d 6 ) δδ ppm 9.64 (s, 1H), 8.52 (d, J=5.5 Hz, 1H), 8.00 (d, J=1.8 Hz, 1H), 7.72 (s, 2H), 7.55 - 7.46 (m, 1H), 7.44 - 7.35 (m, 1H), 7.20 (dt, J=2.4, 8.3 Hz, 1H), 4.84 (s, 2H), 4.27 (t, J=5.3 Hz, 2H), 4.06 (t, J=5.3 Hz, 2H).Example 65: 3-(3-cyclopropylphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0276] Preparation of Example 65:

[0277] The title compound was prepared in analogy to the preparation of Example 28 by using 1-bromo-3-cyclopropyl-benzene instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 65 was obtained as a white solid (15 mg). LCMS (M+H +< ): 359. 1< H NMR (400MHz, chloroform-d) δ ppm 7.76 (s, 1H), 7.39 - 7.31 (m, 5H), 7.10 (br. s, 3H), 7.03 - 6.96 (m, 1H), 6.70 - 6.53 (m, 1H), 4.90 (s, 2H), 4.38 (m, 2H), 4.04 (m, 2H), 2.00 - 1.90 (m, 1H), 1.11 - 0.98 (m, 2H), 0.81 - 0.68 (m, 2H).Example 66: 3-(2-hydroxyphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0278] Preparation of Example 66:

[0279] The title compound was prepared in analogy to the preparation of Example 28 by using 2-bromophenol instead of 2-chloro-4-(trifluoromethyl)pyridine. Example 66 was obtained as a white solid. LCMS (M+H +< ): 335. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.65 (br. s, 1H), 8.84 (s, 1H), 7.64 (s, 1H), 7.43 (d, J=8.0 Hz, 2H), 7.27 - 7.17 (m, 3H), 7.12 (t, J=7.7 Hz, 1H), 6.99 - 6.90 (m, 2H), 6.85 (t, J=7.0 Hz, 1H), 4.76 (s, 2H), 4.21 (m, 2H), 4.00 (m, 2H).Example 67: N-(3-chloro-4-fluoro-phenyl)-3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0280]

[0281] The title compound was prepared according to the following scheme: Step 1: preparation of tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 67a)

[0282] To a solution of tert-butyl 3-iodo-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 1e , 500 mg, 1.4 mmol) in THF (15 mL) was added isopropyl magnesium chloride (1.7 mL, 3.4 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 hours, then 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (380 mg, 2 mmol) in THF (5 mL) was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 1 hour, then quenched with saturated aqueous ammonium chloride solution (20 mL), and extracted with EtOAc (30 mL). The organic layer was washed with brine, and concentrated to afford compound 67a (450 mg) as a white solid. LCMS (M+H +< ): 350.Step 2: preparation of tert-butyl 3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 67b)

[0283] To a mixture of tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 67a, 450 mg, 1.3 mmol), 2-chloro-4-(trifluoromethyl)pyridine (324 mg, 1.8 mmol) and K 2 CO 3 (252 mg, 1.8 mmol) in DMSO / H 2 O (10 mL, 10:1, v / v) was added Pd(dppf)Cl 2 (50 mg) under N 2 . The reaction mixture was stirred at 80 °C for 12 hours. Then the reaction mixture was filtered, the filtrate was purified by column chromatography to afford compound 67b (300 mg) as a white solid. LCMS (M+H +< ): 369.Step 3: preparation of 3-[4-(trifluoromethyl)-2-pyridyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 67c)

[0284] A solution of tert-butyl 3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 67b, 300 mg, 1.7 mmol) in HCl / MeOH (20 mL) was stirred at room temperature for 2 hours. Then the reaction mixture was concentrated in vacuo to afford compound 67c (200 mg) as a slight yellow solid. LCMS (M+H +< ): 269.Step 4: Preparation of N-(3-chloro-4-fluoro-phenyl)-3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 67)

[0285] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline and 3-[4-(trifluoromethyl)-2-pyridyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 67c ) instead of 3-(trifluoromethyl)aniline and 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ), respectively. Example 67 was obtained as a white solid (8 mg). LCMS (M+H +< ): 440. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.13 (br. s, 1H), 8.85 (d, J=5.0 Hz, 1H), 8.35 (s, 1H), 8.08 (br. s, 1H), 7.74 (d, J=4.4 Hz, 1H), 7.52 (d, J=4.3 Hz, 1H), 7.40 (br. s, 1H), 7.36 - 7.24 (m, 1H), 5.09 (s, 2H), 4.26 (m, 2H), 4.01 (m, 2H).Example 68: N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-4-methyl-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0286]

[0287] The title compound was prepared according to the following scheme: Preparation of 3-(5-fluoro-4-methyl-2-pyridyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 68b):

[0288] The compound 68b was prepared in analogy to compound 67c by using 2-chloro-5-fluoro-4-methyl-pyridine instead of 2-chloro-4-(trifluoromethyl)pyridine. Compound 68b was obtained as a white solid (250 mg). LCMS (M+H +< ): 233.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-4-methyl-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 68):

[0289] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline and 3-(5-fluoro-4-methyl-2-pyridyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 68b ) instead of 3-(trifluoromethyl)aniline and 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ), respectively. Example 68 was obtained as a white solid (30 mg). LCMS (M+H +< ): 404. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.09 (s, 1H), 8.45 (d, J=1.0 Hz, 1H), 8.06 (s, 1H), 7.78 - 7.67 (m, 2H), 7.45 - 7.39 (m, 1H), 7.35 - 7.29 (m, 1H), 5.03 (s, 2H), 4.23 (t, J=5.3 Hz, 2H), 3.99 (t, J=5.3 Hz, 2H), 2.32 (s, 3H).Example 69: N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0290]

[0291] The title compound was prepared according to the following scheme: Preparation of 3-(5-fluoro-2-pyridyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 69b):

[0292] The compound 69b was prepared in analogy to compound 67c by using 2-chloro-5-fluoro-pyridine instead of 2-chloro-4-(trifluoromethyl)pyridine. Compound 69b was obtained as a white solid (250 mg). LCMS (M+H +< ): 219.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 69):

[0293] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-(trifluoromethyl)aniline and 3-(5-fluoro-2-pyridyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 69b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 69 was obtained as a white solid (50 mg). LCMS (M+H +< ): 390. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.09 (s, 1H), 8.58 (d, J=2.5 Hz, 1H), 8.10 (s, 1H), 7.78 (s, 3H), 7.45 - 7.39 (m, 1H), 7.36 - 7.29 (m, 1H), 5.04 (s, 2H), 4.24 (t, J=5.3 Hz, 2H), 4.00 (t, J=5.3 Hz, 2H).Example 70: N-(2-chloro-4-pyridyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H -pyrazolo[1,5-a]pyrazine-5-carboxamide

[0294] Preparation of Example 70:

[0295] The title compound was prepared in analogy to the preparation of Example 11 by using 2-chloropyridin-4-amine instead of 3-trifuloromethylaniline and 3-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 70 was obtained as a white solid (27 mg). LCMS (M+H +< ): 390. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.49 (s, 1H), 8.16 (d, J=5.8 Hz, 1H), 7.71 (d, J=1.3 Hz, 1H), 7.61 (d, J=1.3 Hz, 1H), 7.55 - 7.30 (m, 3H), 7.25 - 7.13 (m, 1H), 4.82 (s, 2H), 4.26 (t, J=5.3 Hz, 2H), 4.10 - 3.98 (m, 2H).Example 71: 3-[4-(trifluoromethyl)-2-pyridyl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0296] Preparation of Example 71:

[0297] The title compound was prepared in analogy to Example 11 by using 3,4,5-trifluoroaniline instead of 3-(trifluoromethyl)aniline and 3-[4-(trifluoromethyl)-2-pyridyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 67c ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 71 was obtained as a white solid. LCMS (M+H +< ): 442. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.35 (s, 1H), 8.85 (d, J=5.1 Hz, 1H), 8.35 (s, 1H), 8.09 (s, 1H), 7.52 (d, J=5.0 Hz, 1H), 7.43 (dd, J=6.4, 10.7 Hz, 2H), 5.09 (s, 2H), 4.26 (d, J=5.3 Hz, 2H), 4.03 (d, J=5.4 Hz, 2H).Example 72: N,3-bis(3-chloro-4-fluoro-phenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0298]

[0299] The title compound was prepared according to the following scheme: Preparation of 3-(3-chloro-4-fluoro-phenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 72b):

[0300] The compound 72b was prepared in analogy to compound 11b by using (3-chloro-4-fluoro-phenyl)boronic acid (300 mg) instead of (4-fluoro-phenyl)boronic acid. Compound 72b was obtained as a white solid (250 mg). LCMS (M+H +< ): 252.Preparation of N,3-bis(3-chloro-4-fluoro-phenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 72):

[0301] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-(trifluoromethyl)aniline and 3-(3-chloro-4-fluoro-phenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 72b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 72 was obtained as a white solid (10 mg). LCMS (M+H +< ): 443. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.09 (s, 1H), 7.90 (s, 1H), 7.76 - 7.61 (m, 2H), 7.55 - 7.37 (m, 3H), 7.37 - 7.27 (m, 1H), 4.95 (s, 2H), 4.22 (d, J=4.8 Hz, 2H), 3.99 (m, 2H).Example 73: N-(3-chloro-4-fluoro-phenyl)-3-cyclohexyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0302]

[0303] The title compound was prepared according to the following scheme: Preparation of 3-cyclohexyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 73c):

[0304] The compound 73c was prepared in analogy to compound 26c by using cyclohexen-1-ylboronic acid instead of cyclopenten-1-ylboronic acid. Compound 73c was obtained as a white solid (250 mg). LCMS (M+H +< ): 306.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-cyclohexyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 73):

[0305] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-(trifluoromethyl)aniline and 3-cyclohexyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 73c ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 73 was obtained as a white solid (10 mg). LCMS (M+H +< ): 377. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.98 (s, 1H), 7.75 (dd, J=2.5, 6.8 Hz, 1H), 7.44 (td, J=4.3, 7.2 Hz, 1H), 7.36 - 7.32 (m, 1H), 7.31 - 7.29 (m, 1H), 4.69 (s, 2H), 4.13 - 4.08 (m, 2H), 3.95 - 3.90 (m, 2H), 2.42 (m, 1H), 1.86 - 1.63 (m, 5H), 1.38 - 1.20 (m, 5H).Example 74: N-(3-cyano-4-fluoro-phenyl)-3-(5-fluoro-4-methyl-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0306] Preparation of Example 74:

[0307] The title compound was prepared in analogy to the preparation of Example 11 by using 5-amino-2-fluoro-benzonitrile instead of 3-(trifluoromethyl)aniline and 3-(5-fluoro-4-methyl-2-pyridyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 68b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 74 was obtained as a white solid (16 mg). LCMS (M+H +< ): 396. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.25 (s, 1H), 8.45 (s, 1H), 8.06 (s, 1H), 7.95 (d, J=2.8 Hz, 1H), 7.82 - 7.76 (m, 1H), 7.71 (d, J=6.0 Hz, 1H), 7.51 - 7.43 (m, 1H), 5.05 (s, 2H), 4.24 (t, J=5.2 Hz, 2H), 4.03 - 3.99 (m, 2H), 2.32 (s, 3H).Example 75: 3-(5-fluoro-2-pyridyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5- a]pyrazine-5-carboxamide

[0308] Preparation of Example 75:

[0309] The title compound was prepared in analogy to the preparation of Example 11 by using 3,4,5-trifluoroaniline instead of 3-(trifluoromethyl)aniline and 3-(5-fluoro-2-pyridyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 69b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 75 was obtained as a white solid (50 mg). LCMS (M+H +< ): 392. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.35 - 9.22 (m, 1H), 8.58 (d, J=2.6 Hz, 1H), 8.11 (s, 1H), 7.82 - 7.68 (m, 2H), 7.51 - 7.36 (m, 2H), 5.05 (s, 2H), 4.24 (t, J=5.3 Hz, 2H), 4.01 (t, J=5.0 Hz, 2H).Example 76: N-(3-cyano-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0310] Preparation of Example 76:

[0311] The title compound was prepared in analogy to the preparation of Example 11 by using 5-amino-2-fluoro-benzonitrile instead of 3-(trifluoromethyl)aniline and 3-(5-fluoro-2-pyridyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 69b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 76 was obtained as a white solid (42 mg). LCMS (M+H +< ): 381. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.26 (s, 1H), 8.58 (d, J=2.5 Hz, 1H), 8.11 (s, 1H), 7.94 (dd, J=2.6, 5.8 Hz, 1H), 7.83 - 7.71 (m, 3H), 7.46 (t, J=9.2 Hz, 1H), 5.06 (s, 2H), 4.25 (t, J=5.3 Hz, 2H), 4.01 (t, J=5.3 Hz, 2H).Example 77: 3-(4-fluorophenyl)-N-(1H-indol-6-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0312] Preparation of Example 77:

[0313] The title compound was prepared in analogy to the preparation of Example 11 by using 1H-indol-6-amine instead of 3-(trifluoromethyl)aniline. Example 77 was obtained as a white solid (17 mg). LCMS (M+H +< ):376. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 10.92 (s, 1H), 8.78 (s, 1H), 7.83 (s, 1H), 7.60 (s, 1H), 7.55 - 7.47 (m, 2H), 7.39 (d, J=8.5 Hz, 1H), 7.31 - 7.18 (m, 3H), 7.00 (d, J=8.3 Hz, 1H), 6.33 (s, 1H), 4.96 - 4.93 (m, 2H), 4.25- 4.21 (m, 2H), 4.03-4.00 (m, 2H).Example 78: N-(3-chloro-4-fluoro-phenyl)-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0314] Preparation of Example 78:

[0315] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-(trifluoromethyl)aniline and 3-cyclopentyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 26c ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 78 was obtained as a white solid. LCMS (M+H +< ): 363. 1< H NMR (400 MHz, DMSO-d 6 ) δ ppm 9.00 (s, 1H), 7.76 (dd, J=2.5, 6.8 Hz, 1H), 7.47 - 7.43 (m, 1H), 7.38 - 7.27 (m, 2H), 4.69 (s, 2H), 4.15 - 4.05 (m, 2H), 3.93 (t, J=5.3 Hz, 2H), 2.88 - 2.76 (m, 1H), 2.02 - 1.89 (m, 2H), 1.78 - 1.55 (m, 4H), 1.49 - 1.39 (m, 2H).Example 79: N-(3-cyano-4-fluoro-phenyl)-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0316] Preparation of Example 79:

[0317] The title compound was prepared in analogy to the preparation of Example 11 by using 5-amino-2-fluorobenzonitrile instead of 3-(trifluoromethyl)aniline and 3-cyclopentyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 26c ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 79 was obtained as a white solid. LCMS (M+H +< ): 354. 1< H NMR (400 MHz, DMSO-d 6 ) δ ppm 7.76 - 7.72 (m, 1H), 7.63 (dd, J=2.8, 5.3 Hz, 1H), 7.49 (s, 1H), 7.37 (s, 1H), 7.16 (t, J=8.8 Hz, 1H), 4.74 (s, 2H), 4.23 (t, J=5.3 Hz, 2H), 3.98 (t, J=5.3 Hz, 2H), 2.88 - 2.73 (m, 1H), 2.06 - 1.98 (m, 2H), 1.82 - 1.60 (m, 4H), 1.56 - 1.44 (m, 2H).Example 80: 3-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0318] Preparation of Example 80:

[0319] The title compound was prepared in analogy to the preparation of Example 11 by using 4-fluoro-3-trifluoromethylaniline instead of 3-(trifluoromethyl)aniline. Example 80 was obtained as a white solid (17 mg). LCMS (M+H +< ): 423. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.21 (s, 1H), 7.98 - 7.71 (m, 3H), 7.57 - 7.37 (m, 3H), 7.27 (t, J=8.8 Hz, 2H), 4.94 (s, 2H), 4.23 (d, J=4.8 Hz, 2H), 4.02 (d, J=5.0 Hz, 2H).Example 81: N-(4-fluoro-3-methyl-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5- a]pyrazine-5-carboxamide

[0320] Preparation of Example 81:

[0321] The title compound was prepared in analogy to the preparation of Example 11 by using 4-fluoro-3-methyl-aniline instead of 3-(trifluoromethyl)aniline. Example 81 was obtained as a white solid (36 mg). LCMS (M+H +< ): 369. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.86 (s, 1H), 7.82 (s, 1H), 7.49 (dd, J=5.6, 8.4 Hz, 2H), 7.38 - 7.22 (m, 4H), 7.02 (t, J=9.2 Hz, 1H), 4.91 (s, 2H), 4.21 (t, J=5.1 Hz, 2H), 3.99 (t, J=5.0 Hz, 2H), 2.19 (s, 3H).Example 82: 3-cyclopentyl-N-indan-5-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0322] Preparation of Example 82:

[0323] The title compound was prepared in analogy to the preparation of Example 11 by using indan-5-amine instead of 3-(trifluoromethyl)aniline and 3-cyclopentyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 26c ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 82 was obtained as a white solid. LCMS (M+H +< ): 351. 1< H NMR (400 MHz, chloroform-d) δ ppm 7.50 (s, 1H), 7.30 - 7.24 (m, 1H), 7.16 (d, J=8.0 Hz, 1H), 7.04 (d, J=7.5 Hz, 1H), 6.81 (br. s, 1H), 4.72 (s, 2H), 4.43 - 4.17 (m, 2H), 3.96 (s, 2H), 2.94 - 2.76 (m, 5H), 2.15 - 1.98 (m, 4H), 1.87 - 1.62 (m, 4H), 1.57 - 1.44 (m, 2H).Example 83: 3-cyclopentyl-N-indan-1-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0324] Preparation of Example 83:

[0325] The title compound was prepared in analogy to the preparation of Example 11 by using indan-1-amine instead of 3-(trifluoromethyl)aniline and 3-cyclopentyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 26c ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 83 was obtained as a white solid. LCMS (M+H +< ): 351. 1< H NMR (400 MHz, chloroform-d) δ ppm 7.49 (s, 1H), 7.36 (d, J=6.8 Hz, 1H), 7.32 - 7.29 (m, 2H), 7.28 - 7.24 (m, 1H), 5.45 (d, J=6.8 Hz, 1H), 5.17 - 4.79 (m, 1H), 4.63 (s, 2H), 4.34 (t, J=5.1 Hz, 2H), 3.92 (t, J=5.3 Hz, 2H), 3.09 - 2.99 (m, 1H), 2.96 - 2.76 (m, 2H), 2.72-2.64 (m, 1H), 2.09 - 1.96 (m, 2H), 1.92 - 1.60 (m, 5H), 1.57 - 1.45 (m, 2H).Example 84: N-benzyl-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0326] Preparation of Example 84:

[0327] The title compound was prepared in analogy to the preparation of Example 11 by using benzylamine instead of 3-(trifluoromethyl)aniline and 3-cyclopentyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 26c ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 84 was obtained as a white solid. LCMS (M+H +< ): 325. 1< H NMR (400 MHz, chloroform-d) δ ppm 7.45 (s, 1H), 7.39 - 7.24 (m, 5H), 5.29 (br. s, 1H), 4.66 - 4.56 (m, 2H), 4.50 - 4.37 (m, 2H), 4.27 (t, J=5.1 Hz, 2H), 3.88 (t, J=5.1 Hz, 2H), 2.86 - 2.72 (m, 1H), 2.07 - 1.97 (m, 2H), 1.84 - 1.62 (m, 4H), 1.56 - 1.42 (m, 2H).Example 85: N-(3-cyano-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0328]

[0329] The title compound was prepared according to the following scheme: Preparation of 3-(2,4-difluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 85b):

[0330] The compound 85b was prepared in analogy to compound 53f by using (2,4-difluorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Compound 85b was obtained as a white solid (250 mg). LCMS (M+H +< ): 250.Preparation of N-(3-cyano-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 85):

[0331] The title compound was prepared in analogy to the preparation of Example 11 by using 5-amino-2-fluorobenzonitrile instead of 3-(trifluoromethyl)aniline and 3-(2,4-difluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 85b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 85 was obtained as a white solid (33 mg). LCMS (M+H +< ): 412. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.09 (s, 1H), 7.94 (dd, J=2.7, 5.7 Hz, 1H), 7.82 - 7.75 (m, 1H), 7.73 (d, J=1.9 Hz, 1H), 7.56 (dt, J=6.7, 8.8 Hz, 1H), 7.45 (t, J=9.1 Hz, 1H), 7.40 - 7.36 (m, 1H), 7.19 (dt, J=2.3, 8.3 Hz, 1H), 5.08 (d, J=16.8 Hz, 1H), 4.99 - 4.89 (m, 1H), 4.53 (d, J=16.9 Hz, 1H), 4.32 - 4.14 (m, 2H), 1.20 (d, J=6.8 Hz, 3H).Example 86: N-(3-cyano-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0332] Preparation of Example 86:

[0333] The title compound was prepared in analogy to the preparation of Example 11 by using 5-amino-2-fluoro-benzonitrile instead of 3-trifluoromethylaniline and 3-(4-fluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 53f ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 86 was obtained as a white solid (12 mg). LCMS (M+H +< ): 394. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.16 (s, 1H), 7.96 (dd, J=2.7, 5.7 Hz, 1H), 7.87 (s, 1H), 7.84 - 7.76 (m, 1H), 7.56 (dd, J=5.4, 8.8 Hz, 2H), 7.50 - 7.41 (m, 1H), 7.27 (t, J=8.8 Hz, 2H), 5.22 (d, J=16.7 Hz, 1H), 5.03 - 4.85 (m, 1H), 4.67 (d, J=16.7 Hz, 1H), 4.31 - 4.24 (m, 1H), 4.23 - 4.12 (m, 1H), 1.19 (d, J=6.8 Hz, 3H).Example 87: N-(3-chloro-4-fluoro-phenyl)-3-pyrrolidin-1-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0334]

[0335] The title compound was prepared according to the following scheme: Step 1: preparation of tert-butyl 3-pyrrolidin-1-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 87a)

[0336] To a solution of tert-butyl 3-iodo-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 1e , 350 mg 1.0 mmol), pyrrolidine (140 mg, 2.0 mmol) and K 3 PO 4 (636 mg, 3.0 mmol) in ethane-1,2-diol / propan-2-ol (10 mL, 2:1, v / v) were added CuI (40 mg 0.2 mmol) under N 2 . The reaction mixture was stirred at microwave for 2 hours at 120 °C, and then filtered. The filtrate was concentrated, and the residue was purified by column chromatography to afford compound 87a (100 mg) as a slight yellow oil. LCMS (M+H +< ): 293.Step 2: preparation of 3-pyrrolidin-1-yl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 87b):

[0337] A solution of tert-butyl 3-pyrrolidin-1-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 87a, 88 mg, 0.3 mmol) in HCl / MeOH (20 mL) was stirred at room temperature for 2 hours. Then the reaction mixture was concentrated in vacuo to afford compound 87b (80 mg) as a slight yellow solid. LCMS (M+H +< ): 293.Step 3: preparation of N-(3-chloro-4-fluoro-phenyl)-3-pyrrolidin-1-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 87):

[0338] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-(trifluoromethyl)aniline and 3-pyrrolidin-1-yl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 87b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 87 was obtained as a white solid. LCMS (M+H +< ): 364. 1< H NMR (400MHz, chloroform-d) δ ppm 7.58 (dd, J=2.5, 6.5 Hz, 1H), 7.28 - 7.21 (m, 2H), 7.13 - 7.07 (m, 1H), 6.68 (br. s, 1H), 4.82 (s, 2H), 4.25 (t, J=5.4 Hz, 2H), 4.00 (t, J=5.5 Hz, 2H), 3.15 (m, 4H), 2.00(m, 4H).Example 88: 3-(2,4-difluorophenyl)-6-methyl-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0339] Preparation of Example 88:

[0340] The title compound was prepared in analogy to the preparation of Example 11 by using 2-(trifluoromethyl)pyridin-4-amine instead of 3-(trifluoromethyl)aniline and 3-(2,4-difluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 85b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 88 was obtained as a white solid (28 mg). LCMS (M+H +< ): 438. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.55 (s, 1H), 8.52 (d, J=5.8 Hz, 1H), 8.02 (d, J=1.5 Hz, 1H), 7.78 - 7.70 (m, 2H), 7.62 - 7.52 (m, 1H), 7.43 - 7.33 (m, 1H), 7.20 (dt, J=2.3, 8.4 Hz, 1H), 5.12 (d, J=16.8 Hz, 1H), 5.01 - 4.89 (m, 1H), 4.57 (d, J=17.1 Hz, 1H), 4.35 - 4.28 (m, 1H), 4.27 - 4.19 (m, 1H), 1.22 (d, J=6.8 Hz, 3H).Example 89: N-(3-chloro-4-fluoro-phenyl)-3-(1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0341]

[0342] The title compound was prepared according to the following scheme: Preparation of 3-(1-piperidyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 89b):

[0343] The compound 89b was prepared in analogy to compound 87b by using piperidine instead of pyrrolidine. Compound 89b was obtained as a slight yellow solid (90 mg). LCMS (M+H +< ): 207.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-(1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 89):

[0344] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-(trifluoromethyl)aniline and 3-(1-piperidyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 89b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 89 was obtained as a white solid. LCMS (M+H +< ): 378. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.03 (br. s, 1H), 7.75 (dd, J=2.5, 6.8 Hz, 1H), 7.47 - 7.40 (m, 1H), 7.36 - 7.29 (m, 1H), 7.25 (s, 1H), 4.64 (s, 2H), 4.09 (t, J=5.4 Hz, 2H), 3.91 (t, J=5.3 Hz, 2H), 2.85 - 2.72 (m, 4H), 1.61 (d, J=5.0 Hz, 4H), 1.48 (d, J=5.3 Hz, 2H).Example 90: N-(3-chloro-4-fluoro-phenyl)-3-(4,4-difluoro-1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0345]

[0346] The title compound was prepared according to the following scheme: Preparation of 3-(4,4-difluoro-1-piperidyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 90b):

[0347] The compound 90b was prepared in analogy to compound 87b by using 4,4-difluoropiperidine instead of pyrrolidine. Compound 90b was obtained as a slight yellow solid (90 mg). LCMS (M+H +< ): 243.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-(4,4-difluoro-1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 90):

[0348] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-(trifluoromethyl)aniline and 3-(4,4-difluoro-1-piperidyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 90b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 90 was obtained as a white solid. LCMS (M+H +< ): 414. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.03 (s, 1H), 7.75 (dd, J=2.5, 6.8 Hz, 1H), 7.50 - 7.39 (m, 1H), 7.37 - 7.23 (m, 2H), 4.66 (s, 2H), 4.15 - 4.04 (m, 2H), 3.92 (t, J=5.3 Hz, 2H), 2.96 (t, J=5.4 Hz, 4H), 2.16 - 1.96 (m, 4H).Example 91: N-(3-chloro-4-fluoro-phenyl)-3-thiazol-2-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0349]

[0350] The title compound was prepared according to the following scheme: Preparation of 2-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)thiazole (compound 91b):

[0351] The compound 91b was prepared in analogy to compound 67c by using 2-bromothiazole instead of 2-chloro-4-(trifluoromethyl)pyridine. Compound 91b was obtained as a white solid (250 mg). LCMS (M+H +< ): 207.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-thiazol-2-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 91):

[0352] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-(trifluoromethyl)aniline and 2-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)thiazole (compound 91b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 91 was obtained as a white solid (12 mg). LCMS (M+H +< ): 378. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.20 (s, 1H), 8.00 (s, 1H), 7.85 (d, J=3.3 Hz, 1H), 7.74 (dd, J=2.6, 6.9 Hz, 1H), 7.64 (d, J=3.3 Hz, 1H), 7.43 (dt, J=2.6, 4.5 Hz, 1H), 7.36 - 7.28 (m, 1H), 5.00 (s, 2H), 4.26 (t, J=5.3 Hz, 2H), 4.02 (t, J=5.3 Hz, 2H).Example 92: N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0353] Preparation of Example 92:

[0354] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-(trifluoromethyl)aniline and 3-(2,4-difluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 85b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 92 was obtained as a white solid (24 mg). LCMS (M+H +< ): 421. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.97 (s, 1H), 7.77 - 7.68 (m, 2H), 7.65 - 7.51 (m, 1H), 7.45 - 7.25 (m, 3H), 7.24 - 7.12 (m, 1H), 5.08 (d, J=16.8 Hz, 1H), 4.99 - 4.87 (m, 1H), 4.51 (d, J=16.8 Hz, 1H), 4.32 - 4.24 (m, 1H), 4.24 - 4.16 (m, 1H), 1.19 (d, J=6.8 Hz, 3H).Example 93: N-(2-chloro-4-pyridyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0355] Preparation of Example 93:

[0356] The title compound was prepared in analogy to the preparation of Example 11 by using 2-chloro-pyridin-4-amine instead of 3-(trifluoromethyl)aniline and 3-(2,4-difluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 85b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 93 was obtained as a white solid (10 mg). LCMS (M+H +< ): 404. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.51 (s, 1H), 8.17 (d, J=5.5 Hz, 1H), 7.73 (s, 1H), 7.64 (s, 1H), 7.57 (d, J=7.8 Hz, 1H), 7.47 (s, 1H), 7.42 - 7.32 (m, 1H), 7.19 (s, 1H), 5.10 (d, J=17.3 Hz, 1H), 4.94 (m, 1H), 4.55 (d, J=16.6 Hz, 1H), 4.35 - 4.17 (m, 2H), 1.26 - 1.16 (m, 3H).Example 94: N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0357]

[0358] The title compound was prepared according to the following scheme Preparation of 3-(5-fluoro-2-pyridyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 94c):

[0359] The compound 94c was prepared in analogy to compound 67c by using 2-chloro-5-fluoro-pyridine instead of 2-chloro-4-(trifluoromethyl)pyridine and tert-butyl 3-iodo-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 53d ) instead of tert-butyl 3-iodo-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 1e ). Compound 94c was obtained as a white solid (250 mg). LCMS (M+H +< ): 233.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 94):

[0360] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-(trifluoromethyl)aniline and 3-(5-fluoro-2-pyridyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 94b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 94 was obtained as a white solid (48 mg). LCMS (M+H +< ): 404. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.03 (s, 1H), 8.58 (d, J=2.9 Hz, 1H), 8.14 (s, 1H), 7.84 - 7.72 (m, 3H), 7.47 - 7.40 (m, 1H), 7.37 - 7.30 (m, 1H), 5.44 (d, J=18.1 Hz, 1H), 4.93 - 4.84 (m, 1H), 4.62 (d, J=18.2 Hz, 1H), 4.28 (d, J=4.4 Hz, 1H), 4.23 - 4.17 (m, 1H), 1.18 (d, J=6.8 Hz, 3H).Example 95: N-(3-chloro-4-fluoro-phenyl)-3-(3,3-difluoro-1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0361]

[0362] The title compound was prepared according to the following scheme: Preparation of 3-(3,3-difluoro-1-piperidyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 95b):

[0363] The compound 95b was prepared in analogy to compound 87b by using 4,4-difluoropiperidine instead of pyrrolidine. Compound 95b was afforded as a slight yellow solid (90 mg). LCMS (M+H +< ): 243.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-(3,3-difluoro-1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 95):

[0364] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-(trifluoromethyl)aniline and 3-(3,3-difluoro-1-piperidyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 95b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 95 was obtained as a white solid (10 mg). LCMS (M+H +< ): 414. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.09 (s, 1H), 7.75 (dd, J=2.5, 7.0 Hz, 1H), 7.44 (d, J=7.5 Hz, 1H), 7.35 - 7.28 (m, 2H), 4.65 (s, 2H), 4.10 (d, J=5.0 Hz, 2H), 3.93 (d, J=5.3 Hz, 2H), 3.09 (t, J=11.5 Hz, 2H), 2.84 (m, 2H), 1.97 (dd, J=6.5, 13.6 Hz, 2H), 1.78 (m, 2H).Example 96: N-(2-chloro-4-pyridyl)-3-cyclopentyl-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0365]

[0366] The title compound was prepared according to the following scheme: Preparation of 3-cyclopentyl-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 96c)

[0367] The compound 96c was prepared in analogy to compound 26c by using tert-butyl 3-iodo-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 53d ) instead of tert-butyl 3-iodo-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (compound 1e ). Compound 96c was obtained as a slight yellow solid (90 mg). LCMS (M+H +< ): 257.Preparation of N-(2-chloro-4-pyridyl)-3-cyclopentyl-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 96)

[0368] The title compound was prepared in analogy to the preparation of Example 11 by using 2-chloro-pyridin-4-amine instead of 3-(trifluoromethyl)aniline and 3-cyclopentyl-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 96c ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 96 was obtained as a white solid (8 mg). LCMS (M+H +< ): 360. 1< H NMR (400 MHz, DMSO-d 6 ) δ ppm 9.33 (s, 1H), 8.19 (d, J=5.8 Hz, 1H), 7.68 (d, J=1.8 Hz, 1H), 7.50 (dd, J=1.8, 5.7 Hz, 1H), 7.34 (s, 1H), 5.00 (d, J=16.3 Hz, 1H), 4.94 - 4.82 (m, 1H), 4.40 (d, J=16.2 Hz, 1H), 4.22 - 4.13 (m, 1H), 4.12 - 4.05 (m, 1H), 2.92 - 2.78 (m, 1H), 1.99 (m, 2H), 1.79 - 1.69 (m, 2H), 1.67 - 1.55 (m, 2H), 1.47 (m, 2H), 1.11 (d, J=6.8 Hz, 3H).Example 97: N-(2-cyano-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0369] Preparation of Example 97:

[0370] The title compound was prepared in analogy to the preparation of Example 11 by using 4-aminopyridine-2-carbonitrile instead of 3-(trifluoromethyl)aniline. Example 97 was obtained as a white solid (24 mg). LCMS (M+H +< ): 363. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.75 (br.s, 1 H), 8.50 (d, J=5.6 Hz, 1H), 8.05 (s, 1H), 7.84 (s, 1H), 7.79 - 7.70 (m, 1H), 7.50 (dd, J=5.5, 8.6 Hz, 2H), 7.28 (t, J=8.8 Hz, 2H), 4.98 (s, 2H), 4.25 (t, J=5.1 Hz, 2H), 4.04 (t, J=5.1 Hz, 2H).Example 98: N-(2-chloro-6-methoxy-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0371] Preparation of Example 98:

[0372] The title compound was prepared in analogy to the preparation of Example 11 by using 2-chloro-6-methoxy-pyridin-4-amine instead of 3-(trifluoromethyl)aniline. Example 98 was obtained as a white solid. LCMS (M+H +< ): 402. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.45 (br. s, 1H), 7.83 (s, 1H), 7.49 (dd, J=5.5, 8.7 Hz, 2H), 7.34 - 7.20 (m, 3H), 6.96 (s, 1H), 4.94 (s, 2H), 4.23 (t, J=5.1 Hz, 2H), 4.01 (t, J=5.3 Hz, 2H), 3.80 (s, 3H).Example 99: 3-(5-fluoro-2-pyridyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0373] Preparation of Example 99:

[0374] The title compound was prepared in analogy to the preparation of Example 11 by using 3,4,5-trifluoroaniline instead of 3-(trifluoromethyl)aniline and 3-(5-fluoro-2-pyridyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 94b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 99 was obtained as a white solid (17 mg). LCMS (M+H +< ): 406. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.18 (s, 1H), 8.59 (d, J=2.8 Hz, 1H), 8.14 (s, 1H), 7.85 - 7.73 (m, 2H), 7.43 (dd, J=6.6, 10.7 Hz, 2H), 5.47 - 5.38 (m, 1H), 4.92 - 4.85 (m, 1H), 4.69 - 4.59 (m, 1H), 4.36 - 4.27 (m, 1H), 4.23 - 4.17 (m, 1H), 1.18 (d, J=6.8 Hz, 3H).Example 100: N-(3-cyano-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0375] Preparation of Example 100:

[0376] The title compound was prepared in analogy to the preparation of Example 11 by using 5-amino-2-fluoro-benzonitrile instead of 3-(trifluoromethyl)aniline and 3-(5-fluoro-2-pyridyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 94b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 100 was obtained as a white solid. LCMS (M+H +< ): 395. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.22 (s, 1H), 8.58 (d, J=2.8 Hz, 1H), 8.14 (s, 1H), 7.98 - 7.94 (m, 1H), 7.84 - 7.74 (m, 3H), 7.46 (s, 1H), 5.45 (d, J=18.1 Hz, 1H), 4.95 - 4.87 (m, 1H), 4.69 - 4.605 (m, 1H), 4.34 - 4.28 (m, 1H), 4.23 - 4.18 (m, 1H), 1.19 (d, J=6.8 Hz, 3H).Example 101: (6R)-N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0377]

[0378] The title compound was prepared according to the following scheme: Preparation of (6R)-3-(4-fluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 101f):

[0379] The compound 101f was prepared in analogy to compound 53f by using (2R)-2-aminopropan-1-ol instead of 2-aminopropan-1-ol. Compound 101f was obtained as a white solid. LCMS (M+H +< ): 232.Preparation of (6R)-N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 101):

[0380] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-trifluoromethylaniline and (6R)-3-(4-fluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 101f ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 101 was obtained as a white solid (8 mg). LCMS (M+H +< ): 403. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.81 (s, 1H), 7.63 (dd, J=2.6, 6.7 Hz, 1H), 7.54 (dd, J=5.3, 8.8 Hz, 2H), 7.37 - 7.33 (m, 1H), 7.18 (dt, J=1.9, 8.8 Hz, 3H), 5.23 (d, J=16.6 Hz, 1H), 5.07 - 4.97 (m, 1H), 4.72 (d, J=16.3 Hz, 1H), 4.37 (dd, J=4.3, 12.5 Hz, 1H), 4.23 (d, J=13.8 Hz, 1H), 1.29 (d, J=6.8 Hz, 3H).Example 102: (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0381]

[0382] The title compound was prepared according to the following scheme: Preparation of (6S)-3-(4-fluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 102f):

[0383] The compound 102f was prepared in analogy to compound 53f by using (2S)-2-aminopropan-1-ol instead of 2-aminopropan-1-ol. Compound 102f was obtained as a white solid (2 g). LCMS (M+H +< ): 232.Preparation of (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 102):

[0384] The title compound was prepared in analogy to the preparation of Example 11 by using 3-chloro-4-fluoroaniline instead of 3-trifluoromethylaniline and (6S)-3-(4-fluorophenyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 102f ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 102 was obtained as a white solid (8 mg). LCMS (M+H +< ): 403. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.81 (s, 1H), 7.63 (dd, J=2.6, 6.7 Hz, 1H), 7.54 (dd, J=5.3, 8.8 Hz, 2H), 7.37 - 7.33 (m, 1H), 7.18 (dt, J=1.9, 8.8 Hz, 3H), 5.23 (d, J=16.6 Hz, 1H), 5.07 - 4.97 (m, 1H), 4.72 (d, J=16.3 Hz, 1H), 4.37 (dd, J=4.3, 12.5 Hz, 1H), 4.23 (d, J=13.8 Hz, 1H), 1.29 (d, J=6.8 Hz, 3H).Example 103: N-(2-chloro-4-pyridyl)-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0385] Preparation of Example 103:

[0386] The title compound was prepared in analogy to the preparation of Example 11 by using 2-chloro-pyridin-4-amine instead of 3-(trifluoromethyl)aniline and 3-cyclopentyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 26c ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 103 was obtained as a white solid (15 mg). LCMS (M+H +< ): 346. 1< H NMR (400 MHz, DMSO-d 6 ) δ ppm 9.44 (s, 1H), 8.18 (d, J=5.6 Hz, 1H), 7.66 (d, J=1.5 Hz, 1H), 7.48 (dd, J=1.6, 5.6 Hz, 1H), 7.32 (s, 1H), 4.71 (s, 2H), 4.13 (t, J=5.2 Hz, 2H), 3.95 (t, J=5.1 Hz, 2H), 2.89 - 2.76 (m, 1H), 1.96 (d, J=6.8 Hz, 2H), 1.78 - 1.55 (m, 4H), 1.52 - 1.40 (m, 2H).Example 104: N-(benzofuran-6-yl)-3-cyclopentyl-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0387] Preparation of Example 104:

[0388] The title compound was prepared in analogy to the preparation of Example 11 by using benzofuran-6-amine instead of 3-(trifluoromethyl)aniline and 3-cyclopentyl-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 96c ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 104 was obtained as a white solid. LCMS (M+H +< ): 365. 1< H NMR (400 MHz, chloroform-d) δ ppm 7.80 (s, 1H), 7.61 (d, J=2.3 Hz, 1H), 7.52 (d, J=8.3 Hz, 1H), 7.41 (s, 1H), 7.14 (dd, J=1.9, 8.4 Hz, 1H), 6.74 (d, J=1.3 Hz, 1H), 6.61 (s, 1H), 4.99 - 4.83 (m, 2H), 4.52 (d, J=15.3 Hz, 1H), 4.31 (dd, J=4.1, 12.7 Hz, 1H), 4.16 (d, J=12.5 Hz, 1H), 2.90 - 2.81 (m, 1H), 2.10 - 1.99 (m, 2H), 1.83 - 1.55 (m, 6H), 1.25 (d, J=6.8 Hz, 3H).Example 105: N-(3-cyano-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0389] Preparation of Example 105:

[0390] The title compound was prepared in analogy to the preparation of Example 11 by using 5-amino-2-fluoro-benzonitrile instead of 3-(trifluoromethyl)aniline. Example 105 was obtained as a white solid (22 mg). LCMS (M+H +< ): 380. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 9.28 (s, 1H), 7.95 (dd, J=2.6, 5.6 Hz, 1H), 7.86 - 7.76 (m, 2H), 7.54 - 7.40 (m, 3H), 7.27 (t, J=8.8 Hz, 2H), 4.95 (s, 2H), 4.23 (t, J=5.1 Hz, 2H), 4.02 (t, J=5.3 Hz, 2H).Example 106: N-(3-cyano-5-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0391]

[0392] The title compound was prepared according to the following scheme: Preparation of Example 106:

[0393] To a solution of 3-amino-5-fluoro-benzonitrile (30 mg, 0.2 mmol) in DCM (1 mL), was added trichloromethyl carbonochloridate (19 mg, 0.1 mmol). Then the reaction mixture was stirred at room temperature for 10 mins, to previous reaction mixture was added another mixture of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b , 22 mg, 0.1 mmol) and DIPEA (65 mg, 0.5 mmol) in DCM (1 mL) slowly. The resulting mixture was stirred at room temperature for 5 min and then diluted with EtOAc (10 mL), washed with water (5 mL), brine (5 mL). The organic layer was dried over Na 2 SO 4 and concentrated. The residue was purified by prep-HPLC to afford Example 106 (4 mg) as a white solid. LCMS (M+H +< ): 380. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.71 - 7.60 (m, 2H), 7.49 (dd, J=5.3, 8.8 Hz, 2H), 7.25 - 7.12 (m, 3H), 5.00 (s, 2H), 4.32 (t, J=5.5 Hz, 2H), 4.11 (t, J=5.5 Hz, 2H).Example 107: 3-(4-fluorophenyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0394] Preparation of Example 107:

[0395] The title compound was prepared in analogy to the preparation of Example 106 by using 4-methyl-3-trifluoromethyl-aniline instead of 3-amino-5-fluoro-benzonitrile. Example 107 was obtained as a white solid (30 mg). LCMS (M+H +< ): 419. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.79 - 7.71 (m, 2H), 7.54 (dd, J=2.1, 8.4 Hz, 1H), 7.49 (dd, J=5.3, 8.8 Hz, 2H), 7.28 (d, J=8.3 Hz, 1H), 7.22 - 7.11 (m, 2H), 4.98 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.09 (t, J=5.4 Hz, 2H), 2.42 (d, J=1.5 Hz, 3H).Example 108: N-[3-chloro-5-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0396] Preparation of Example 108:

[0397] The title compound was prepared in analogy to the preparation of Example 106 by using 3-chloro-5-(trifluoromethyl)aniline instead of 3-amino-5-fluoro-benzonitrile. Example 108 was obtained as a white solid (10 mg). LCMS (M+H +< ): 439. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.87 - 7.81 (m, 1H), 7.80 - 7.72 (m, 2H), 7.49 (dd, J=5.3, 8.8 Hz, 2H), 7.33 (s, 1H), 7.18 (t, J=8.9 Hz, 2H), 5.00 (s, 2H), 4.32 (t, J=5.4 Hz, 2H), 4.11 (t, J=5.4 Hz, 2H).Example 109: N-(3,4-difluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0398] Preparation of Example 109:

[0399] The title compound was prepared in analogy to the preparation of Example 106 by using 3,4-difluoroaniline instead of 3-amino-5-fluoro-benzonitrile. Example 109 was obtained as a white solid (9 mg). LCMS (M+H +< ): 373. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.53 - 7.41 (m, 3H), 7.23 - 7.10 (m, 4H), 4.97 (s, 2H), 4.30 (t, J=5.4 Hz, 2H), 4.10 (t, J=5.4 Hz, 2H).Example 110: N-(3-chloro-4-cyano-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0400] Preparation of Example 110:

[0401] The title compound was prepared in analogy to the preparation of Example 106 by using 4-amino-2-chloro-benzonitrile instead of 3-amino-5-fluoro-benzonitrile. Example 110 was obtained as a white solid (5 mg). LCMS (M+H +< ): 396. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.89 - 7.84 (m, 1H), 7.77 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.58 - 7.44 (m, 3H), 7.18 (t, J=8.8 Hz, 2H), 5.00 (s, 2H), 4.30 (t, J=5.4 Hz, 2H), 4.10 (t, J=5.4 Hz, 2H).Example 111: 3-(4-fluorophenyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0402] Preparation of Example 111:

[0403] The title compound was prepared in analogy to the preparation of Example 106 by using 3,4,5-trifluoroaniline instead of 3-amino-5-fluoro-benzonitrile. Example 111 was obtained as a white solid (5 mg). LCMS (M+H +< ): 391. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.49 (dd, J=5.3, 8.8 Hz, 2H), 7.27 (dd, J=6.5, 10.3 Hz, 2H), 7.18 (t, J=8.9 Hz, 2H), 4.97 (s, 2H), 4.30 (t, J=5.4 Hz, 2H), 4.08 (t, J=5.4 Hz, 2H).Example 112: N-(3,5-difluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0404] Preparation of Example 112:

[0405] The title compound was prepared in analogy to the preparation of Example 106 by using 3,5-difluoroaniline instead of 3-amino-5-fluoro-benzonitrile. Example 112 was obtained as a white solid (10 mg). LCMS (M+H +< ): 373. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.49 (dd, J=5.4, 8.9 Hz, 2H), 7.23 - 7.08 (m, 4H), 6.64 - 6.49 (m, 1H), 4.98 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.10 (t, J=5.4 Hz, 2H).Example 113: N-[4-chloro-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0406] Preparation of Example 113:

[0407] The title compound was prepared in analogy to the preparation of Example 106 by using 4-chloro-3-(trifluoromethyl)aniline instead of 3-amino-5-fluoro-benzonitrile. Example 113 was obtained as a white solid (12 mg). LCMS (M+H +< ): 439. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.93 (d, J=2.5 Hz, 1H), 7.77 (s, 1H), 7.69 (dd, J=2.5, 8.8 Hz, 1H), 7.55 - 7.43 (m, 3H), 7.18 (t, J=8.8 Hz, 2H), 5.00 (s, 2H), 4.32 (t, J=5.4 Hz, 2H), 4.12 (t, J=5.4 Hz, 2H).Example 114: N-(3-ethylphenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0408] Preparation of Example 114:

[0409] The title compound was prepared in analogy to the preparation of Example 106 by using 3-ethylaniline instead of 3-amino-5-fluoro-benzonitrile. Example 114 was obtained as a white solid (11 mg). LCMS (M+H +< ): 365. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.58 - 7.42 (m, 2H), 7.32 - 7.07 (m, 5H), 6.99 - 6.81 (m, 1H), 4.98 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.09 (t, J=5.4 Hz, 2H), 2.63 (q, J=7.5 Hz, 2H), 1.24 (t, J=7.7 Hz, 3H).Example 115: N-(3-ethynylphenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0410] Preparation of Example 115:

[0411] The title compound was prepared in analogy to the preparation of Example 106 by using 3-ethynylaniline instead of 3-amino-5-fluoro-benzonitrile. Example 115 was obtained as a white solid (12 mg). LCMS (M+H +< ): 361. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.56 (t, J=1.8 Hz, 1H), 7.53 - 7.46 (m, 2H), 7.45 - 7.40 (m, 1H), 7.27 (t, J=8.0 Hz, 1H), 7.22 - 7.12 (m, 3H), 4.98 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.10 (t, J=5.5 Hz, 2H), 3.47 (s, 1H).Example 116: 3-(4-fluorophenyl)-N-(3-isopropylphenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0412] Preparation of Example 116:

[0413] The title compound was prepared in analogy to the preparation of Example 106 by using 3-isopropylaniline instead of 3-amino-5-fluoro-benzonitrile. Example 116 was obtained as a white solid (17 mg). LCMS (M+H +< ): 379. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.50 (dd, J=5.4, 8.9 Hz, 2H), 7.28 (s, 1H), 7.25 - 7.12 (m, 4H), 7.01 - 6.90 (m, 1H), 4.98 (s, 2H), 4.31 (t, J=5.5 Hz, 2H), 4.10 (t, J=5.5 Hz, 2H), 2.91 - 2.83 (m, 1H), 1.25 (d, J=7.0 Hz, 6H).Example 117: 3-(4-fluorophenyl)-N-(3-methoxyphenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0414] Preparation of Example 117:

[0415] The title compound was prepared in analogy to the preparation of Example 106 by using 3-methoxyl aniline instead of 3-amino-5-fluoro-benzonitrile. Example 117 was obtained as a white solid (10 mg). LCMS (M+H +< ): 367. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.49 (dd, J=5.3, 8.8 Hz, 2H), 7.18 (dt, J=3.6, 8.5 Hz, 3H), 7.07 (t, J=2.2 Hz, 1H), 6.96 (dd, J=1.2, 8.1 Hz, 1H), 6.63 (dd, J=1.8, 8.2 Hz, 1H), 4.97 (s, 2H), 4.31 (t, J=5.5 Hz, 2H), 4.09 (t, J=5.5 Hz, 2H), 3.78 (s, 3H).Example 118: N-phenyl-3-[2-(trifluoromethoxy)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0416] Preparation of Example 118:

[0417] The title compound was prepared in analogy to the preparation of Example 1 by using 2-(trifluoromethoxy)phenyl-boronic acid instead of (4-fluorophenyl)boronic acid. Example 118 was obtained as a white solid (21 mg). LCMS (M+H +< ): 403. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.69 (s, 1H), 7.56 - 7.48 (m, 1H), 7.47 - 7.42 (m, 3H), 7.41 - 7.34 (m, 2H), 7.33 - 7.24 (m, 2H), 7.10 - 7.01 (m, 1H), 4.84 (s, 2H), 4.34 (t, J=5.5 Hz, 2H), 4.10 (t, J=5.5 Hz, 2H).Example 119: 3-(3-chloro-4-fluoro-phenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0418] Preparation of Example 119:

[0419] The title compound was prepared in analogy to the preparation of Example 1 by using (3-chloro-4-fluorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 119 was obtained as a white solid (32 mg). LCMS (M+H +< ): 371. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.80 (s, 1H), 7.59 (dd, J=1.9, 7.0 Hz, 1H), 7.49 - 7.35 (m, 3H), 7.35 - 7.23 (m, 3H), 7.12 - 7.01 (m, 1H), 4.98 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.09 (t, J=5.4 Hz, 2H).Example 120: 3-(m-tolyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0420] Preparation of Example 120:

[0421] The title compound was prepared in analogy to the preparation of Example 1 by using (3-methyl-phenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 120 was obtained as a white solid. LCMS (M+H +< ): 333. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.43 - 7.36 (m, 2H), 7.34 - 7.21 (m, 5H), 7.15 - 7.01 (m, 2H), 4.99 (s, 2H), 4.31 (t, J=5.5 Hz, 2H), 4.09 (t, J=5.5 Hz, 2H), 2.40 (s, 3H).Example 121: 3-(3-bromophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0422] Preparation of Example 121:

[0423] The title compound was prepared in analogy to the preparation of Example 1 by using (3-bromophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Example 121 was obtained as a white solid (14 mg). LCMS (M+H +< ): 397. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.82 (s, 1H), 7.65 (s, 1H), 7.50 - 7.42 (m, 2H), 7.41 - 7.34 (m, 3H), 7.33 - 7.24 (m, 2H), 7.10 - 7.01 (m, 1H), 5.00 (s, 2H), 4.32 (t, J=5.5 Hz, 2H), 4.10 (t, J=5.4 Hz, 2H).Example 122: N-(3-ethynyl-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0424] Preparation of Example 122:

[0425] The title compound was prepared in analogy to the preparation of Example 106 by using 3-ethynyl-4-fluoro-aniline instead of 3-amino-5-fluoro-benzonitrile. Example 122 was obtained as a white solid (10 mg). LCMS (M+H +< ): 379. 1< H NMR (400MHz, CD 3 OD) δ ppm 8.57 (s, 1H), 7.77 (s, 1H), 7.55 (dd, J=2.8, 6.3 Hz, 1H), 7.52 - 7.47 (m, 1H), 7.44 - 7.39 (m, 1H), 7.18 (t, J=8.8 Hz, 2H), 7.08 (t, J=9.0 Hz, 1H), 4.97 (s, 2H), 4.31 (t, J=5.5 Hz, 2H), 4.09 (t, J=5.4 Hz, 2H), 3.76 (s, 1H).Example 123: N-(3-chloro-5-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0426] Preparation of Example 123:

[0427] The title compound was prepared in analogy to the preparation of Example 106 by using 3-chloro-5-fluoro-aniline instead of 3-amino-5-fluoro-benzonitrile. Example 123 was obtained as a white solid (9 mg). LCMS (M+H +< ): 389. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.53 - 7.45 (m, 2H), 7.35 (d, J=0.9 Hz, 1H), 7.28 (td, J=2.1, 11.2 Hz, 1H), 7.22 - 7.14 (m, 2H), 6.84 (td, J=2.0, 8.5 Hz, 1H), 4.98 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.09 (t, J=5.5 Hz, 2H).Example 124: N-(2-chloro-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0428] Preparation of Example 124:

[0429] The title compound was prepared in analogy to the preparation of Example 106 by using 2-chloropyridin-4-amine instead of 3-amino-5-fluoro-benzonitrile. Example 124 was obtained as a white solid (10 mg). LCMS (M+H +< ): 372. 1< H NMR (400MHz, CD 3 OD) δ ppm 8.15 (d, J=5.9 Hz, 1H), 7.77 (s, 1H), 7.69 (d, J=1.9 Hz, 1H), 7.53 - 7.43 (m, 3H), 7.19 (t, J=8.8 Hz, 2H), 5.00 (s, 2H), 4.32 (t, J=5.4 Hz, 2H), 4.11 (t, J=5.4 Hz, 2H).Example 125: N-(2,6-dimethyl-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0430] Preparation of Example 125:

[0431] The title compound was prepared in analogy to the preparation of Example 106 by using 2,6-dimethylpyridin-4-amine instead of 3-amino-5-fluoro-benzonitrile. Example 125 was obtained as a white solid (10 mg). LCMS (M+H +< ): 366. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.48 (dd, J=5.3, 8.8 Hz, 2H), 7.41 (s, 2H), 7.18 (t, J=8.8 Hz, 2H), 5.00 (s, 2H), 4.32 (t, J=5.5 Hz, 2H), 4.11 (t, J=5.5 Hz, 2H), 2.52 (s, 6H).Example 126: 3-(4-fluorophenyl)-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0432] Preparation of Example 126:

[0433] The title compound was prepared in analogy to the preparation of Example 106 by using 2-(trifluoromethyl)pyridin-4-amine instead of 3-amino-5-fluoro-benzonitrile. Example 126 was obtained as a white solid (9 mg). LCMS (M+H +< ): 406. 1< H NMR (400MHz, CD 3 OD) δ ppm 8.48 (d, J=5.8 Hz, 1H), 8.02 (d, J=2.0 Hz, 1H), 7.77 (s, 1H), 7.74 (dd, J=2.0, 5.6 Hz, 1H), 7.49 (dd, J=5.3, 8.8 Hz, 2H), 7.26 - 7.13 (m, 2H), 5.02 (s, 2H), 4.36 - 4.32 (t, J=5.5 Hz, 2H), 4.13 (t, J=5.5 Hz, 2H).Example 127: N-(3-chloro-4-fluoro-phenyl)-1-(4-fluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide

[0434] Preparation of Example 127:

[0435] The title compound was prepared in analogy to the preparation of Example 106 by using 3-chloro-4-fluoroaniline instead of 3-amino-5-fluoro-benzonitrile and 1-(4-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 9e ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 127 was obtained as a white solid (21 mg). LCMS (M+H +< ): 389. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.76 (s, 1H), 7.69 - 7.59 (m, 3H), 7.35 - 7.31 (m, 1H), 7.23 - 7.11 (m, 3H), 4.99 (s, 2H), 4.27 (t, J=5.4 Hz, 2H), 3.99 (t, J=5.4 Hz, 2H).Example 128: N-(3-bromo-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0436] Preparation of Example 128:

[0437] The title compound was prepared in analogy to the preparation of Example 106 by using 3-bromo-4-fluoro-aniline instead of 3-amino-5-fluoro-benzonitrile. Example 128 was obtained as a white solid (3 mg). LCMS (M+H +< ): 433. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.80 - 7.70 (m, 2H), 7.49 (dd, J=5.3, 9.0 Hz, 2H), 7.39 - 7.35 (m, 1H), 7.23 - 7.08 (m, 3H), 4.97 (s, 2H), 4.31 (t, J=5.5 Hz, 2H), 4.08 (t, J=5.4 Hz, 2H).Example 129: N-[3-(difluoromethoxy)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0438] Preparation of Example 129:

[0439] The title compound was prepared in analogy to the preparation of Example 106 by using 3-(difluoromethoxy)aniline instead of 3-amino-5-fluoro-benzonitrile. Example 129 was obtained as a white solid (6 mg). LCMS (M+H +< ): 403. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.49 (dd, J=5.3, 8.8 Hz, 2H), 7.36 - 7.22 (m, 3H), 7.18 (t, J=8.8 Hz, 2H), 6.80 (t, J=76 Hz, 1H), 6.83 (d, J=7.8 Hz, 1H), 4.98 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.10 (t, J=5.5 Hz, 2H).Example 130: 3-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0440] Preparation of Example 130:

[0441] The title compound was prepared in analogy to the preparation of Example 106 by using 4-fluoro-3-(trifluoromethoxy)aniline instead of 3-amino-5-fluoro-benzonitrile. Example 130 was obtained as a white solid (6 mg). LCMS (M+H +< ): 439. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.62 (dd, J=1.1, 6.9 Hz, 1H), 7.53 - 7.46 (m, 2H), 7.42 - 7.38 (m, 1H), 7.29 - 7.11 (m, 3H), 4.98 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.09 (t, J=5.5 Hz, 2H).Example 131: N-[3-(difluoromethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0442] Preparation of Example 131:

[0443] The title compound was prepared in analogy to the preparation of Example 106 by using 3-(difluoromethyl)aniline instead of 3-amino-5-fluoro-benzonitrile. Example 131 was obtained as a white solid (12 mg). LCMS (M+H +< ): 387. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.65 (s, 1H), 7.59 - 7.45 (m, 3H), 7.41 (t, J=7.9 Hz, 1H), 7.24 - 7.13 (m, 3H), 6.73 (t, J=56 Hz, 1H), 4.99 (s, 2H), 4.32 (t, J=5.4 Hz, 2H), 4.11 (t, J=5.4 Hz, 2H).Example 132: 3-(4-fluorophenyl)-N-(m-tolyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0444] Preparation of Example 132:

[0445] The title compound was prepared in analogy to the preparation of Example 106 by using 3-methylaniline instead of 3-amino-5-fluoro-benzonitrile. Example 132 was obtained as a white solid (5 mg). LCMS (M+H +< ): 351. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.49 (dd, J=5.3, 8.5 Hz, 2H), 7.27 - 7.08 (m, 5H), 6.90 (d, J=3.8 Hz, 1H), 4.97 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.09 (t, J=5.4 Hz, 2H), 2.32 (s, 3H).Example 133: N-phenyl-3-[3-(trifluoromethoxy)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0446] Preparation of Example 133:

[0447] The title compound was prepared in analogy to the preparation of Example 1 by using 3-(trifluoromethoxy)phenyl-boronic acid instead of (4-fluorophenyl)boronic acid. Example 133 was obtained as a white solid (21 mg). LCMS (M+H +< ): 403. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.86 (s, 1H), 7.58 - 7.44 (m, 2H), 7.42 - 7.36 (m, 3H), 7.29 (t, J=7.9 Hz, 2H), 7.21 (d, J=8.0 Hz, 1H), 7.11 - 7.02 (m, 1H), 5.02 (s, 2H), 4.33 (t, J=5.4 Hz, 2H), 4.11 (t, J=5.4 Hz, 2H).Example 134: 1-(2,4-difluorophenyl)-N-(3-ethynyl-4-fluoro-phenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide

[0448]

[0449] The title compound was prepared according to the following scheme: Preparation of 1-(2,4-difluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 134b):

[0450] The compound 134b was prepared in analogy to compound 9e by using (2,4-difluorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Compound 134b was obtained as a white solid (250 mg). LCMS (M+H +< ): 236.Preparation of 1-(2,4-difluorophenyl)-N-(3-ethynyl-4-fluoro-phenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide (Example 134):

[0451] The title compound was prepared in analogy to the preparation of Example 106 by using 3-ethynyl-4-fluoro-aniline instead of 3-amino-5-fluoro-benzonitrile and 1-(2,4-difluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 134b ) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b ). Example 134 was obtained as a white solid (11 mg). LCMS (M+H +< ): 397. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.81 (s, 1H), 7.70 - 7.59 (m, 1H), 7.53 (dd, J=2.8, 6.3 Hz, 1H), 7.41 - 7.37 (m, 1H), 7.15 - 7.01 (m, 3H), 4.81 (s, 2H), 4.28 (t, J=5.5 Hz, 2H), 3.99 (J=5.5 Hz, 2H), 3.75 (s, 1H).Example 135: N-(3-chloro-4-fluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide

[0452] Preparation of Example 135:

[0453] The title compound was prepared in analogy to the preparation of Example 106 by using 3-chloro-4-fluoro-aniline instead of 3-amino-5-fluoro-benzonitrile and 1-(2,4-difluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 134b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 135 was obtained as a white solid (18 mg). LCMS (M+H +< ): 407. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.82 (s, 1H), 7.69 - 7.56 (m, 2H), 7.32 - 7.28 (m, 1H), 7.20 - 7.00 (m, 3H), 4.81 (d, J=1.0 Hz, 2H), 4.28 (t, J=5.4 Hz, 2H), 3.99 (J=5.5 Hz, 2H).Example 136: N-(3-cyano-4-fluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide

[0454] Preparation of Example 136:

[0455] The title compound was prepared in analogy to the preparation of Example 106 by using 5-amino-2-fluoro-benzonitrile instead of 3-amino-5-fluoro-benzonitrile and 1-(2,4-difluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 134b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 136 was obtained as a white solid (23 mg). LCMS (M+H +< ): 398. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.87 - 7.76 (m, 2H), 7.74 - 7.58 (m, 2H), 7.28 (t, J=9.0 Hz, 1H), 7.15 - 7.04 (m, 2H), 4.82 (d, J=1.0 Hz, 2H), 4.29 (t, J=5.5 Hz, 2H), 4.00 (t, J=5.5 Hz, 2H).Example 137: N-(3-cyano-4,5-difluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H -imidazo[1,5-a]pyrazine-7-carboxamide

[0456] Preparation of Example 137:

[0457] The title compound was prepared in analogy to the preparation of Example 106 by using 5-amino-2,3-difluoro-benzonitrile instead of 3-amino-5-fluoro-benzonitrile and 1-(2,4-difluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 134b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 137 was obtained as a white solid (8 mg). LCMS (M+H +< ): 416. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.83 (s, 1H), 7.70 - 7.53 (m, 2H), 7.29 - 7.25 (m, 1H), 7.13 - 7.02 (m, 2H), 4.85 (d, J=1.0 Hz, 2H), 4.32 (t, J=5.4 Hz, 2H), 4.03 (t, J=5.4 Hz, 2H).Example 138: 1-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide

[0458] Preparation of Example 138:

[0459] The title compound was prepared in analogy to the preparation of Example 106 by using 3,4,5-trifluoroaniline instead of 3-amino-5-fluoro-benzonitrile and 1-(2,4-difluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 134b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 138 was obtained as a white solid (10 mg). LCMS (M+H +< ): 409. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.82 (s, 1H), 7.64 (dt, J=6.5, 8.7 Hz, 1H), 7.30 - 7.17 (m, 2H), 7.14 - 7.02 (m, 2H), 4.80 (d, J=1.0 Hz, 2H), 4.28 (t, J=5.4 Hz, 2H), 3.98 (t, J=5.4 Hz, 2H).Example 139: 3-(2,4-difluorophenyl)-N-(3-ethynyl-4-fluoro-phenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0460] Preparation of Example 139:

[0461] The title compound was prepared in analogy to the preparation of Example 106 by using 3-ethynyl-4-fluoro-aniline instead of 3-amino-5-fluoro-benzonitrile and 3-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 60b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 70 was obtained as a white solid (9 mg). LCMS (M+H +< ): 397. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.72 (d, J=1.5 Hz, 1H), 7.57 - 7.44 (m, 2H), 7.42 - 7.38 (m, 1H), 7.17 - 6.99 (m, 3H), 4.86 (s, 2H), 4.32 (t, J=5.5 Hz, 2H), 4.09 (t, J=5.5 Hz, 2H), 3.76 (s, 1H).Example 140: N-(6-chloro-5-fluoro-2-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0462]

[0463] The title compound was prepared according to the following scheme: Step 1: preparation of tert-butyl N-(6-chloro-5-fluoro-2-pyridyl)carbamate (compound 140b)

[0464] To a solution of 6-chloro-5-fluoro-pyridine-2-carboxylic acid (compound 140a, 1.8 g, 10 mmol) and Et 3 N (1.4 mL, 10 mmol) in tert-butanol (40 mL) was added diphenylphosphoryl azide (2.1 mL, 10 mmol) and the reaction mixture was stirred at 85 °C for 2 hours. Then the reaction mixture was concentrated and the residue was purified by column chromatography (eluting with 5%∼30% EtOAc in petroleum ether) to afford compound 140b (1.5 g) as a slight yellow oil. LCMS (M+H +< ): 247.Step 2: preparation of 6-chloro-5-fluoro-pyridin-2-amine (compound 140c)

[0465] A solution of tert-butyl N-(6-chloro-5-fluoro-2-pyridyl)carbamate (compound 140b, 1.5 g, 6 mmol) in TFA / DCM (10 mL, 1:1, v / v) was stirred at room temperature for 2 hours. The reaction mixture was concentrated, the residue was diluted with EtOAc (30 mL), washed with saturated aqueous NaHCO 3 (50 mL) and brine (500 mL). The organic layer was dried over Na 2 SO 4 and concentrated to afford compound 140c (880 mg) which was used directly in next step.Step 3: preparation of phenyl N-(6-chloro-5-fluoro-2-pyridyl)carbamate (compound 140d)

[0466] To a solution of 6-chloro-5-fluoro-pyridin-2-amine (compound 140c, 880 mg, 6 mmol) and Pyridine (2 mL) in THF / DCM (10 mL, 1:1, v / v) was added phenyl carbonochloridate (1.4 g, 9 mmol) slowly at 0 °C. The resulting mixture was stirred at room temperature for 2 hours, then poured into water (20 mL) and extracted with EtOAc (20 mL) twice. The organic layers were combined and concentrated, the residue was purified by column chromatography (eluting with 5%∼30% EtOAc in petroleum ether) to afford compound 140d (800 mg) as a white solid. LCMS (M+H +< ): 267.Step 4: preparation of N-(6-chloro-5-fluoro-2-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 140):

[0467] A mixture of phenyl N-(6-chloro-5-fluoro-2-pyridyl)carbamate (compound 140d, 27 mg, 0.1 mmol), 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b, 22 mg, 0.1 mmol) and DIPEA (65 mg, 0.5 mmol) in DMF (2 mL) was stirred at 70 °C for 1 hour. Then the reaction mixture was purified by prep-HPLC to afford Example 140 as a white solid. LCMS (M+H +< ): 390. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.83 (dd, J=3.1, 8.9 Hz, 1H), 7.77 (s, 1H), 7.65 (dd, J=8.0, 8.8 Hz, 1H), 7.49 (dd, J=5.3, 8.8 Hz, 2H), 7.17 (t, J=8.9 Hz, 2H), 4.98 (s, 2H), 4.30 (t, J=5.4 Hz, 2H), 4.09 (t, J=5.4 Hz, 2H).Example 141: N-(3-cyclopropylphenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0468] Preparation of Example 141:

[0469] The title compound was prepared in analogy to the preparation of Example 106 by using 3-cyclopropylaniline (CAS: 485402-64-0, catalog number: AQ14074, Shanghai AQBioPharma Co. Ltd) instead of 3-amino-5-fluoro-benzonitrile. Example 141 was obtained as a white solid (6 mg). LCMS (M+H +< ): 377. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.49 (dd, J=5.3, 8.8 Hz, 2H), 7.25 - 7.04 (m, 5H), 6.87 - 6.73 (m, 1H), 4.97 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.09 (t, J=5.4 Hz, 2H), 1.96 - 1.79 (m, 1H), 1.00 - 0.90 (m, 2H), 0.74 - 0.60 (m, 2H).Example 142: N-(3-cyano-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0470] Preparation of Example 142:

[0471] The title compound was prepared in analogy to the preparation of Example 106 by using 5-amino-2-fluoro-benzonitrile instead of 3-amino-5-fluoro-benzonitrile and 3-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 50b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 142 was obtained as a white solid (4 mg). LCMS (M+H +< ): 398. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.87 - 7.77 (m, 1H), 7.75 - 7.65 (m, 2H), 7.54 - 7.40 (m, 1H), 7.29 (t, J=8.9 Hz, 1H), 7.15 - 7.01 (m, 2H), 4.87 (s, 2H), 4.33 (t, J=5.4 Hz, 2H), 4.11 (t, J=5.5 Hz, 2H).Example 143: N-(6-chloro-5-fluoro-2-pyridyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0472] Preparation of Example 143:

[0473] The title compound was prepared in analogy to the preparation of Example 140 by using 3-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 60b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 143 was obtained as a white solid. LCMS (M+H +< ): 408. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.81 (dd, J=3.0, 8.8 Hz, 1H), 7.71 (d, J=1.3 Hz, 1H), 7.64 (t, J=8.4 Hz, 1H), 7.54 - 7.42 (m, 1H), 7.14 - 7.02 (m, 2H), 4.87 (s, 2H), 4.32 (t, J=5.5 Hz, 2H), 4.12 (t, J=5.5 Hz, 2H).Example 144: N-(3,4-difluoro-5-methyl-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0474] Preparation of Example 144:

[0475] The title compound was prepared in analogy to the preparation of Example 106 by using 3,4-difluoro-5-methyl-aniline (CAS: 1505944-46-6, catalog number: AQ14079, Shanghai AQBioPharma Co. Ltd) instead of 3-amino-5-fluoro-benzonitrile. Example 144 was obtained as a white solid (10 mg). LCMS (M+H +< ): 387. 1< H NMR (400MHz, DMSO-d 6 ) δ ppm 8.99 (s, 1H), 7.83 (s, 1H), 7.49 (dd, J=5.4, 8.9 Hz, 2H), 7.44 - 7.38 (m, 1H), 7.32 - 7.22 (m, 2H), 7.11 (d, J=6.0 Hz, 1H), 4.92 (s, 2H), 4.21 (t, J=5.4 Hz, 2H), 3.99 (t, J=5.4 Hz, 2H), 2.24 (d, J=2.0 Hz, 3H).Example 145: N-(3-chloro-4,5-difluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0476] Preparation of Example 145:

[0477] The title compound was prepared in analogy to the preparation of Example 106 by using 3-chloro-4,5-difluoro-aniline (CAS: 149144-05-8, catalog number: AQ14076, Shanghai AQBioPharma Co. Ltd) instead of 3-amino-5-fluoro-benzonitrile. Example 145 was obtained as a white solid (10 mg). LCMS (M+H +< ): 407. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.50 - 7.35 (m, 4H), 7.18 (t, J=8.8 Hz, 2H), 4.97 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.08 (t, J=5.4 Hz, 2H).Example 146: N-(3-cyclopropyl-4,5-difluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0478] Preparation of Example 146:

[0479] The title compound was prepared in analogy to the preparation of Example 106 by using 3-cyclopropyl-4,5-difluoro-aniline (catalog number: AQ14078, Shanghai AQBioPharma Co. Ltd) instead of 3-amino-5-fluoro-benzonitrile. Example 146 was obtained as a white solid (10 mg). LCMS (M+H +< ): 413. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.48 (dd, J=5.3, 8.8 Hz, 2H), 7.29 - 7.12 (m, 3H), 6.79 - 6.69 (m, 1H), 4.95 (s, 2H), 4.30 (t, J=5.5 Hz, 2H), 4.07 (t, J=5.5 Hz, 2H), 2.16 - 2.03 (m, 1H), 1.09 - 0.98 (m, 2H), 0.80 - 0.68 (m, 2H).Example 147: N-[3-(1,1-difluoroethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0480]

[0481] The title compound was prepared according to the following scheme: Step 1: preparation of 3-(1,1-difluoroethyl)aniline (compound 147b):

[0482] To a mixture of 1-bromo-3-(1,1-difluoroethyl)benzene (compound 147a, 440 mg, 2 mmol)), diphenylmethanimine (545 mg, 3 mmol), 2-Dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl (164 mg, 0.4 mmol) and CS 2 CO 3 (1.4 g, 4 mmol) in toluene (20 mL) was added Pd 2 (dba) 3 (163 mg, 0.2 mmol) under nitrogen. The reaction mixture was stirred at 110 °C for 16 hours under nitrogen. After cooled down to room temperature, the reaction mixture was washed with brine (20 mL) and the organic layer was concentrated. The residue was dissolved in THF (10 mL) and hydrochloride acid (2 mL, 12 M). The reaction mixture was stirred at room temperature for 2 hours and then diluted with EtOAc and petroleum ether (20 mL, 1: 1, v / v), washed with Hydrochloride acid (20 mL, 2 M). The aqueous layer was neutralized to pH ∼7 and extracted with EtOAc (20 mL) twice. The organic layer was dried and concentrated to afford compound 147b (158 mg) as a slight yellow oil. LCMS (M+H +< ): 158.Step 2: preparation of phenyl N-[3-(1,1-difluoroethyl)phenyl]carbamate (compound 147c):

[0483] To a solution of 3-(1,1-difluoroethyl)aniline (compound 147b, 158 mg, 1 mmol) and Pyridine (0.5 mL) in THF / DCM (5 mL, 1:1, v / v) was added phenyl carbonochloridate (234 mg, 1.5 mmol) slowly at 0 °C. The resulting mixture was stirred at room temperature for 2 hours, poured into water (20 mL) and extracted with EtOAc (20 mL) twice. The organic layer was combined and concentrated, the residue was purified by column chromatography (eluting with 0%∼20% EtOAc in petroleum ether) to afford compound 147c (80 mg) as a white solid. LCMS (M+H +< ): 278.Step 3: preparation of N-[3-(1,1-difluoroethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 147):

[0484] The title compound was prepared in analogy to the preparation of Example 140 by using N-[3-(1,1-difluoroethyl)phenyl]carbamate (compound 147c) instead of N-(6-chloro-5-fluoro-2-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (compound 140d). Example 147 was obtained as a white solid (4 mg). LCMS (M+H +< ): 401. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.77 (s, 1H), 7.63 (s, 1H), 7.50 (dd, J=5.3, 8.8 Hz, 2H), 7.38 (t, J=7.9 Hz, 1H), 7.26 - 7.13 (m, 4H), 4.99 (s, 2H), 4.32 (t, J=5.5 Hz, 2H), 4.11 (t, J=5.5 Hz, 2H), 1.91 (t, J=18.2 Hz, 3H).Example 148 and Example 149: N-(3-chloro-4-fluoro-phenyl)-3-(4-chloro-5-fluoro-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide and N-(3-chloro-4-fluoro-phenyl)-3-(2-chloro-5-fluoro-4-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0485]

[0486] The title compound was prepared according to the following scheme: Preparation of [3-(4-chloro-5-fluoro-2-pyridyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine and 3-(2-chloro-5-fluoro-4-pyridyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine] (compound 148b):

[0487] The compound 148b was prepared in analogy to compound 67c by using 2,4-dichloro-5-fluoro-pyridine instead of 2-chloro-4-(trifluoromethyl)pyridine. Compound 148b was obtained as a white solid (50 mg). LCMS (M+H +< ): 253.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-(4-chloro-5-fluoro-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide and N-(3-chloro-4-fluoro-phenyl)-3-(2-chloro-5-fluoro-4-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide (Example 148 and 149):

[0488] The title compound was prepared in analogy to the preparation of Example 140 by using phenyl N-(3-chloro-4-fluoro-phenyl)carbamate (compound 12i) instead of phenyl N-(6-chloro-5-fluoro-2-pyridyl)carbamate (compound 140d) and compound 148b instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b).

[0489] Example 148 (2 mg) was obtained as a white solid. LCMS (M+H +< ): 424. 1< H NMR (400MHz, CD 3 OD) δ ppm 8.36 (d, J=2.3 Hz, 1H), 7.96 (d, J=2.5 Hz, 1H), 7.61 (dd, J=2.5, 6.8 Hz, 1H), 7.58 (d, J=5.5 Hz, 1H), 7.34 - 7.30 (m, 1H), 7.17 (t, J=9.0 Hz, 1H), 5.00 (s, 2H), 4.34 (t, J=5.4 Hz, 2H), 4.11 (t, J=5.5 Hz, 2H).

[0490] Example 149 (18 mg) was obtained as a white solid. LCMS (M+H +< ): 424. 1< H NMR (400MHz, CD 3 OD) δ ppm 8.55 (d, J=1.3 Hz, 1H), 8.07 (s, 1H), 7.90 (d, J=5.8 Hz, 1H), 7.62 (dd, J=2.6, 6.7 Hz, 1H), 7.36 - 7.31 (m, 1H), 7.17 (t, J=9.0 Hz, 1H), 5.16 (s, 2H), 4.31 (t, J=5.4 Hz, 2H), 4.06 (t, J=5.5 Hz, 2H).Example 150 N-(3-cyclopropyl-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0491] Preparation of Example 150:

[0492] The title compound was prepared in analogy to the preparation of Example 106 by using 3-cyclopropyl-4-fluoro-aniline (CAS: 890129-90-5, catalog number: AQ14079, Shanghai AQBioPharma Co. Ltd) instead of 3-amino-5-fluoro-benzonitrile and 3-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 60b, 40 mg) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 150 was obtained as a white solid (13 mg). LCMS (M+H +< ): 413. 1< H NMR (400MHz, chloroform-d) δ ppm 7.68 (s, 1H), 7.38 - 7.27 (m, 1H), 7.10 - 6.86 (m, 5H), 6.57 (br. s, 1H), 4.74 (s, 2H), 4.36 (br. s, 2H), 4.04 (br. s, 2H), 2.09 - 2.03 (m, 1H), 1.04 - 0.91 (m, 2H), 0.77 - 0.63 (m, 2H).Example 151: N-(2-chloro-4-pyridyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H -imidazo[1,5-a]pyrazine-7-carboxamide

[0493] Preparation of Example 151:

[0494] The title compound was prepared in analogy to the preparation of Example 106 by using 2-chloro-pyridin-4-amine instead of 3-amino-5-fluoro-benzonitrile and 1-(2,4-difluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 134b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 151 was obtained as a white solid (2 mg). LCMS (M+H +< ): 390. 1< H NMR (400MHz, CD 3 OD) δ ppm 8.13 (d, J=5.8 Hz, 1H), 7.82 (s, 1H), 7.70 - 7.59 (m, 2H), 7.44 (dd, J=2.0, 5.8 Hz, 1H), 7.16 - 7.02 (m, 2H), 4.83 (s, 2H), 4.30 (t, J=5.5 Hz, 2H), 4.01 (t, J=5.5 Hz, 2H).Example 152: 1-(2,4-difluorophenyl)-N-[2-(trifluoromethyl)-4-pyridyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide

[0495] Preparation of Example 152:

[0496] The title compound was prepared in analogy to the preparation of Example 106 by using 2-(trifluoromethyl)pyridine-4-amine instead of 3-amino-5-fluoro-benzonitrile and 1-(2,4-difluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 134b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 152 was obtained as a white solid (2 mg). LCMS (M+H +< ): 424. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.99 (s, 1H), 7.78 (s, 1H), 7.75 (d, J=1.3 Hz, 1H), 7.54 - 7.45 (m, 2H), 7.41 (dd, J=1.9, 8.9 Hz, 1H), 7.18 (t, J=8.8 Hz, 1H), 5.01 (s, 2H), 4.33 (t, J=5.5 Hz, 2H), 4.12 (t, J=5.4 Hz, 2H).Example 153: N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide

[0497] Preparation of Example 153:

[0498] The title compound was prepared in analogy to the preparation of Example 140 by using phenyl N-(3-chloro-4-fluoro-phenyl)carbamate (compound 12i) instead of phenyl N-(6-chloro-5-fluoro-2-pyridyl)carbamate (compound 140d) and 3-(4-fluorophenyl)-4,5,6,7-tetrahydrotriazolo[1,5-a]pyrazine (compound 10e) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 153 was obtained as a white solid (5 mg). LCMS (M+H +< ): 390. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.85 - 7.75 (m, 2H), 7.64 (dd, J=2.6, 6.7 Hz, 1H), 7.37 - 7.33 (m, 1H), 7.27 (t, J=8.8 Hz, 2H), 7.18 (t, J=9.0 Hz, 1H), 5.09 (s, 2H), 4.58 (t, J=5.4 Hz, 2H), 4.11 ((t, J=5.4 Hz, 2H).Example 154: N-(6-chloro-5-fluoro-2-pyridyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide

[0499] Preparation of Example 154:

[0500] The title compound was prepared in analogy to the preparation of Example 140 by using 1-(2,4-difluorophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (compound 134b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 154 was obtained as a white solid (5 mg). LCMS (M+H +< ): 408. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.84 - 7.77 (m, 2H), 7.69 - 7.59 (m, 2H), 7.15 - 7.01 (m, 2H), 4.82 (d, J=0.8 Hz, 2H), 4.29 (t, J=5.5 Hz, 2H), 4.00 (t, J=5.5 Hz, 2H).Example 155: N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide

[0501]

[0502] The title compound was prepared according to the following scheme: Preparation of 3-(2,4-difluorophenyl)-4,5,6,7-tetrahydrotriazolo[1,5-a]pyrazine (compound 155b):

[0503] The compound 155b was prepared in analogy to compound 10e by using (2,4-difluorophenyl)boronic acid instead of (4-fluorophenyl)boronic acid. Compound 155b was obtained as a white solid (50 mg). LCMS (M+H +< ): 237.Preparation of N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide (Example 155):

[0504] The title compound was prepared in analogy to the preparation of Example 140 by using phenyl N-(3-chloro-4-fluoro-phenyl)carbamate (compound 12i) instead of phenyl N-(6-chloro-5-fluoro-2-pyridyl)carbamate (compound 140d) and 3-(2,4-difluorophenyl)-4,5,6,7-tetrahydrotriazolo[1,5-a]pyrazine (compound 155b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 155 was obtained as a white solid (7 mg). LCMS (M+H +< ): 408. 1< H NMR (400MHz, CD 3 OD) δ ppm 7.80 (dt, J=6.5, 8.8 Hz, 1H), 7.61 (dd, J=2.6, 6.7 Hz, 1H), 7.35 - 7.27 (m, 1H), 7.23 - 7.11 (m, 3H), 4.94 (s, 2H), 4.60 (t, J=5.5 Hz, 2H), 4.13 (t, J=5.5 Hz, 2H).Example 156: N-(3,4-difluoro-5-methyl-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0505] Preparation of Example 156:

[0506] The title compound was prepared in analogy to the preparation of Example 106 by using 3,4-difluoro-5-methyl-aniline (CAS: 1505944-46-6, catalog number: AQ14079, Shanghai AQBioPharma Co. Ltd) instead of 3-amino-5-fluoro-benzonitrile and 3-(5-fluoro-2-pyridyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 94b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 156 was obtained as a white solid (8 mg). LCMS (M+H +< ): 402. 1< H NMR (400MHz, CD 3 OD) δ ppm 8.50 (d, J=3.0 Hz, 1H), 8.06 (s, 1H), 7.75 (dd, J=4.1, 8.9 Hz, 1H), 7.61 (dt, J=3.0, 8.7 Hz, 1H), 7.30-7.26 (m, 1H), 7.10 - 6.96 (m, 1H), 5.46 (d, J=18.1 Hz, 1H), 5.04 - 4.94 (m, 1H), 4.83 (d, J=17.8 Hz, 1H), 4.37 (dd, J=4.5, 12.8 Hz, 1H), 4.29 - 4.17 (m, 1H), 2.30 (d, J=2.3 Hz, 3H), 1.29 (d, J=6.8 Hz, 3H).Example 157: N-(3-cyclopropyl-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0507] Preparation of Example 157:

[0508] The title compound was prepared in analogy to the preparation of Example 106 by using 3-cyclopropyl-4-fluoro-aniline instead of 3-amino-5-fluoro-benzonitrile and 3-(5-fluoro-2-pyridyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 94b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 157 was obtained as a white solid (9 mg). LCMS (M+H +< ): 410. 1< H NMR (400MHz, CD 3 OD) δ ppm 8.50 (d, J=3.0 Hz, 1H), 8.06 (s, 1H), 7.74 (dd, J=4.3, 8.8 Hz, 1H), 7.61 (dt, J=3.0, 8.7 Hz, 1H), 7.19 - 7.15 (m, 1H), 7.06 - 6.92 (m, 2H), 5.46 (d, J=17.8 Hz, 1H), 5.06 - 4.96 (m, 1H), 4.82 (d, J=18.1 Hz, 1H), 4.37 (dd, J=4.3, 12.5 Hz, 1H), 4.22 (d, J=12.3 Hz, 1H), 2.18 - 2.01 (m, 1H), 1.28 (d, J=7.0 Hz, 3H), 1.04 - 0.92 (m, 2H), 0.81 - 0.67 (m, 2H).Example 158: N-(3-chloro-4,5-difluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0509] Preparation of Example 158:

[0510] The title compound was prepared in analogy to the preparation of Example 106 by using 3-chloro-4,5-difluoro-aniline (CAS: 149144-05-8, catalog number: AQ14076, Shanghai AQBioPharma Co. Ltd) instead of 3-amino-5-fluoro-benzonitrile and 3-(5-fluoro-2-pyridyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 94b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 158 was obtained as a white solid (11 mg). LCMS (M+H +< ): 422. 1< H NMR (400MHz, CD 3 OD) δ ppm 8.51 (d, J=3.0 Hz, 1H), 8.06 (s, 1H), 7.75 (dd, J=4.4, 8.9 Hz, 1H), 7.61 (dt, J=3.0, 8.7 Hz, 1H), 7.51 - 7.40 (m, 2H), 5.47 (d, J=17.8 Hz, 1H), 5.05 - 4.97 (m, 1H), 4.84 (d, J=18.1 Hz, 1H), 4.38 (dd, J=4.6, 12.9 Hz, 1H), 4.23 (d, J=12.5 Hz, 1H), 1.29 (d, J=6.8 Hz, 3H).Example 159: N-(3,4-difluoro-5-methoxy-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide

[0511] Preparation of Example 159:

[0512] The title compound was prepared in analogy to the preparation of Example 106 by using 3,4-difluoro-5-methoxyl-aniline (CAS: 1195190-12-5, catalog number: AQ12805, Shanghai AQBioPharma Co. Ltd) instead of 3-amino-5-fluoro-benzonitrile and 3-(5-fluoro-2-pyridyl)-6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 94b) instead of 3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (compound 11b). Example 159 was obtained as a white solid (5 mg). LCMS (M+H +< ): 418. 1< H NMR (400MHz, CD 3 OD) δ ppm 8.51 (d, J=3.0 Hz, 1H), 8.07 (s, 1H), 7.75 (dd, J=4.3, 8.8 Hz, 1H), 7.61 (dt, J=2.9, 8.6 Hz, 1H), 7.10 - 6.97 (m, 2H), 5.48 (d, J=17.8 Hz, 1H), 5.05 - 4.99 (m, 1H), 4.84 (d, J=18.1 Hz, 1H), 4.38 (dd, J=4.4, 12.9 Hz, 1H), 4.23 (d, J=13.3 Hz, 1H), 3.90 (s, 3H), 1.30 (d, J=7.0 Hz, 3H).Example 160: N-(3-cyclopropyl-4,5-difluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H -pyrazolo[1,5-a]pyrazine-5-carboxamide

[0513] Preparation of Example 160...

Claims

1. A compound of formula (I), wherein R1 is heterocyclyl, said heterocyclyl being unsubstituted or substituted with one, two or three substituents independently selected from (C1-6alkyl)2aminocarbonyl, (C1-6alkyl)2morpholinylcarbonyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxycarbonyl, C1-6alkyl, C1-6alkyl(C1-6alkylsulfonyl)amino, C1-6alkylaminocarbonyl, C1-6alkylcarbonyl, C1-6alkylcarbonylamino, C1-6alkylimidazolyl, C1-6alkylmorpholinylcarbonyl, C1-6alkyloxadiazolyl, C1-6alkyloxazolyl, C1-6alkylpyrazolyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonylC1-6alkyl, carbamoyl, cyano, dioxopyrrolidinyl, haloC1-6alkyl, haloC1-6alkyloxadiazolyl, halogen, halopiperidinylcarbonyl, halopyridinyl, halopyrimidinylamino, halopyrimidinyloxy, halopyrrolidinylcarbonyl, hydroxy, hydroxyazetidinylcarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl(C1-6alkyl)aminocarbonyl, hydroxyC1-6alkylaminocarbonyl, hydroxypyrrolidinylcarbonyl, morpholinylcarbonyl, oxadiazolyl, oxazolyl, oxazolylaminocarbonyl, oxazolyl(C1-6alkyl)aminocarbonyl, oxazolylcarbonyl, oxazolylcarbonyl(C1-6alkyl)amino, oxomorpholinyl, oxooxazolidinyl, oxopyrrolidinyl, phenyl, phenylcarbonyl, pyrazolylC1-6alkyl, pyridinyl, pyrimidinyl, pyrimidinylamino, pyrimidinyl(C1-6alkyl)amino, pyrimidinyloxy, pyrimidinyloxyC1-6alkyl, pyrrolidinylcarbonyl and thiazolyl; heteroaryl, said heteroaryl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C1-6alkyl ,haloC1-6alkyl, hydroxy C1-6alkyl and C1-6alkoxyC1-6alkyl; phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, C3-7cycloalkyl, haloC1-6alkoxy and haloC1-6alkyl; or C3-7cycloalkyl; R2 and R3 are independently selected from hydrogen and C1-6alkyl; R4 is heteroaryl, said heteroaryl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, C3-7cycloalkyl and (C1-6alkyl)2amino; aryl, said aryl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C3-7cycloalkyl, C1-6alkyl, C2-6alkynyl, C1-6alkoxy, haloC1-6alkyl and haloC1-6alkoxy; phenylC1-6alkyl, said phenylC1-6alkyl being unsubstituted or substituted with one, two or three halogen; or C3-7cycloalkyl; Y and Q are independently selected from CH and N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

2. A compound of formula (I) according to claim 1, wherein R1 is azabicyclo[3.1.0]hexanyl; dioxopiperazinyl; dioxopyrimidinyl; dioxotetrahydropyrrolo[1,2-a]pyrazinyl; morpholinyl, said morpholinyl being unsubstituted or substituted with one, two or three C1-6alkyl; oxaazabicyclo[3.2.1]octanyl; oxoazabicyclo[3.1.0]hexanyl; oxoazaspiro[2.4]heptanyl, said oxoazaspiro[2.4]heptanyl being unsubstituted or substituted with hydroxy; oxoazaspiro [4.4] nonanyl; oxoazaspiro[3.4]octanyl, said oxoazaspiro[3.4]octanyl being unsubstituted or substituted with hydroxy; oxodiazaspiro[3.4]octanyl, said oxodiazaspiro[3.4]octanyl being unsubstituted or substituted with one, two or three substituents independently selected from C1-6alkylcarbonyl, C1-6alkoxycarbonyl, oxazolylcarbonyl and pyrimidinyl; oxodihydropyrazolo[1,5-a]pyrazinyl; oxohexahydropyrimidinyl; oxoimidazolidinyl, said oxoimidazolidinyl being unsubstituted or substituted with one, two or three substituents independently selected from C1-6alkyl, C1-6alkylcarbonyl, C1-6alkylsulfonyl, phenyl, phenylcarbonyl and pyrimidinyl; oxoindolinyl; oxoisoindolinyl; oxomorpholinyl, said oxomorpholinyl being unsubstituted or substituted with one, two or three substituents independently selected from C1-6alkyl and oxazolyl; oxooxaazaspiro[2.4]heptanyl; oxooxaazaspiro[3.4]octanyl; oxooxaazaspiro[4.4]nonanyl; oxooxaazaspiro[4.5]decanyl; oxooxazinanyl, said oxooxazinanyl being unsubstituted or substituted with one, two or three substituents independently selected from C1-6alkyl, C1-6alkoxy and morpholinylcarbonyl; oxooxazolidinyl, said oxooxazolidinyl being unsubstituted or substituted with one, two or three substituents independently selected from C1-6alkyl, phenyl, pyridinyl, halopyridinyl, oxazolyl, C1-6alkylimidazolyl and C1-6alkyloxadiazolyl; oxopiperidyl, said oxopiperidyl being unsubstituted or substituted with one, two or three substituents independently selected from C1-6alkyl and hydroxy; oxopyrrolidinyl, said oxopyrrolidinyl being unsubstituted or substituted with one, two or three substituents independently selected from (C1-6alkyl)2aminocarbonyl, (C1-6alkyl)2morpholinylcarbonyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkyl, C1-6alkyl(C1-6alkylsulfonyl)amino, C1-6alkylaminocarbonyl, C1-6alkylcarbonylamino, C1-6alkylmorpholinylcarbonyl, C1-6alkyloxadiazolyl, C1-6alkyloxazolyl, C1-6alkylpyrazolyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonylC1-6alkyl, cyano, dioxopyrrolidinyl, haloC1-6alkyl, haloC1-6alkyloxadiazolyl, halopiperidinylcarbonyl, halopyrimidinylamino, halopyrimidinyloxy, halopyrrolidinylcarbonyl, hydroxy, hydroxyazetidinylcarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl(C1-6alkyl)aminocarbonyl, hydroxyC1-6alkylaminocarbonyl, hydroxypyrrolidinylcarbonyl, morpholinylcarbonyl, oxadiazolyl, oxazolyl, oxazolylaminocarbonyl, oxazolyl(C1-6alkyl)aminocarbonyl, oxazolylcarbonyl(C1-6alkyl)amino, oxomorpholinyl, oxooxazolidinyl, oxopyrrolidinyl, phenyl, pyrazolylC1-6alkyl, pyridinyl, pyrimidinyl, pyrimidinylamino, pyrimidinylC1-6alkylamino, pyrimidinyloxy, pyrimidinyloxyC1-6alkyl, pyrrolidinylcarbonyl and thiazolyl; oxopyrrolo[3,2-c]pyridinyl; oxopyrrolo[3,4-b]pyridinyl; oxotetrahydrofuro[3,4-c]pyrrolyl; oxotetrahydroimidazo[5,1-c][1,4]oxazinyl; piperidinyl, said piperidinyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, hydroxy and C1-6alkylcarbonyl; pyrazolyl, said pyrazolyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C1-6alkyl, hydroxyC1-6alkyl and C1-6alkoxyC1-6alkyl; pyridinyl, said pyridinyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C1-6alkyl and haloC1-6alkyl; pyrimidinyl, said pyrimidinyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen and C1-6alkyl; pyrrolidinyl, said pyrrolidinyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, hydroxy, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy and C1-6alkoxyC1-6alkyl; tetrahydrofuranyl; thiazolyl, said thiazolyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen and haloC1-6alkyl; phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, hydroxy, C3-7cycloalkyl, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl and haloC1-6alkoxy;or C3-7cycloalkyl; R2 and R3 are independently selected from hydrogen and C1-6alkyl; R4 is benzofuranyl; benzothiophenyl; benzoxazolyl; indolyl; C1-6alkylbenzothiazolyl; pyridinyl, said pyridinyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkyl and (C1-6alkyl)2amino; bicyclo[4.2.0]octa-1(6),2,4-trienyl; indanyl; phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C3-7cycloalkyl, C1-6alkyl, C2-6alkynyl, C1-6alkoxy, haloC1-6alkyl and haloC1-6alkoxy; phenylC1-6alkyl, said phenylC1-6alkyl being unsubstituted or substituted with one, two or three halogen; or C3-7cycloalkyl; Y and Q are independently selected from CH and N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

3. A compound of formula (I) according to claim 1 or 2, wherein R1 is pyrazolyl substituted by halogen, cyano, C1-6alkyl, hydroxyC1-6alkyl or C1-6alkoxyC1-6alkyl; pyridinyl, said pyridinyl being unsubstituted or substituted with one or two substituents independently selected from halogen, cyano, C1-6alkyl and haloC1-6alkyl; pyrimidinyl substituted with one or two substituents independently selected from halogen and C1-6alkyl; thiazolyl, said thiazolyl being unsubstituted or substituted by halogen or haloC1-6alkyl; phenyl, said phenyl being unsubstituted or substituted with one or two substituents independently selected from halogen, cyano, hydroxy, C3-7cycloalkyl, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl and haloC1-6alkoxy; R2 and R3 are independently selected from hydrogen and C1-6alkyl with the proviso that R2 and R3 are not C1-6alkyl simultaneously; R4 is benzothiophenyl; benzoxazolyl; indolyl; benzothiazolyl substituted by C1-6alkyl; pyridinyl, said pyridinyl being unsubstituted or substituted with one or two substituents independently selected from halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkyl and (C1-6alkyl)2amino; bicyclo[4.2.0]octa-l(6),2,4-trienyl; phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C3-7cycloalkyl, C1-6alkyl, C2-6alkynyl, C1-6alkoxy, haloC1-6alkyl and haloC1-6alkoxy; phenylC1-6alkyl, said phenylC1-6alkyl being unsubstituted or substituted with one or two halogen; or C3-7cycloalkyl; Y and Q are independently selected from CH and N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

4. A compound of formula (I) according to claim 3, wherein R1 is fluorophenyl, phenyl, chlorophenyl, trifluoromethylphenyl, cyanophenyl, methoxyphenyl, methylphenyl, difluorophenyl, fluorochlorophenyl, difluoromethylphenyl, methylfluorophenyl, cyclopropylphenyl, hydroxyphenyl, trifluoromethoxyphenyl, bromophenyl, methylpyrazolyl, cyanopyrazolyl, fluoropyrazolyl, hydroxymethylpyrazolyl, methoxymethylpyrazolyl, trifluoromethylpyridinyl, cyanopyridinyl, methylfluoropyridinyl, pyridinyl, chloropyridinyl, fluoropyridinyl, fluorochloropyridinyl, fluoropyrimidinyl, methylfluoropyrimidinyl, thiazolyl, trifluoromethylthiazolyl or chlorothiazolyl; R2 and R3 are independently selected from hydrogen and methyl with the proviso that R2 and R3 are not methyl simultaneously; R4 is phenyl, trifluoromethylphenyl, fluorochlorophenyl, fluorophenyl, chlorophenyl, cyanophenyl, pyridinyl, methylfluoropyridinyl, fluorotrifluoromethylphenyl, trifluorophenyl, fluorochlorobenzyl, dichlorobenzyl, methylchloropyridinyl, methylbenzothiazolyl, benzothiophenyl, trifluoromethylpyridinyl, difluorophenyl, fluorocyanophenyl, indolyl, methylfluorophenyl, chloropyridinyl, cyanopyridinyl, chloromethoxypyridinyl, methyltrifluoromethylphenyl, chlorotrifluoromethylphenyl, chlorocyanophenyl, ethylphenyl, ethynylphenyl, isopropylphenyl, methoxyphenyl, ethynylfluorophenyl, dimethylpyridinyl, fluorobromophenyl, difluoromethoxyphenyl, fluorotrifluoromethoxyphenyl, difluoromethylphenyl, methylphenyl, difluorocyanophenyl, fluorochloropyridinyl, cyclopropylphenyl, methyldifluorophenyl, difluorochlorophenyl, cyclopropyldifluorophenyl, difluoroethylphenyl, cyclopropylfluorophenyl, methoxydifluorophenyl, benzyl, fluoropyridinyl, benzoxazolyl, methylpyridinyl, difluoropyridinyl, cyclopentyl, cyclohexyl, bicyclo[4.2.0]octa-1(6),2,4-trienyl, bromopyridinyl, cyclopropylpyridinyl, dimethylaminopyridinyl or difluoromethylpyridinyl; Y and Q are independently selected from CH and N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

5. A compound of formula (I) according to claim 3 or 4, wherein R1 is phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, hydroxy, C3-7cycloalkyl, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl and haloC1-6alkoxy; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

6. A compound of formula (I) according to claim 5, wherein R1 is phenyl, bromophenyl, chlorophenyl, cyanophenyl, cyclopropylphenyl, difluorophenyl, difluoromethylphenyl, fluorophenyl, fluorochlorophenyl, fluoromethylphenyl, hydroxyphenyl, methoxyphenyl, methylphenyl, trifluoromethoxyphenyl or trifluoromethylphenyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

7. A compound of formula (I) according to any one of claims 3 to 6, wherein R4 is phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C3-7cycloalkyl, C1-6alkyl, C2-6alkynyl, C1-6alkoxy, haloC1-6alkyl and haloC1-6alkoxy; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

8. A compound of formula (I) according to claim 7, wherein R4 is phenyl, chlorophenyl, chlorocyanophenyl, chlorotrifluoromethylphenyl, cyanophenyl, cyclopropylphenyl, difluorophenyl, difluoroethylphenyl, difluoromethoxyphenyl, difluoromethylphenyl, ethylphenyl, ethynylphenyl, fluorophenyl, fluorobromophenyl, fluorochlorophenyl, fluorocyanophenyl, fluorocyclopropylphenyl, fluoroethynylphenyl, difluorochlorophenyl, difluorocyanophenyl, difluorocyclopropylphenyl, methoxydifluorophenyl, methyldifluorophenyl, methylfluorophenyl, fluorotrifluoromethoxyphenyl, fluorotrifluoromethylphenyl, isopropylphenyl, methoxyphenyl, methylphenyl, methyltrifluoromethylphenyl, trifluorophenyl or trifluoromethylphenyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

9. A compound of formula (I) according to claim 3 or 4, wherein R1 is pyrazolyl substituted by halogen or hydroxyC1-6alkyl; pyridinyl substituted by halogen; pyrimidinyl substituted by halogen; phenyl substituted once or twice by halogen; R2 is H; R3 is H or C1-6alkyl; R4 is pyridinyl substituted by haloC1-6alkyl; or phenyl substituted with one, two or three substituents independently selected from halogen and cyano; Y and Q are independently selected from CH and N, with proviso that Y and Q are not CH simultaneously; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

10. A compound of formula (I) according to claim 9, wherein R1 is fluoropyrazolyl, hydroxymethylpyroazolyl, fluoropyridinyl, fluoropyrimidinyl, fluorophenyl or difluorophenyl; R2 is H; R3 is H or methyl; R4 is difluoromethylpyridinyl, fluorochlorophenyl, fluorocyanophenyl or trifluorophenyl; Y and Q are independently selected from CH and N, with proviso that Y and Q are not CH simultaneously; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

11. A compound according to claim 8 or 9, selected from N-(3-cyano-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-fluoro-2-pyridyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 1-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluoropyrazol-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[2-(difluoromethyl)-4-pyridyl]-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5-fluoropyrimidin-2-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; and (6S)-3-[4-(hydroxymethyl)pyrazol-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

12. A compound of formula (I) according to claim 1 or 2, wherein R1 is azabicyclo[3.1.0]hexanyl; morpholinyl, said morpholinyl being unsubstituted or substituted twice by C1-6alkyl; oxaazabicyclo[3.2.1]octanyl; piperidinyl, said piperidinyl being unsubstituted or substituted with one or two substituents independently selected from halogen, hydroxy and C1-6alkylcarbonyl; pyrrolidinyl, said pyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from halogen, cyano, hydroxy, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy and C1-6alkoxyC1-6alkyl; tetrahydrofuranyl; or C3-7cycloalkyl; R2 is H; R3 is H or C1-6alkyl; R4 is benzofuranyl; pyridinyl, said pyridinyl being substituted with one or two substituents independently selected from halogen and haloC1-6alkyl; indanyl; phenyl, said phenyl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano and C1-6alkyl; or phenylC1-6alkyl; Y is CH when Q is N; or Y is N when Q is CH; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

13. A compound of formula (I) according to claim 12, wherein R1 is azabicyclo[3.1.0]hexanyl, cyclohexyl, cyclopentyl, morpholinyl, dimethylmorpholinyl, oxaazabicyclo[3.2.1]octanyl, piperidinyl, difluoropiperidinyl, hydroxypiperidinyl, acetylpiperidinyl, pyrrolidinyl, methylpyrrolidinyl, methoxymethylpyrrolidinyl, methoxypyrrolidinyl, trifluoromethylpyrrolidinyl, cyanopyrrolidinyl, methylhydroxypyrrolidinyl, difluoropyrrolidinyl or tetrahydrofuranyl; R2 is H; R3 is H or methyl; R4 is benzofuranyl, indanyl, benzyl, phenyl, fluorochlorophenyl, fluorocyanophenyl, trifluorophenyl, methyldifluorophenyl, chloropyridinyl, fluorochloropyridinyl or trifluoromethylpyridinyl; Y is CH when Q is N; or Y is N when Q is CH; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

14. A compound of formula (I) according to claim 1 or 2, wherein R1 is dioxopiperazinyl; dioxopyrimidinyl dioxotetrahydropyrrolo[1,2-a]pyrazinyl; oxoazabicyclo[3 .

1. 0]hexanyl; oxoazaspiro[2.4]heptanyl, said oxoazaspiro[2.4]heptanyl being unsubstituted or substituted with hydroxy; oxoazaspiro [4.4] nonanyl; oxoazaspiro[3.4]octanyl, said oxoazaspiro[3.4]octanyl being unsubstituted or substituted with hydroxy; oxodiazaspiro[3.4]octanyl, said oxodiazaspiro[3.4]octanyl being substituted by C1-6alkylcarbonyl, C1-6alkoxycarbonyl, oxazolylcarbonyl or pyrimidinyl; oxodihydropyrazolo[1,5-a]pyrazinyl; oxohexahydropyrimidinyl; oxoimidazolidinyl, said oxoimidazolidinyl being unsubstituted or substituted with one or two substituents independently selected from C1-6alkyl, C1-6alkylcarbonyl, C1-6alkylsulfonyl, phenyl, phenylcarbonyl and pyrimidinyl; oxoindolinyl; oxomorpholinyl, said oxomorpholinyl being unsubstituted or substituted with one or two substituents independently selected from C1-6alkyl and oxazolyl; oxooxaazaspiro[2.4]heptanyl; oxooxaazaspiro[3.4]octanyl; oxooxaazaspiro[4.4]nonanyl; oxooxaazaspiro[4.5]decanyl; oxooxazinanyl, said oxooxazinanyl being unsubstituted or substituted with one or two substituents independently selected from C1-6alkyl, C1-6alkoxy and morpholinylcarbonyl; oxooxazolidinyl, said oxooxazolidinyl being unsubstituted or substituted with one or two substituents independently selected from C1-6alkyl, phenyl, pyridinyl, halopyridinyl, oxazolyl, C1-6alkylimidazolyl and C1-6alkyloxadiazolyl; oxopiperidyl substituted by C1-6alkyl or hydroxy; oxopyrrolidinyl, said oxopyrrolidinyl being unsubstituted or substituted with one, two or three substituents independently selected from (C1-6alkyl)2aminocarbonyl, (C1-6alkyl)2morpholinylcarbonyl, C1-6alkoxy, C1- 6alkoxyC1-6alkyl, C1-6alkyl, C1-6alkyl(C1-6alkylsulfonyl)amino, C1-6alkylaminocarbonyl, C1-6alkylcarbonylamino, C1-6alkylmofpholinylcarbonyl, C1-6alkyloxadiazolyl, C1-6alkyloxazolyl, C1-6alkylpyrazolyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonylC1-6alkyl, cyano, dioxopyrrolidinyl, haloC1-6alkyl, haloC1-6alkyloxadiazolyl, halopiperidinylcarbonyl, halopyrimidinylamino, halopyrimidinyloxy, halopyrrolidinylcarbonyl, hydroxy, hydroxyazetidinylcarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl(C1-6alkyl)aminocarbonyl, hydroxyC1-6alkylaminocarbonyl, hydroxypyrrolidinylcarbonyl, morpholinylcarbonyl, oxadiazolyl, oxazolyl, oxazolylaminocarbonyl, oxazolyl(C1-6alkyl)aminocarbonyl, oxazolylcarbonyl(C1-6alkyl)amino, oxomorpholinyl, oxooxazolidinyl, oxopyrrolidinyl, phenyl, pyrazolylC1-6alkyl, pyridinyl, pyrimidinyl, pyrimidinylamino, pyrimidinyl(C1-6alkyl)amino, pyrimidinyloxy, pyrimidinyloxyC1-6alkyl, pyrrolidinylcarbonyl and thiazolyl; oxopyrrolo[3,2-c]pyridinyl; oxopyrrolo[3,4-b]pyridinyl; oxotetrahydrofuro[3,4-c]pyrrolyl; oxotetrahydroimidazo[5,1-c][1,4]oxazinyl; R2 and R3 are independently selected from hydrogen and C1-6alkyl with the proviso that R2 is not C1-6alkyl when R3 is H; R4 is pyridinyl substituted with one or two substituents independently selected from halogen and haloC1-6alkyl; phenyl substituted with one, two or three substituents independently selected from halogen and haloC1-6alkyl; Y is CH; Q is N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

15. A compound of formula (I) according to claim 14, wherein R1 is dioxopiperazinyl, dioxopyrimidinyl, dioxotetrahydropyrrolo[1,2-a]pyrazinyl, oxoazabicyclo[3.1.0]hexanyl, oxoazaspiro[2.4]heptanyl, hydroxy oxoazaspiro[2.4]heptanyl, oxoazaspiro[4.4]nonanyl, oxoazaspiro[3.4]octanyl, hydroxyoxoazaspiro[3.4]octanyl, acetyloxodiazaspiro[3.4]octanyl, methoxycarbonyloxodiazaspiro[3.4]octanyl, ethoxycarbonyloxodiazaspiro[3.4]octanyl, oxazolylcarbonyloxodiazaspiro[3.4]octanyl, pyrimidinyloxodiazaspiro[3.4]octanyl, oxodihydropyrazolo[1,5-a]pyrazinyl, oxohexahydropyrimidinyl, oxoimidazolidinyl, acetyloxoimidazolidinyl, benzoyloxoimidazolidinyl, dimethyloxoimidazolidinyl, methyloxoimidazolidinyl, methylsulfonyloxoimidazolidinyl, phenyloxoimidazolidinyl, pyrimidinyloxoimidazolidinyl, oxoindolinyl, oxoisoindolinyl, oxomorpholinyl, methyloxomorpholinyl, dimethyloxomorpholinyl, oxazolyloxomorpholinyl, oxooxaazaspiro[4.5]decanyl, oxooxaazaspiro[4.4]nonanyl, oxooxaazaspiro[2.4]heptanyl, oxooxaazaspiro[3.4]octanyl, oxooxazinanyl, methyloxooxazinanyl, dimethyloxooxazinanyl, methoxyoxooxazinanyl, morpholinylcarbonyl(methyl)oxooxazinanyl, oxooxazolidinyl, dimethyloxooxazolidinyl, chloropyridinyloxooxazolidinyl, fluoropyridinyloxooxazolidinyl, methyloxooxazolidinyl, methylimidazolyloxooxazolidinyl, methyloxadiazolyloxooxazolidinyl, oxazolyloxooxazolidinyl, phenyloxooxazolidinyl, pyridinyloxooxazolidinyl, hydroxyoxopiperidyl, methyloxopiperidyl, oxopyrrolidinyl, acetylaminooxopyrrolidinyl, cyanooxopyrrolidinyl, difluoropiperidinylcarbonyl(methyl)oxopyrrolidinyl, difluoropyrrolidinylcarbonyloxopyrrolidinyl, difluoropyrrolidinylcarbonyl(methyl)oxopyrrolidinyl, dihydroxyoxopyrrolidinyl, dimethyloxopyrrolidinyl, dimethylaminocarbonyloxopyrrolidinyl, dimethylmorpholinylcarbonyloxopyrrolidinyl, dioxopyrrolidinyloxopyrrolidinyl, ethyloxopyrrolidinyl, fluoropyrimidinylaminooxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, hydroxyoxopyrrolidinyl, hydroxyazetidinylcarbonyloxopyrrolidinyl, hydroxyethyl(methyl)aminocarbonyloxopyrrolidinyl, hydroxy(dimethyl)oxopyrrolidinyl, hydroxydimethylethylaminooxopyrrolidinyl, hydroxymethyloxopyrrolidinyl, hydroxy(methyl)cyanooxopyrrolidinyl, hydroxymethyl(cyano)oxopyrrolidinyl, hydroxymethylethyloxopyrrolidinyl, hydroxypyrrolidinylcarbonyloxopyrrolidinyl, methoxyoxopyrrolidinyl, methoxymethyloxopyrrolidinyl, methyloxopyrrolidinyl, methyl(methylsulfonyl)aminooxopyrrolidinyl, methylaminocarbonyloxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, methylmorpholinylcarbonyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, methyloxadiazolyl(methyl)oxopyrrolidinyl, methyloxazolyloxopyrrolidinyl, methylpyrazolyloxopyrrolidinyl, methylsulfonyloxopyrrolidinyl, methylsulfonylaminooxopyrrolidinyl, methylsulfonylmethyloxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, morpholinylcarbonyl(methyl)oxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, oxadiazolyl(methyl)oxopyrrolidinyl, oxazolyloxopyrrolidinyl, oxazolylaminocarbonyloxopyrrolidinyl, oxazolylcarbonyl(methyl)aminooxopyrrolidinyl, oxazolyl(methyl)aminocarbonyloxopyrrolidinyl, oxomorpholinyloxopyrrolidinyl, oxooxazolidinyloxopyrrolidinyl, oxopyrrolidinyloxopyrrolidinyl, phenyloxopyrrolidinyl, phenyl(hydroxy)oxopyrrolidinyl, pyrazolylmethyloxopyrrolidinyl, pyridinyloxopyrrolidinyl, pyrimidinyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, pyrimidinyl(methyl)aminooxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, pyrimidinyloxy(hydroxy)(methyl)oxopyrrolidinyl, pyrimidinyloxymethyloxopyrrolidinyl, pyrrolidinylcarbonyloxopyrrolidinyl, thiazolyloxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, trifluoromethyloxadiazolyloxopyrrolidinyl, oxotetrahydrofuro[3,4-c]pyrrolyl, oxotetrahydroimidazo[5,1-c][1,4]oxazinyl, oxopyrrolo[3,4-b]pyridinyl or oxopyrrolo[3,2-c]pyridinyl; R2 and R3 are independently selected from hydrogen and methyl with the proviso that R2 is not methyl when R3 is H; R4 is chloropyridinyl, difluoromethylpyridinyl, fluorochloropyridinyl, fluorodifluoromethylpyridinyl, trifluoromethylpyridinyl, difluorochlorophenyl, difluorodifluoromethylphenyl, fluorochlorophenyl, fluorotrifluoromethylphenyl, trifluorophenyl; Y is CH; Q is N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

16. A compound of formula (I) according to claim 14 or 15, wherein R1 is oxoazabicyclo[3 .

1. 0]hexanyl; oxodiazaspiro[3.4]octanyl substituted by C1-6alkoxycarbonyl or pyrimidinyl; oxoimidazolidinyl; oxoindolinyl; oxomorpholinyl, said oxomorpholinyl being unsubstituted or substituted once or twice by C1-6alkyl; oxooxaazaspiro[2.4]heptanyl; oxooxaazaspiro[4.5]decanyl; oxooxazinanyl, said oxooxazinanyl being unsubstituted or substituted once or twice by C1-6alkyl; oxooxazolidinyl, said oxooxazolidinyl being unsubstituted or substituted twice by C1-6alkyl; oxopyrrolidinyl said oxopyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from (C1-6alkyl)2aminocarbonyl, C1-6alkyl, C1-6alkoxy, C1-6alkyloxadiazolyl, cyano, halopyrimidinyloxy, haloC1-6alkyl, hydroxy, hydroxyC1-6alkyl, morpholinylcarbonyl, oxadiazolyl, pyrimidinylamino, pyrimidinyloxy and pyrrolidinylcarbonyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

17. A compound of formula (I) according to any one of claims 14 to 16, wherein R1 is oxoazabicyclo[3.1.0]hexanyl, methoxycarbonyloxodiazaspiro[3.4]octanyl, ethoxycarbonyloxodiazaspiro[3.4]octanyl, pyrimidinyloxodiazaspiro[3.4]octanyl, oxoimidazolidinyl, oxoindolinyl, oxomorpholinyl, dimethyloxomorpholinyl, oxooxaazaspiro[4.5]decanyl, oxooxaazaspiro[2.4]heptanyl, oxooxazinanyl, methyloxooxazinanyl, dimethyloxooxazinanyl, oxooxazolidinyl, dimethyloxooxazolidinyl, oxopyrrolidinyl, cyanooxopyrrolidinyl, hydroxyoxopyrrolidinyl, methoxyoxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, hydroxymethylcyanooxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, dimethylaminocarbonyloxopyrrolidinyl or pyrrolidinylcarbonyloxopyrrolidinyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

18. A compound of formula (I) according to any one of claims 14 to 17, wherein R4 is pyridinyl substituted by haloC1-6alkyl; or phenyl substituted with two or three substituents independently selected from halogen and haloC1-6alkyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

19. A compound of formula (I) according to any one of claims 14 to 18, wherein R4 is difluoromethylpyridinyl, fluorochlorophenyl, difluorodifluoromethylphenyl or trifluorophenyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

20. A compound of formula (I) according to any one of claims 14 to 19, wherein R1 is oxoazabicyclo[3.1.0]hexanyl; oxodiazaspiro[3.4]octanyl substituted with C1-6alkoxycarbonyl or pyrimidinyl; oxoimidazolidinyl; oxoindolinyl; oxomorpholinyl, said oxomorpholinyl being unsubstituted or substituted once or twice by C1-6alkyl; oxooxaazaspiro[2.4]heptanyl; oxooxaazaspiro[4.5]decanyl; oxooxazinanyl, said oxooxazinanyl being unsubstituted or substituted once ro twice by C1-6alkyl; oxooxazolidinyl, said oxooxazolidinyl being unsubstituted or substituted once or twice by C1-6alkyl; oxopyrrolidinyl said oxopyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from (C1-6alkyl)2aminocarbonyl, C1-6alkyl, C1-6alkoxy, C1-6alkyloxadiazolyl, cyano, halopyrimidinyloxy, haloC1-6alkyl, hydroxy, hydroxyC1-6alkyl, morpholinylcarbonyl, oxadiazolyl, pyrimidinylamino, pyrimidinyloxy and pyrrolidinylcarbonyl; R2 is H; R3 is H or C1-6alkyl; R4 is pyridinyl substituted by haloC1-6alkyl; or phenyl substituted with two or three substituents independently selected from halogen and haloC1-6alkyl; Y is CH; Q is N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

21. A compound of formula (I) according to any one of claims 14 to 20, wherein R1 is oxoazabicyclo[3.1.0]hexanyl, methoxycarbonyloxodiazaspiro[3.4]octanyl, ethoxycarbonyloxodiazaspiro[3.4]octanyl, pyrimidinyloxodiazaspiro[3.4]octanyl, oxoimidazolidinyl, oxoindolinyl, oxomorpholinyl, dimethyloxomorpholinyl, oxooxaazaspiro[4.5]decanyl, oxooxaazaspiro[2.4]heptanyl, oxooxazinanyl, methyloxooxazinanyl, dimethyloxooxazinanyl, oxooxazolidinyl, dimethyloxooxazolidinyl, oxopyrrolidinyl, cyanooxopyrrolidinyl, hydroxyoxopyrrolidinyl, methoxyoxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, hydroxymethylcyanooxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, dimethylaminocarbonyloxopyrrolidinyl or pyrrolidinylcarbonyloxopyrrolidinyl; R 2 is H; R3 is H or methyl; R4 is difluoromethylpyridinyl, fluorochlorophenyl, difluorodifluoromethylphenyl or trifluorophenyl; Y is CH; Q is N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

22. A compound according to claim 20 or 21, selected from N-(3-chloro-4-fluoro-phenyl)-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-hydroxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(3-oxomorpholin-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxooxazolidin-3-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-methoxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-3-azabicyclo[3.1.0]hexan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrimidin-2-ylamino)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-methyl-2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5,5-dimethyl-2-oxo-1,3-oxazinan-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-oxo-8-oxa-2-azaspiro[4.5]decan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-oxo-4-oxa-6-azaspiro[2.4]heptan-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; methyl 6-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate; ethyl 6-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate; (6S)-6-methyl-3-(7-oxo-2-pyrimidin-2-yl-2,6-diazaspiro[3.4]octan-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxoindolin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-cyano-4-(hydroxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-4-methyl-2-oxo-pyrrolidin-1-yl)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(hydroxymethyl)-4-methyl-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(2,2-dimethyl-5-oxo-morpholin-4-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(2-oxoimidazolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4S)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-(5-fluoropyrimidin-2-yl)oxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(dimethylcarbamoyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrrolidine-1-carbonyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4R)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-cyano-2-methyl-5-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5-hydroxy-2-oxo-1,3-oxazinan-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; and (6S)-3-[(3S,4R)-3-hydroxy-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

23. A compound of formula (I) according to claim 1 or 2, wherein R1 is oxopyrrolidinyl, said oxopyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from (C1-6alkyl)2aminocarbonyl, (C1-6alkyl)2morpholinylcarbonyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkyl, C1-6alkyl(C1-6alkylsulfonyl)amino, C1-6alkylaminocarbonyl, C1-6alkylcarbonylamino, C1-6alkylmorpholinylcarbonyl, C1-6alkyloxadiazolyl, C1-6alkyloxazolyl, C1-6alkylpyrazolyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonylC1-6alkyl, cyano, dioxopyrrolidinyl, haloC1-6alkyl, haloC1-6alkyloxadiazolyl, halopiperidinylcarbonyl, halopyrimidinylamino, halopyrimidinyloxy, halopyrrolidinylcarbonyl, hydroxy, hydroxyazetidinylcarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyl(C1-6alkyl)aminocarbonyl, hydroxyC1-6alkylaminocarbonyl, hydroxypyrrolidinylcarbonyl, morpholinylcarbonyl, oxadiazolyl, oxazolyl, oxazolylaminocarbonyl, oxazolyl(C1-6alkyl)aminocarbonyl, oxazolylcarbonyl(C1-6alkyl)amino, oxomorpholinyl, oxooxazolidinyl, oxopyrrolidinyl, phenyl, pyrazolylC1-6alkyl, pyridinyl, pyrimidinyl, pyrimidinylamino, pyrimidinyl(C1-6alkyl)amino, pyrimidinyloxy, pyrimidinyloxyC1-6alkyl, pyrrolidinylcarbonyl and thiazolyl; R2 and R3 are independently selected from hydrogen and C1-6alkyl with the proviso that R2 is not C1-6alkyl when R3 is H; R4 is pyridinyl substituted with one or two substituents independently selected from halogen and haloC1-6alkyl; phenyl substituted with one, two or three substituents independently selected from halogen and haloC1-6alkyl; Y is CH; Q is N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

24. A compound of formula (I) according to claim 23, wherein R1 is oxopyrrolidinyl, acetylaminooxopyrrolidinyl, cyanooxopyrrolidinyl, difluoropiperidinylcarbonyl(methyl)oxopyrrolidinyl, difluoropyrrolidinylcarbonyloxopyrrolidinyl, difluoropyrrolidinylcarbonyl(methyl)oxopyrrolidinyl, dihydroxyoxopyrrolidinyl, dimethyloxopyrrolidinyl, dimethylaminocarbonyloxopyrrolidinyl, dimethylmorpholinylcarbonyloxopyrrolidinyl, dioxopyrrolidinyloxopyrrolidinyl, ethyloxopyrrolidinyl, fluoropyrimidinylaminooxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, hydroxyoxopyrrolidinyl, hydroxyazetidinylcarbonyloxopyrrolidinyl, hydroxyethyl(methyl)aminocarbonyloxopyrrolidinyl, hydroxy(dimethyl)oxopyrrolidinyl, hydroxydimethylethylaminooxopyrrolidinyl, hydroxymethyloxopyrrolidinyl, hydroxy(methyl)cyanooxopyrrolidinyl, hydroxymethyl(cyano)oxopyrrolidinyl, hydroxymethylethyloxopyrrolidinyl, hydroxypyrrolidinylcarbonyloxopyrrolidinyl, methoxyoxopyrrolidinyl, methoxymethyloxopyrrolidinyl, methyloxopyrrolidinyl, methyl(methylsulfonyl)aminooxopyrrolidinyl, methylaminocarbonyloxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, methylmorpholinylcarbonyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, methyloxadiazolyl(methyl)oxopyrrolidinyl, methyloxazolyloxopyrrolidinyl, methylpyrazolyloxopyrrolidinyl, methylsulfonyloxopyrrolidinyl, methylsulfonylaminooxopyrrolidinyl, methylsulfonylmethyloxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, morpholinylcarbonyl(methyl)oxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, oxadiazolyl(methyl)oxopyrrolidinyl, oxazolyloxopyrrolidinyl, oxazolylaminocarbonyloxopyrrolidinyl, oxazolylcarbonyl(methyl)aminooxopyrrolidinyl, oxazolyl(methyl)aminocarbonyloxopyrrolidinyl, oxomorpholinyloxopyrrolidinyl, oxooxazolidinyloxopyrrolidinyl, oxopyrrolidinyloxopyrrolidinyl, phenyloxopyrrolidinyl, phenyl(hydroxy)oxopyrrolidinyl, pyrazolylmethyloxopyrrolidinyl, pyridinyloxopyrrolidinyl, pyrimidinyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, pyrimidinyl(methyl)aminooxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, pyrimidinyloxy(hydroxy)(methyl)oxopyrrolidinyl, pyrimidinyloxymethyloxopyrrolidinyl, pyrrolidinylcarbonyloxopyrrolidinyl, thiazolyloxopyrrolidinyl, trifluoromethyloxopyrrolidinyl or trifluoromethyloxadiazolyloxopyrrolidinyl; R2 and R3 are independently selected from hydrogen and methyl with the proviso that R2 is not methyl when R3 is H; R4 is chloropyridinyl, difluoromethylpyridinyl, fluorochloropyridinyl, trifluoromethylpyridinyl, difluorochlorophenyl, difluorodifluoromethylphenyl, fluorochlorophenyl, fluorotrifluoromethylphenyl or trifluorophenyl; Y is CH; Q is N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

25. A compound of formula (I) according to claim 23 or 24, wherein R1 is oxopyrrolidinyl, said oxopyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from (C1-6alkylhaminocarbonyl, C1-6alkoxy, C1-6alkyl, C1-6alkyloxadiazolyl, cyano, haloC1-6alkyl, halopyrimidinyloxy, hydroxy, hydroxyC1-6alkyl, morpholinylcarbonyl, oxadiazolyl, pyrimidinylamino, pyrimidinyloxy and pyrrolidinylcarbonyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

26. A compound of formula (I) according to any one of claims 23 to 25, wherein R1 is oxopyrrolidinyl, cyanooxopyrrolidinyl, hydroxyoxopyrrolidinyl, methoxyoxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, hydroxymethylcyanooxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, dimethylaminocarbonyloxopyrrolidinyl or pyrrolidinylcarbonyloxopyrrolidinyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

27. A compound of formula (I) according to any one of claims 23 to 26, wherein R2 is H; R3 is H or C1-6alkyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

28. A compound of formula (I) according to any one of claims 23 to 27, wherein R2 is H; R3 is H or methyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

29. A compound of formula (I) according to any one of claims 23 to 28, wherein R4 is pyridinyl substituted by haloC1-6alkyl; or phenyl substituted with one, two or three substituents independently selected from halogen and haloC1-6alkyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

30. A compound of formula (I) according to any one of claims 23 to 29, wherein R4 is difluoromethylpyridinyl, fluorochlorophenyl, difluorodifluoromethylphenyl or trifluorophenyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

31. A compound of formula (I) according to any one of claims 23 to 30, wherein R1 is oxopyrrolidinyl, said oxopyrrolidinyl being unsubstituted or substituted with one or two substituents independently selected from (C1-6alkyl)2aminocarbonyl, C1-6alkoxy, C1-6alkyl, C1-6alkyloxadiazolyl, cyano, haloC1-6alkyl, halopyrimidinyloxy, hydroxy, hydroxyC1-6alkyl, morpholinylcarbonyl, oxadiazolyl, pyrimidinylamino, pyrimidinyloxy and pyrrolidinylcarbonyl; R2 is H; R3 is H or C1-6alkyl; R4 is pyridinyl substituted by haloC1-6alkyl; or phenyl substituted with one, two or three substituents independently selected from halogen and haloC1-6alkyl; Y is CH; Q is N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

32. A compound of formula (I) according to any one of claims 23 to 31, wherein R1 is oxopyrrolidinyl, cyanooxopyrrolidinyl, hydroxyoxopyrrolidinyl, methoxyoxopyrrolidinyl, trifluoromethyloxopyrrolidinyl, pyrimidinylaminooxopyrrolidinyl, oxadiazolyloxopyrrolidinyl, methyloxadiazolyloxopyrrolidinyl, hydroxymethylcyanooxopyrrolidinyl, methylcyanooxopyrrolidinyl, methyl(hydroxymethyl)oxopyrrolidinyl, pyrimidinyloxyoxopyrrolidinyl, pyrimidinyloxy(hydroxy)oxopyrrolidinyl, fluoropyrimidinyloxyoxopyrrolidinyl, morpholinylcarbonyloxopyrrolidinyl, dimethylaminocarbonyloxopyrrolidinyl or pyrrolidinylcarbonyloxopyrrolidinyl; R2 is H; R3 is H or C1-6alkyl; R4 is difluoromethylpyridinyl, fluorochlorophenyl, difluorodifluoromethylphenyl or trifluorophenyl; Y is CH; Q is N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

33. A compound according to any one of claims 23 to 32, selected from N-(3-chloro-4-fluoro-phenyl)-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-hydroxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-methoxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrimidin-2-ylamino)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-cyano-4-(hydroxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-4-methyl-2-oxo-pyrrolidin-1-yl)-N-[3-(difluoromethyl)-4,5-difluorophenyl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(hydroxymethyl)-4-methyl-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4S)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-(5-fluoropyrimidin-2-yl)oxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(morpholine-4-carbonyl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(dimethylcarbamoyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrrolidine-1-carbonyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4R)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-cyano-2-methyl-5-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; and (6S)-3-[(3S,4R)-3-hydroxy-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

34. A compound according to any one of claims 1 or 2, selected from 3-(4-fluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N,3-diphenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-fluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-chlorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-fluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-chlorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[2-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 1-(4-fluorophenyl)-N-phenyl-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 3-(4-fluorophenyl)-N-phenyl-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-[3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-8-(4-fluorophenyl)-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carboxamide; N-(2-fluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N,3-bis(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chlorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyanophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(4-chlorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-cyanophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-fluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(4-chloro-3-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(4-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(4-cyanophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-methoxyphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-cyclopentyl-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-methoxyphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-cyano-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chlorophenyl)-3-(2-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chlorophenyl)-3-(o-tolyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(5-fluoro-6-methyl-2-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-(2-fluorophenyl)-N-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-chlorophenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chlorophenyl)-3-(2,3-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-cyano-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-chloro-2-fluoro-phenyl)-N-(3-chlorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-chloro-2-fluoro-phenyl)-N-(3-chlorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chlorophenyl)-3-(2,5-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-[3-(difluoromethyl)phenyl]-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-fluoro-6-methyl-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-fluoro-4-methyl-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-(2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide+H31; N-phenyl-3-thiazol-2-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[4-(trifluoromethyl)thiazol-2-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-chlorothiazol-2-yl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3,4-difluorophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(6-chloro-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluoro-3-methyl-phenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-[(3-chloro-4-fluoro-phenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-[(3,5-dichlorophenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(4-chloro-5-methyl-2-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-(4-chloro-2-pyridyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[(2-chloro-3-fluoro-phenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-[(2,6-dichlorophenyl)methyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-(2,4-difluorophenyl)-N-(5-fluoro-6-methyl-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-(4-fluorophenyl)-N-(2-methyl-1,3-benzothiazol-5-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(benzothiophen-3-yl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-(3-cyclopropylphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2-hydroxyphenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-4-methyl-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(2-chloro-4-pyridyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-[4-(trifluoromethyl)-2-pyridyl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N,3-bis(3-chloro-4-fluoro-phenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-cyclohexyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(5-fluoro-4-methyl-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(5-fluoro-2-pyridyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-(4-fluorophenyl)-N-(1H-indol-6-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(4-fluoro-3-methyl-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-cyclopentyl-N-indan-5-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-cyclopentyl-N-indan-1-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-benzyl-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-pyrrolidin-1-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-6-methyl-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4,4-difluoro-1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-thiazol-2-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3,3-difluoro-1-piperidyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(2-chloro-4-pyridyl)-3-cyclopentyl-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-cyano-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-6-methoxy-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-(5-fluoro-2-pyridyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6R)-N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-3-cyclopentyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(benzofuran-6-yl)-3-cyclopentyl-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-5-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-[3-chloro-5-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3,4-difluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-cyano-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3,5-difluorophenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[4-chloro-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-ethylphenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-ethynylphenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(3-isopropylphenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(3-methoxyphenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[2-(trifluoromethoxy)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-chloro-4-fluoro-phenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(m-tolyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-bromophenyl)-N-phenyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-ethynyl-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-chloro-5-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2,6-dimethyl-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-1-(4-fluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-bromo-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[3-(difluoromethoxy)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[3-(difluoromethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(m-tolyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-phenyl-3-[3-(trifluoromethoxy)phenyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 1-(2,4-difluorophenyl)-N-(3-ethynyl-4-fluoro-phenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-chloro-4-fluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7 -carboxamide; N-(3-cyano-4-fluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7 -carboxamide; N-(3-cyano-4,5-difluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7 -carboxamide; 1-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 3-(2,4-difluorophenyl)-N-(3-ethynyl-4-fluoro-phenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(6-chloro-5-fluoro-2-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyclopropylphenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyano-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(6-chloro-5-fluoro-2-pyridyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3,4-difluoro-5-methyl-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4,5-difluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyclopropyl-4,5-difluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[3-(1,1-difluoroethyl)phenyl]-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-chloro-5-fluoro-2-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2-chloro-5-fluoro-4-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyclopropyl-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 1-(2,4-difluorophenyl)-N-[2-(trifluoromethyl)-4-pyridyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide; N-(6-chloro-5-fluoro-2-pyridyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-triazolo[1,5-a]pyrazine-5-carboxamide; N-(3,4-difluoro-5-methyl-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyclopropyl-4-fluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4,5-difluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3,4-difluoro-5-methoxy-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-cyclopropyl-4,5-difluoro-phenyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(6-chloro-5-fluoro-2-pyridyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-1-cyclopentyl-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 1-cyclopentyl-N-(3,4,5-trifluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; 1-cyclopentyl-N-(3,4-difluoro-5-methyl-phenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-cyclopropyl-4,5-difluoro-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3,4-difluoro-5-methoxy-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3,4-difluoro-5-methyl-phenyl)-1-(2,4-difluorophenyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2-methylpyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-morpholino-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-methylpyrazol-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-benzyl-3-(4-fluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(2-fluoro-4-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-(2,4-difluorophenyl)-N-(2-fluoro-4-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(1,3-benzoxazol-6-yl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(4-fluorophenyl)-N-(2-methyl-4-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2,6-difluoro-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 3-(2,4-difluorophenyl)-N-(5-fluoro-4-methyl-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-cyclopentyl-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-cyclohexyl-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-tetrahydrofuran-3-yl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; 6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(4-bicyclo[4.2.0]octa-1(6),2,4-trienyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoropyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(5-fluoro-4-methyl-pyrimidin-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-6-methyl-N-(2-methyl-4-pyridyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(2-chloro-4-pyridyl)-3-(5-fluoro-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-methylpyrazol-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(2-chloro-4-pyridyl)-6-methyl-3-[4-(trifluoromethyl)-2-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-chloro-4-pyridyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5 -carboxamide; N-(2-bromo-4-pyridyl)-3-(4-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-2-methyl-4-pyridyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-(5-fluoro-2-methyl-4-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(5-chloro-2-methyl-4-pyridyl)-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[(2-chloro-3-fluoro-phenyl)methyl]-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-(5-fluoro-6-methyl-2-pyridyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5-fluoro-2-pyridyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(4-methylpyrazol-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-cyanopyrazol-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluoropyrazol-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[4-fluoro-3-(trifluoromethyl)phenyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-cyclopentyl-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-cyclopentyl-6-methyl-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(6-chloro-5-fluoro-2-pyridyl)-3-cyclopentyl-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(2-cyclopropyl-4-pyridyl)-3-(2,4-difluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(2,4-difluorophenyl)-N-[2-(dimethylamino)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-[2-(methoxymethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-[3-(methoxymethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3-methoxypyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4,4-dimethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-[3-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3-cyanopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(3-azabicyclo[3.1.0]hexan-3-yl)-N-(3-chloro-4-fluoro-phenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3-hydroxy-3-methyl-pyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,2-dimethylmorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-[2-(difluoromethyl)-4-pyridyl]-3-(2,4-difluorophenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(3-methyl-5-oxo-morpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(3,3-difluoropyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-[trans-2,6-dimethylmorpholin-4-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-[cis-2,6-dimethylmorpholin-4-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-hydroxy-1-piperidyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-methyl-2-oxo-imidazolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(4-fluorophenyl)-7-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4,5-difluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-hydroxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(3-oxomorpholin-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 3-(1-acetyl-4-piperidyl)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4,5-difluoro-phenyl)-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-[4-(methylcarbamoyl)-2-oxo-pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxooxazolidin-3-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-methoxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(2-acetyl-7-oxo-2,6-diazaspiro[3.4]octan-6-yl)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-methyl-5-oxo-morpholin-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-(3-chloro-4-fluoro-phenyl)-3-(2,5-dioxopiperazin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4,4-dimethyl-2-oxo-imidazolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(3,6-dioxo-4,7,8,8a-tetrahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(4-oxazol-5-yl-2-oxo-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(3-methylsulfonyl-5-oxo-imidazolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S,7S)-6,7-dimethyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(6-oxo-5-azaspiro[2.4]heptan-5-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-3-azabicyclo[3.1.0]hexan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(4-methyl-2-oxo-pyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(3-hydroxy-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4,4-dimethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-(4,4-dimethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(2-chloro-4-pyridyl)-6-methyl-3-[2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S,7R)-6,7-dimethyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(3S)-3-hydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(6-chloro-5-fluoro-2-pyridyl)-3-(4,4-dimethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(3R)-3-hydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[6-(difluoromethyl)-5-fluoro-2-pyridyl]-6-methyl-3-(3-oxo-2-azaspiro[4.4]nonan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-(3-oxo-2-azaspiro[4.4]nonan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrimidin-2-yloxymethyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrazol-1-ylmethyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrimidin-2-ylamino)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[(5-fluoropyrimidin-4-yl)amino]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S,7S)-6,7-dimethyl-3-(2-oxoimidazolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S,7S)-6,7-dimethyl-3-(3-oxomorpholin-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-benzoyl-5-oxo-imidazolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[6-(difluoromethyl)-5-fluoro-2-pyridyl]-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-methyl-2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(2,4-dioxo-1H-pyrimidin-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(2,4-dioxopyrimidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-oxo-3-pyrimidin-2-yl-imidazolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-(5-fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[5-(1-methylimidazol-2-yl)-2-oxo-oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-thiazol-5-yl-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-thiazol-2-yl-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxohexahydropyrimidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5,5-dimethyl-2-oxo-1,3-oxazinan-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-[4-(methoxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-oxo-8-oxa-2-azaspiro[4.5]decan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; 6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-methyl-2-oxo-pyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-[4-(hydroxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(methoxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(methoxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(4-oxo-3,3a,6,6a-tetrahydro-1H-furo[3,4-c]pyrrol-5-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-ethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(8-oxo-2-oxa-7-azaspiro[4.4]nonan-7-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(4-methylsulfonyl-2-oxo-pyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(4-hydroxy-2-oxo-1-piperidyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(methylsulfonylmethyl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-[[methyl(methylsulfonyl)amino]methyl]-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxopyrrolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-phenyl-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(1-hydroxy-1-methyl-ethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-acetamido-2-oxo-pyrrolidin-1-yl)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-[4-(methanesulfonamido)-2-oxo-pyrrolidin-1-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-[4-[methyl(methylsulfonyl)amino]-2-oxopyrrolidin-1-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(2,5-dioxopyrrolidin-1-yl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(2-oxopyrrolidin-1-yl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; N-methyl-N-[1-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-5-oxo-pyrrolidin-3-yl]oxazole-5-carboxamide; N-methyl-N-[1-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-5-oxo-pyrrolidin-3-yl]oxazole-4-carboxamide; N-methyl-N-[1-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-5-oxo-pyrrolidin-3-yl]oxazole-2-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(2-oxooxazolidin-3-yl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(3-oxomorpholin-4-yl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(5-methyl-2-oxo-oxazolidin-3-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[5,1-c][1,4]oxazin-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[5,1-c][1,4]oxazin-2-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(2-chloro-4-pyridyl)-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5,5-dimethyl-2-oxo-oxazolidin-3-yl)-6-methyl-N-[2-(trifluoromethyl)-4-pyridyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(4-methyl-2-oxo-imidazolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4R)-2-oxo-4-phenyl-oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4S)-2-oxo-4-phenyl-oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-phenyl-imidazolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4,4-dimethyl-2-oxo-imidazolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-oxo-4-oxa-6-azaspiro[2.4]heptan-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(6-oxo-5-oxa-7-azaspiro[3.4]octan-7-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; methyl 6-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate; ethyl 6-[(6S)-6-methyl-5-[(3,4,5-trifluorophenyl)carbamoyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]-7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate; (6S)-6-methyl-3-(5-methyl-2-oxo-pyrrolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-(oxazole-2-carbonyl)-7-oxo-2,6-diazaspiro[3.4]octan-6-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(7-oxo-2-pyrimidin-2-yl-2,6-diazaspiro[3.4]octan-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxoindolin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(1-oxoisoindolin-2-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-oxo-7H-pyrrolo[3,4-b]pyridin-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5-fluoropyrimidin-2-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(hydroxymethyl)pyrazol-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(methoxymethyl)pyrazol-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-5-phenyl-oxazolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-5-(2-pyridyl)oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-5-(4-pyridyl)oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-5-(3-pyridyl)oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-oxazol-4-yl-2-oxo-oxazolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(2-methyloxazol-5-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(2-methyloxazol-4-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(3-pyridyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(4-oxazol-4-yl-2-oxo-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(2-pyridyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(4-pyridyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(5-methyl-2-oxo-1-piperidyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-2-oxo-pyrrolidin-1-yl)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-cyano-4-(hydroxymethyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(4-cyano-4-methyl-2-oxo-pyrrolidin-1-yl)-N-[3-(difluoromethyl)-4,5-difluorophenyl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(hydroxymethyl)-4-methyl-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-[methyl(pyrimidin-2-yl)amino]-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxooxazolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(2-chloro-4-pyridyl)-6-methyl-3-(3-oxomorpholin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxoimidazolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-(3-chloro-4-fluoro-phenyl)-3-(2,2-dimethyl-5-oxo-morpholin-4-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(3S)-3-methyl-5-oxo-morpholin-4-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[3-(difluoromethyl)-4,5-difluoro-phenyl]-6-methyl-3-(2-oxoimidazolidin-1-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-acetyl-5-oxo-imidazolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-(2,2-dimethyl-5-oxo-morpholin-4-yl)-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-hydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-hydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4R)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-N-[2-(difluoromethyl)-4-pyridyl]-3-[(4S)-4-methoxy-2-oxo-pyrrolidin-1-yl]-6-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4S)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(4S)-4-(5-fluoropyrimidin-2-yl)oxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[2-hydroxyethyl(methyl)carbamoyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[(2-hydroxy-1,1-dimethyl-ethyl)carbamoyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(morpholine-4-carbonyl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[(3S)-3-hydroxypyrrolidine-1-carbonyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[(3R)-3-hydroxypyrrolidine-1-carbonyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(3-hydroxyazetidine-1-carbonyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(dimethylcarbamoyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[2-oxo-4-(pyrrolidine-1-carbonyl)pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(oxazol-2-ylcarbamoyl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(2,2-dimethylmorpholine-4-carbonyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-[(2R)-2-methylmorpholine-4-carbonyl]-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-[(2S)-2-methylmorpholine-4-carbonyl]-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[trans-2,6-dimethylmorpholine-4-carbonyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[cis-2,6-dimethylmorpholine-4-carbonyl]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(3,3-difluoropyrrolidine-1-carbonyl)-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-[methyl(oxazol-2-yl)carbamoyl]-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(3,3-difluoropyrrolidine-1-carbonyl)-4-methyl-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-(4,4-difluoropiperidine-1-carbonyl)-4-methyl-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-methyl-4-(morpholine-4-carbonyl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-methyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-methyl-4-(1,3,4-oxadiazol-2-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-methyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(2S)-2-oxazol-5-yl-5-oxo-morpholin-4-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-oxazolidin-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[5-(6-chloro-3-pyridyl)-2-oxo-oxazolidin-3-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[5-(5-fluoro-2-pyridyl)-2-oxo-oxazolidin-3-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[5-(6-fluoro-2-pyridyl)-2-oxo-oxazolidin-3-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[4-(1-methylpyrazol-4-yl)-2-oxo-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-pyrimidin-5-yl-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[4-[(5-fluoropyrimidin-2-yl)amino]-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[(4R)-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(3R,4R)-3,4-dihydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-hydroxy-4,4-dimethyl-2-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-3H-pyrrolo[3,2-c]pyridin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(6-oxo-4,7-dihydropyrazolo[1,5-a]pyrazin-5-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-cyano-2-methyl-5-oxo-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(5-hydroxy-2-oxo-1,3-oxazinan-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(7-oxo-6-azaspiro[3.4]octan-6-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(8-hydroxy-7-oxo-6-azaspiro[3.4]octan-6-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(7-hydroxy-6-oxo-5-azaspiro[2.4]heptan-5-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(6-methyl-2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(4-methyl-2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(3S,4R)-3,4-dihydroxy-2-oxo-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(3S,4R)-3-hydroxy-2-oxo-4-pyrimidin-2-yloxy-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-[5-methyl-5-(morpholine-4-carbonyl)-2-oxo-1,3-oxazinan-3-yl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(2R,3R,4S)-4-hydroxy-2-methyl-5-oxo-3-pyrimidin-2-yloxy-pyrrolidin-1-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-6-methyl-3-(2-oxo-4-pyrimidin-2-yl-pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-(3-hydroxy-2-oxo-4-phenyl-pyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; (6S)-3-[(5S)-5-methoxy-2-oxo-1,3-oxazinan-3-yl]-6-methyl-N-(3,4,5trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; and (6S)-3-[(5R)-5-methoxy-2-oxo-1,3-oxazinan-3-yl]-6-methyl-N-(3,4,5trifluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxamide; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

35. A process for the preparation of a compound according to any one of claims 1 to 34 comprising the following steps: (a) the reaction of a compound of formula (V), with an acid followed by urea formation with amine R4NH2 in the presence of a phosgene equivalent; (b) the reaction of a compound of formula (VII), with an acid followed by urea formation with amine R4NH2 in the presence of a phosgene equivalent; (c) the reaction of a compound of formula (IX), with R7-B(OH)2; (d) the reaction of a compound of formula (X), with halide via Suzuki-Miyaura reaction; wherein R2 and R3 are independently selected from hydrogen and C1-6alkyl; R4 is heteroaryl, said heteroaryl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, C3-7cycloalkyl and (C1-6alkyl)2amino; aryl, said aryl being unsubstituted or substituted with one, two or three substituents independently selected from halogen, cyano, C3-7cycloalkyl, C1-6alkyl, C2-6alkynyl, C1-6alkoxy, haloC1-6alkyl and haloC1-6alkoxy; phenylC1-6alkyl, said phenylC1-6alkyl being unsubstituted or substituted with one, two or three halogen; or C3-7cycloalkyl; R5 and R6 together with the nitrogen atom they are attached to form a 3-7 membered heterocyclyl, and R7 is aryl or heteroaryl.

36. A compound or pharmaceutically acceptable salts, enantiomers or diastereomers according to any one of claims 1 to 34 for use as therapeutically active substance.

37. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 34 and a therapeutically inert carrier.

38. The use of a compound according to any one of claims 1 to 34 for the preparation of a medicament for the treatment or prophylaxis of hepatitis B virus infection.

39. A compound or pharmaceutically acceptable salt, enantiomer or diastereomer according to any one of claims 1 to 34, when manufactured according to a process of claim 35.